Document:

EX-10.46

 Exhibit 10.46 

***Text Omitted and Filed Separately with the Securities and Exchange Commission. 

Confidential Treatment Requested Under 

17 C.F.R. Sections 200.80(b)(4) and 240.24b-2 

AMENDED AND RESTATED 

COLLABORATION AND LICENSE AGREEMENT FOR THE UNITED STATES 

by and between 
 POZEN INC.

 and 
 ASTRAZENECA AB

 November 18, 2013 

 TABLE OF CONTENTS 
  

					
	 	  	Page	 
	 1. DEFINITIONS
	  	 	1	  
		
	 2. COLLABORATION GOVERNANCE
	  	 	11	  
		
	 2.1 Establishment
	  	 	11	  
		
	 2.2 Membership and Procedures
	  	 	12	  
		
	 2.3 Decision-Making
	  	 	13	  
		
	 2.4 Operating Principles
	  	 	14	  
		
	 3. [Intentionally Omitted]
	  	 	14	  
		
	 4. REGULATORY MATTERS
	  	 	14	  
		
	 4.1 Responsibilities; Diligence
	  	 	14	  
		
	 4.2 Access to Filings
	  	 	14	  
		
	 4.3 Interactions with Regulatory Authorities
	  	 	14	  
		
	 4.4 Exchange of Know-How; Information Sharing
	  	 	15	  
		
	 4.5 Regulatory Audits
	  	 	15	  
		
	 4.6 Adverse Event Reporting
	  	 	16	  
		
	 4.7 Records and Reports
	  	 	16	  
		
	 5. DEVELOPMENT AND COMMERCIALIZATION
	  	 	16	  
		
	 5.1 Development and Commercialization
	  	 	16	  
		
	 5.2 Regulatory Obligations during Commercialization
	  	 	16	  
		
	 5.3 Performance; Diligence
	  	 	16	  
		
	 5.4 Threatened Removal
	  	 	17	  
		
	 5.5 Compliance
	  	 	17	  
		
	 5.6 Branding; Trademarks; Domain Names; Trade Dress; Logos
	  	 	17	  
		
	 5.7 Commercial Supply
	  	 	18	  
		
	 6. [Intentionally Omitted]
	  	 	18	  
		
	 7. LICENSES
	  	 	18	  
		
	 7.1 Licensed Technology
	  	 	18	  
		
	 7.2 Trademarks
	  	 	18	  

 TABLE OF CONTENTS (cont’d) 
  

					
	 	 	Page	 
	 7.3 Sublicenses
	 	 	18	  
		
	 7.4 Reservation of Rights; No Implied Licenses
	 	 	19	  
		
	 7.5 Restrictive Covenant
	 	 	19	  
		
	 8. FINANCIAL TERMS
	 	 	20	  
		
	 8.1 Royalties
	 	 	20	  
		
	 8.2 Payments and Sales Reporting
	 	 	21	  
		
	 8.3 Records; Audit
	 	 	22	  
		
	 8.4 Taxes
	 	 	22	  
		
	 9. INTELLECTUAL PROPERTY
	 	 	23	  
		
	 9.1 Prosecution and Maintenance of Licensed Patents
	 	 	23	  
		
	 9.2 Prosecution and Maintenance of Joint Patents
	 	 	23	  
		
	 9.3 Ownership of Inventions
	 	 	23	  
		
	 9.4 Disclosure
	 	 	24	  
		
	 9.5 Cooperation
	 	 	24	  
		
	 9.6 Enforcement of Licensed Patents
	 	 	24	  
		
	 9.7 Defense of Infringement Claims
	 	 	26	  
		
	 9.8 Patent Term Extension and Supplementary Protection Certificate
	 	 	26	  
		
	 9.9 Consequence of Patent Challenge
	 	 	26	  
		
	 9.10 Patent Certifications
	 	 	27	  
		
	 9.11 Patent Marking
	 	 	27	  
		
	 10. REPRESENTATIONS, WARRANTIES; COVENANTS
	 	 	27	  
		
	 10.1 POZEN Representations and Warranties
	 	 	27	  
		
	 10.2 Reciprocal Representations and Warranties
	 	 	27	  
		
	 10.3 DISCLAIMER OF WARRANTY
	 	 	28	  
		
	 10.4 POZEN Non-Compete
	 	 	28	  
		
	 10.5 Other Covenants
	 	 	28	  
		
	 11. CONFIDENTIALITY
	 	 	28	  
		
	 11.1 Definition
	 	 	28	  
		
	 11.2 Exclusions
	 	 	29	  
		
	 11.3 Disclosure and Use Restriction
	 	 	29	  

  
 -ii- 

 TABLE OF CONTENTS (cont’d) 
  

					
	 	 	Page	 
	 11.4 Authorized Disclosure
	 	 	30	  
		
	 11.5 Use of Name
	 	 	30	  
		
	 11.6 Press Releases
	 	 	31	  
		
	 11.7 Terms of Agreement to be Maintained in Confidence
	 	 	31	  
		
	 12. TERM AND TERMINATION
	 	 	31	  
		
	 12.1 Amended and Restated Effective Date
	 	 	31	  
		
	 12.2 Term
	 	 	32	  
		
	 12.3 Termination for Material Breach
	 	 	32	  
		
	 12.4 Termination for Cause
	 	 	32	  
		
	 12.5 Consequences of Expiration and Termination
	 	 	32	  
		
	 12.6 Termination for Insolvency
	 	 	33	  
		
	 12.7 Effect of Bankruptcy
	 	 	33	  
		
	 12.8 Formulation Technology
	 	 	33	  
		
	 12.9 Survival
	 	 	34	  
		
	 13. INDEMNIFICATION AND INSURANCE
	 	 	34	  
		
	 13.1 Indemnification by POZEN
	 	 	34	  
		
	 13.2 Indemnification by Licensee
	 	 	34	  
		
	 13.3 Indemnification Procedure
	 	 	35	  
		
	 13.4 Expenses
	 	 	36	  
		
	 13.5 Insurance
	 	 	36	  
		
	 14. LIMITATION OF LIABILITY
	 	 	37	  
		
	 15. MISCELLANEOUS
	 	 	37	  
		
	 15.1 Assignment
	 	 	37	  
		
	 15.2 Termination of Certain Rights Upon POZEN Change of Corporate Control
	 	 	37	  
		
	 15.3 Severability
	 	 	38	  
		
	 15.4 Governing Law; Dispute Resolution
	 	 	38	  
		
	 15.5 Notices
	 	 	39	  
		
	 15.6 Entire Agreement; Modifications
	 	 	39	  
		
	 15.7 Relationship of the Parties
	 	 	40	  
		
	 15.8 Waiver    
	 	 	40	  

  
 -iii- 

 TABLE OF CONTENTS (cont’d) 
  

					
	 	 	Page	 
	 15.9 Counterparts
	 	 	40	  
		
	 15.10 No Benefit to Third Parties
	 	 	40	  
		
	 15.11 Further Assurance
	 	 	40	  
		
	 15.12 No Drafting Party
	 	 	40	  
		
	 15.13 Construction
	 	 	40	  
		
	 15.14 Assignment to Horizon
	 	 	41	  
		
	 15.15 Amendment and Restatement; No Novation
	 	 	41	  

 SCHEDULES 
 Schedule 1.43
– Licensed Patents 
 Schedule 1.83 – Vimovo Trademarks 

Schedule 8.1.3 – Market Reduction Example 

  
 -iv- 

 AMENDED AND RESTATED COLLABORATION AND LICENSE AGREEMENT 

FOR THE UNITED STATES 

THIS AMENDED AND RESTATED COLLABORATION AND LICENSE AGREEMENT FOR THE UNITED STATES (the “Agreement”) is made and
entered into as of November 18, 2013 (the “Amended and Restated Execution Date”), by and between POZEN INC., a Delaware corporation having offices at 1414 Raleigh Road, Suite 400, Chapel Hill, North Carolina
(“POZEN”), and ASTRAZENECA AB, a Swedish corporation having an office at SE-431 83, Mölndal, Sweden (“Licensee”). POZEN and Licensee each may be referred to herein individually as a
“Party,” or collectively as the “Parties.” 
 RECITALS 

A. WHEREAS, POZEN and Licensee are parties to that certain Collaboration and License Agreement, dated as of August 1, 2006 and as
amended as of September 6, 2007, October 1, 2008 and September 16, 2013 (as amended, the “Original Agreement”); 

B. WHEREAS, Licensee is in discussions with Horizon Pharma USA, Inc. (“Horizon”) to divest Licensee’s (and its
Affiliates’) rights to Products (as defined below) in the United States (such transaction, the “Divestiture”); and 

C. WHEREAS, to facilitate the proposed Divestiture, Licensee and POZEN desire to amend and restate the terms of the Original Agreement
in two separate agreements: (a) this Agreement, which contains the terms and conditions pursuant to which Licensee (or its assignee) will have a license to POZEN’s intellectual property to manufacture, develop and commercialize the
Products (as defined below) in the United States, which will be assigned to Horizon in connection with the Divestiture, and (b) another agreement that contains the terms and conditions pursuant to which Licensee (or its designee) will have a
license to POZEN’s intellectual property to manufacture, develop and commercialize the Products throughout the world outside of the United States and Japan (the “ROW Agreement”). 

In consideration of the foregoing premises, the mutual promises and covenants set forth in this Agreement, and other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, POZEN and Licensee hereby agree as follows: 
 AGREEMENT

 1. DEFINITIONS 
 When used
in this Agreement, capitalized terms will have the meanings as defined below and throughout the Agreement. All financial and accounting terms not otherwise defined in this Agreement, whether capitalized or not, shall have the meanings assigned to
them in accordance with generally accepted accounting principles based on International Accounting Standards/International Financial Reporting Standards as in effect from time to time (“IFRS”). 

 1.1 “Adverse Event” means any adverse medical occurrence in a patient or
clinical investigation subject that is administered a pharmaceutical product, as designated under 21 CFR § 312.32 and any other Applicable Law in the Territory. 

1.2 “Affiliate” means a legal entity that, directly or indirectly, through one or more intermediaries, controls, is
controlled by, or is under common control with an entity. For purposes of this definition only, “control” and, with correlative meanings, the terms “controlled by” and “under common control with” means (a) the
possession, directly or indirectly, of the power to direct the management or policies of a legal entity, whether through the ownership of voting securities or by contract relating to voting rights or corporate governance, or (b) the ownership,
directly or indirectly, of more than 50% of the voting securities or other ownership interest of a legal entity; provided, that if local law restricts foreign ownership, control will be established by direct or indirect ownership of the maximum
ownership percentage that may, under such local law, be owned by foreign interests. 
 1.3 “Amended and Restated Effective
Date” has the meaning set forth in Section 12.1. 
 1.4 “Amended and Restated Execution Date” has the
meaning set forth in the preamble. 
 1.5 “Applicable Law” means the laws, rules, and regulations, including any
statutes, rules, regulations, guidelines, or other requirements that may be in effect from time to time and apply to the activities contemplated by this Agreement in the Territory. 

1.6 “Blocking Patent” means a Patent owned or controlled by a Third Party, one or more Valid Claims of which, in the absence
of a license thereunder, would be infringed by the making, use, sale, offering for sale, or importation of a POZEN Product in the Territory. 

1.7 “Business Combination” means any merger, consolidation, sale of stock, sale or transfer of all or substantially all of
the assets, or other similar transaction to which POZEN is a party, other than (i) any merger, consolidation, or similar transaction following which the individuals and entities who were the beneficial owners of the outstanding voting
securities of POZEN immediately prior to such transaction still beneficially own, directly or indirectly, more than fifty percent (50%) of the voting power of the surviving entity immediately after such transaction; or (ii) any merger,
consolidation, sale of stock, sale or transfer of all or substantially all of the assets, or other similar transaction permitted under Section 15.1 (Assignment). 

1.8 “Business Day” means any day other than (i) Saturday or Sunday or (ii) any other day on which banks in New
York, New York, United States, the United Kingdom or Sweden are permitted or required to be closed. 
 1.9 “Calendar
Quarter” means the respective periods of three (3) consecutive calendar months ending on March 31, June 30, September 30 and December 31. 

1.10 “cGCP” means current good clinical practices as defined in U.S. Regulations 21 CFR §§ 50, 54, 56, 312 and 314,
(or in the case of foreign jurisdictions, comparable regulatory standards), the International Conference of Harmonization (ICH) E6 “Good Clinical Practice: 

  
 - 2 - 

 
Consolidated Guidance,” and in any successor regulation or any official guidance documents issued by an applicable Regulatory Authority. 

1.11 “cGLP” means current good laboratory practice standards as defined by the FDA pursuant to 21 CFR Part 58 (or in the case
of foreign jurisdictions, comparable regulatory standards), and in any successor regulation or any official guidance documents issued by a Regulatory Authority. 

1.12 “cGMP” means current good manufacturing practices as contained in 21 CFR Parts 210 and 211 as amended from time to time
and any equivalents contained in regulations in countries outside the U.S. 
 1.13 “Change of Corporate Control”
means the occurrence of either of the following: 
 (a) a Business Combination involving POZEN; or 

(b) the acquisition (whether in a single transaction or series of related transactions) after the Effective Date by a Third Party or
Group of beneficial ownership of [...***...] ([...***...]) [...***...] of POZEN’s voting securities. 
 1.14
“Combination Product” means a Product that includes one or more pharmaceutically active ingredients (in addition to a single Gastroprotective Agent and a single NSAID) and is sold in final form either in a single fixed combination oral
solid dosage or as separate doses in a single package and priced as one item. 
 1.15 “Commercial Launch” means the
nationwide commercial sale, promotion and distribution of POZEN Product in the Territory following receipt of Marketing Approval in the Territory. 

1.16 “Commercialization” means all activities relating to the manufacture, marketing, promotion, advertising, selling and
distribution of Product in the Territory, including pre-Commercial Launch market development activities conducted in anticipation of Marketing Approval of Product, including, without limitation, seeking pricing and reimbursement approvals for
Product, preparing advertising and promotional materials, sales force training, and all interactions and activities (e.g., dossier preparations and filings) associated with Regulatory Authorities regarding the commercialization
of Product and the maintenance of Marketing Approvals. The term “Commercialize” has a correlative meaning. 
 1.17
“Commercialized POZEN Product” has the meaning set forth in Section 12.8 (Formulation Technology). 
 1.18
“Competing Product” means, with respect to a particular Product being Commercialized by Licensee or any of its Affiliates or Sublicensees in the Territory, a product being marketed by or on behalf of a Third Party (other than a
Sublicensee) in the Territory containing at least [...***...] that are [...***...] those in the [...***...] and are [...***...]. 

  
  

***Confidential Treatment Requested 

- 3 - 

 1.19 “Controlled” means, with respect to any Know-How, Patent, or other
intellectual property right, the possession of the right, whether directly or indirectly, and whether by ownership, license or otherwise, to assign, or grant a license, sublicense or other right to or under, such Know-How, Patent or right as
provided for herein without violating the terms of any agreement or other arrangements with any Third Party. 
 1.20
“Develop” or “Development” means all activities relating to pre-clinical and clinical development of a Product and all development activities relating to the preparation and filing of NDAs and obtaining of Marketing
Approvals, price and reimbursement approvals in the Territory, including, without limitation, preparing and conducting pre-clinical testing, toxicology testing, human clinical studies, regulatory affairs. 

1.21 “Diligent Efforts” means, with respect to the Development, Manufacture or Commercialization by Licensee of a product, at
any given time as the case may be, efforts and resources reasonably used by Licensee or its Affiliates (giving due consideration to relevant industry standards) for Licensee’s own products (including internally developed, acquired and
in-licensed products) with similar commercial potential at a similar stage in their lifecycle (assuming continuing development of such product), taking into consideration their safety, tolerability and efficacy, the profitability (taking into
account any payments payable under this Agreement or the Three-Party Agreement), the extent of market exclusivity, patent protection, cost to develop the product, promotable claims, and health economic claims. 

1.22 “Divestiture” has the meaning set forth in the recitals. 

1.23 “Duexis” means the pharmaceutical product containing ibuprofen and famotidine in a single fixed combination dosage form,
which product is being commercialized as of the Amended and Restated Effective Date by Horizon or its Affiliates in the Territory as Duexis®. 

1.24 “Effective Date” means the date on which the Original Agreement became effective pursuant to the terms thereof. 

 1.25 “Esomeprazole” means that certain pharmaceutical compound with the name
(5-methoxy-2-{(S)-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole), including any [...***...]. 
 1.26
“Execution Date” means August 1, 2006. 
 1.27 “FDA” means the United States Food and Drug
Administration, or any successor agency thereto. 
 1.28 “Field of Use” means the treatment of human diseases and
conditions by means of a pharmaceutical product. 
 1.29 “First Commercial Sale” means, with respect to a Product,
the date on which Licensee or its Affiliate or Sublicensee first sells the Product intended for commercial distribution to any Third Party after receipt of NDA Approval of such Product in the Territory (including, without limitation, sale in an
individual state or similar sub-national political subdivision in which Marketing Approval may be received); provided, that with respect to the  

  
  

***Confidential Treatment Requested 

- 4 - 

 
Initial Pozen Product, “First Commercial Sale” means July 6, 2010. Sale of a Product for clinical studies, compassionate use, named patient programs, under a treatment
IND, test marketing, any clinical studies, or any similar instance where the Product is supplied with or without charge will not constitute a First Commercial Sale. 

1.30 “Formulation Technology” means any Know-How Controlled by Licensee in the Licensee Inventions that are used by Licensee
in the manufacture, use, sale or import of the formulation of a Commercialized POZEN Product, and any Patents Controlled by Licensee claiming such Licensee Inventions; provided, that Formulation Technology will not include any Patents or Know-How to
the extent directed to a Gastroprotective Agent, non-steroidal anti-inflammatory, or other drug or chemical agent, or any methods of manufacture or use thereof. 

1.31 “Gastroprotective Agent” means proton pump inhibitors and H2 receptor antagonists for the treatment, prevention or
amelioration of injury to the gastrointestinal tract. 
 1.32 “Group” means a group of related persons or entities
deemed a “person” for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended. 
 1.33
“Horizon” has the meaning set forth in the recitals. 
 1.34 “IND” means an Investigational New Drug
Application filed with the FDA pursuant to 21 CFR § 312.20. 
 1.35 “Indirect Tax” means value added
taxes, sales taxes, consumption taxes and other similar taxes. 
 1.36 “Initial POZEN Product” means the POZEN
Product containing non-enteric coated Esomeprazole and enteric-coated Naproxen that is the subject of NDA #22-511.  
 1.37
“Invention” means any invention, discovery or Know-How that is conceived during the Term in the performance of activities undertaken pursuant to this Agreement by employees, agents, or independent contractors of either Party, its
Affiliates or Sublicensees and is Controlled by such Party, Affiliates or Sublicensees. 
 1.38 “Joint Invention”
means any Invention that is conceived jointly by one or more employees, agents, or independent contractors of Licensee or its Affiliate(s) and one or more employees, agents, or independent contractors of POZEN or its Affiliate(s). 

1.39 “Joint Patent” means a Patent claiming a Joint Invention. 

1.40 “JSC” has the meaning set forth in Section 2.1.2 (Joint Steering Committee). 

1.41 “Know-How” means any non-public, documented or otherwise recorded or memorialized knowledge, experience, know-how,
technology, information, and data, including formulas and formulations, processes, techniques, unpatented inventions, discoveries, ideas, and developments, test procedures, and results, together with all documents and files embodying the
foregoing. 

  
 - 5 - 

 1.42 “Licensed Know-How” means any Know-How that is necessary or useful for the
Development, Manufacture or Commercialization of Product in the Field of Use in the Territory and that is Controlled by POZEN or any of its Affiliates as of the Effective Date or during the Term. 

1.43 “Licensed Patents” means: (a) the Patents set forth on Schedule 1.43, and any substitutions, divisions,
continuations, continuations-in-part, reissues, renewals, registrations, confirmations, re-examinations, or extensions of such Patents, (b) any Patents in the Territory Controlled by POZEN or any of its Affiliates as of the Effective Date or
during the Term that claim Inventions (including without limitation POZEN’s interest in Joint Inventions), and (c) all other Patents in the Territory Controlled by POZEN or any of its Affiliates as of the Effective Date or during the Term
that are necessary or useful for the Development, Manufacture or Commercialization of a Product in the Territory. Notwithstanding anything in this Section 1.43 to the contrary, Licensed Patents shall not include any Patents Controlled by POZEN
with Valid Claims that do not cover any Product (e.g., any Patents with Valid Claims solely directed to any product containing acetyl salicylic acid). 

1.44 “Licensed Technology” means the Licensed Patents and the Licensed Know-How. 

1.45 “Licensee House Marks” means any trademarks, trade names, domain names, or other names or marks used or registered by
Licensee or its Affiliates at any time during the Term to identify itself. 
 1.46 “Licensee Invention” means any
Invention that is conceived solely by one or more employees, agents, or independent contractors of Licensee or its Affiliate(s). 

1.47 “Manufacture” means all activities related to the manufacturing of a Product, or any ingredient thereof, in the
Territory, including but not limited to formulation development and process development for the manufacture of a Product, manufacturing supplies for Development, manufacturing for commercial sale, packaging, in-process and finished product testing,
release of product or any component or ingredient thereof, quality assurance activities related to manufacturing and release of product, ongoing stability tests and regulatory activities related to any of the foregoing. “Manufacture” shall
not include any of the above activities with respect to Esomeprazole as an active ingredient. 
 1.48 “Market
Reduction” has the meaning set forth in Section 8.1.3 (Rate Step Down for Competing Product Entrants). 
 1.49
“Marketing Approval” means all approvals (including NDA Approvals and, where available under Applicable Law, pricing and reimbursement approvals in accordance with Applicable Law) of any Regulatory Authority in the Territory, that are
necessary or useful to be obtained prior to the manufacture or Commercialization of a Product in the Territory. For purposes of clarification, “Marketing Approval” in the U.S. shall have the same meaning as NDA Approval in the U.S.

  
 - 6 - 

 1.50 “Naproxen” means that certain pharmaceutical compound with the chemical
name (S)-6-methoxy-(alpha)-methyl-2-naphthaleneacetic acid, including any [...***...]. 

1.51 “NDA” means a New Drug Application filed with the FDA as described in 21 CFR § 314. 

1.52 “NDA Approval” means receipt of a letter from the FDA approving an NDA. 

1.53 “Net Sales” means with respect to any Product, the gross amounts recognized by Licensee, its Sublicensees or its
Affiliates from Third Party customers for sales of a Product in the Territory, less the following deductions made by Licensee (to the extent not already taken by Licensee in the Product invoice or in amounts recognized), its Sublicensees or its
Affiliates in arriving at net sales as reported in the Licensee statutory accounts prepared in accordance with IFRS: 
 (a)
actual credited allowances to such Third Party customers for spoiled, damaged, rejected, recalled, outdated and returned Product and for retroactive price reductions; 

(b) the amounts of trade and cash discounts actually granted to Third Party customers, to the extent such trade and cash discounts are
specifically allowed on account of the purchase of such Product; 
 (c) sales taxes, excise taxes and import/export duties actually
due or incurred in connection with the sales of a Product to any Third Party customer; 
 (d) allowances, adjustments, reimbursements,
discounts, chargebacks and rebates actually granted to Third Party customers (not in excess of the selling price per unit of such Product); 

(e) other deductions from gross sales made in arriving at net sales as reported in the Licensee statutory accounts; and 

(f) allowance for transportation costs, distribution expenses, special packaging and related insurance charges in the amount of
[...***...] ([...***...]) of the Net Sales calculated after applying the deductions of items (a)-(e) above. 
 Net Sales shall be
calculated using Licensee’s internal audited systems used to report such sales as adjusted for any of items (a)-(f) above not taken into account in such systems. Notwithstanding the foregoing, if Product is sold as a Combination Product,
the Net Sales used for the calculation of the royalties under Section 8.1 (Royalties) shall be determined as follows: 
  

			
	    A    	  	x Net Sales of the Combination Product, where:
	A+B	  
		
	A =	  	Standard Sales Price of the ready-for-sale form of the Product if sold separately from the Combination Product in question, in the Territory.

  
  

***Confidential Treatment Requested 

- 7 - 

			
		
	B =	  	Standard Sales Price of the ready-for-sale form of a product containing the same amount of the other therapeutically active ingredient(s) that is contained in the Combination Product in question, in the Territory.

 If (a) the other therapeutically active ingredient(s) in such Combination Product are not sold separately in the
Territory, Net Sales shall be adjusted by multiplying actual Net Sales of such Combination Product by the fraction A/C, where C is the Standard Sales Price in the Territory of such Combination Product, and (b) if a Product contained in the
Combination Product is not sold separately, Net Sales shall be calculated by multiplying actual Net Sales of such Combination Product by the fraction (C-B)/C, where B is the Standard Sales Price in the Territory of the other therapeutically active
ingredient(s) in the Combination Product and C is the Standard Sales Price in the Territory of the Combination Product. If both a Product in a Combination Product and a product containing the other active ingredients in such Combination Product are
not sold separately, a market price for such Product and such other active ingredients shall be negotiated by the Parties in good faith based upon the market price of products that are comparable to such Product or such other active ingredients, as
applicable. If the Product in the Combination Product is marketed in the Territory, the Standard Sales Price of the Product in such Combination Product for purposes of calculating the royalty payable to POZEN will be no less than [...***...]
([...***...]) of the Standard Sales Price of the Product sold outside of such Combination Product in the Territory. 
 In addition, and
notwithstanding the foregoing, if a Product is sold together with other goods with or without a separate price for such Product (such group of products including the Product a “Product Set”), then the Net Sales applicable to the
quantity of such Product included in any such transaction will be calculated as follows: 
  

			
	    A      	  	x Net Sales of the Product Set, where:
	A+B	  
		
	A =	  	Standard Sales Price of the Product if sold separately from the Product set in question, in the Territory.
		
	B =	  	The total of the Standard Sales Prices of all products in the Product Set other than the Product, in the Territory.

 1.54 “Nexium” means AstraZeneca AB’s and its Affiliates’ products containing
Esomeprazole as the sole active ingredient in any presentation form. 
 1.55 “Nexium Business” means AstraZeneca
AB’s and its Affiliates’ development and commercialization activities pertaining to Esomeprazole and Esomeprazole based products. 

1.56 “NSAID” means any non-steroidal anti-inflammatory drug, the primary mechanism of action of which is inhibition of
cyclooxygenase, but excluding acetyl salicylic acid (including salts and derivatives thereof). 
 1.57 “Original
Agreement” has the meaning set forth in the recitals. 

  
  

***Confidential Treatment Requested 

- 8 - 

 1.58 “Patent Challenge” has the meaning set forth in Section 9.9.

 1.59 “Patents” means (a) all patents and patent applications in any country or supranational jurisdiction, and
(b) any substitutions, divisions, continuations, continuations-in-part, reissues, renewals, registrations, confirmations, re-examinations, extensions, supplementary protection certificates and the like, and any provisional applications, of any
such patents or patent applications. 
 1.60 “Post-Approval Failure” means: (a) a mandatory withdrawal or
recall of a Product by a Regulatory Authority, or (b) any voluntary withdrawal or recall of a Product that arises from risks associated with a serious adverse health consequence or death reported to a Regulatory Authority anywhere in the world.
Notwithstanding the foregoing, any such recall that results primarily from Licensee’s or its Affiliate’s or Sublicensee’s gross negligence, willful misconduct, or failure to comply with Applicable Law in the Development, Manufacture
or Commercialization of a Product in the Territory shall not be considered a Post-Approval Failure for purposes of this Agreement. 

1.61 “POZEN House Marks” means any trademarks, trade names, domain names, or other names or marks used or registered by POZEN
or its Affiliates at any time during the Term to identify itself. 
 1.62 “POZEN Invention” means any Invention that
is conceived solely by one or more employees, agents, or independent contractors of POZEN or its Affiliate(s). 
 1.63 “POZEN
Product” means any product that combines a Gastroprotective Agent and any NSAID in a single fixed combination dosage form, that would, if made, used, sold, offered for sale, had made, imported or exported in the Territory without a license
from POZEN of the Licensed Patents, infringe one or more Valid Claims of the Licensed Patents. 
 1.64 “Product”
means: (a) any POZEN Product, and (b) any other product that combines a Gastroprotective Agent and any NSAID in a single fixed combination oral solid dosage form (with or without one or more additional therapeutically active agents), which
product is developed or commercialized by or for, invented or acquired by, or comes under the Control of Licensee or its Affiliates during the Term, but in each case excluding Duexis. For the avoidance of doubt, “Product” does not include
any product containing acetyl salicylic acid (including salts and derivatives thereof). 
 1.65 “Product Labeling”
means (a) the full prescribing information for a POZEN Product approved by the applicable Regulatory Authority in the Territory, and (b) all labels and other written, printed or graphic information included in or placed upon any container,
wrapper or package insert used with or for the POZEN Product in the Territory. 
 1.66 “Product Trademarks”
means (a) the VIMOVO Trademarks and (b) any other trademarks, trade dress (including packaging design), logos, slogans, domain names and designs, whether or not registered in a country or territory, selected by Licensee and used to
identify or promote a POZEN Product, but excluding any POZEN House Marks and Licensee House Marks. 

  
 - 9 - 

 1.67 “Promotional Materials” means all sales representative training materials
and all written, printed, graphic, electronic, audio or video presentations of information, including, without limitation, journal advertisements, sales visual aids, formulary binders, reprints, direct mail, direct-to-consumer advertising, internet
postings, broadcast advertisements and sales reminder aides (for example, note pads, pens and other such items) intended for use or used by Licensee or its Affiliates in connection with any promotion of the Initial POZEN Product hereunder in the
Territory, but excluding Product Labeling. 
 1.68 “PT” means Licensee’s product team operating pursuant
to Licensee’s instructions for product teams for the Initial POZEN Product in the Territory with representatives of Licensee having expertise in the areas of research & development, marketing, regulatory, intellectual property,
finance, toxicology, and other areas. 
 1.69 “PT Chair” will have the meaning set forth in
Section 2.2.1 (PT). 
 1.70 “Regulatory Authority” means, in a particular country or jurisdiction, any
applicable government regulatory authorities involved in granting approval to market or sell a Product, including any pricing and reimbursement approvals, in such country or jurisdiction, including, (a) in the United States, the FDA, and any
successor government authority having substantially the same function, (b) any non-United States equivalent thereof, and (c) in the EU, the European Medicines Agency, or any successor agency thereto, and any national regulatory authority
in any EU country. 
 1.71 “Regulatory Materials” means regulatory applications, submissions, notifications,
registrations, Marketing Approvals or other submissions made to or with a Regulatory Authority that are necessary or reasonably desirable in order to develop, manufacture, market, sell or otherwise Commercialize the Initial POZEN Product in the
Territory. Regulatory Materials include, without limitation, INDs and NDAs, and amendments and supplements for any of the foregoing, and applications for pricing and reimbursement approvals. 

1.72 “ROW Agreement” has the meaning set forth in the recitals. 

1.73 “ROW Party” has the meaning set forth in Section 7.4(b). 

1.74 “Royalty Term” has the meaning set forth in Section 8.1.2 (Royalty Term). 

1.75 “Standard Sales Price” means, as reported by IMS (or ACNielsen in the case of over-the-counter products) in the
Territory, the average sales price for the preceding Calendar Quarter for the Product or, in the case of a Combination Product, the average sales price for the applicable presentation and dosage strength of all marketed brands of the other
therapeutically active ingredient(s). As used herein, “presentation” means the method of administration of a pharmaceutical substance into the human body, including, but not limited to, solid oral (including tablets, capsules, gelcaps,
sachets and caplets), other oral (including suspension and solution), parenteral (including intramuscular, subcutaneous and intravenous), transdermal, suppository and intranasal. 

  
 - 10 - 

 1.76 “Sublicense Agreement” means any agreement under which Licensee grants a
Third Party a sublicense, option or other right under the Licensed Technology to make, use, have made, sell, offer for sale, import and export Products in the Field of Use in the Territory. 

1.77 “Sublicensee” means any Third Party that has entered into a Sublicense Agreement. 

1.78 “Term” has the meaning assigned to it in Section 12.2 (Term). 

1.79 “Territory” means the United States. 

1.80 “Third Party” means any entity other than POZEN, Licensee, or any of their respective Affiliates. 

1.81 “Third Party Royalties” means upfront, commercialization milestone, royalty and any other similar payments paid by
Licensee or any Licensee Affiliate or Sublicensee to any Third Party in consideration for a license to a Blocking Patent for the Development or Commercialization of POZEN Products in the Territory. 

1.82 “Three-Party Agreement” means that certain letter agreement of even date herewith by and among AstraZeneca AB,
POZEN and Horizon.  
 1.83 “Vimovo Trademarks” means the trademark VIMOVO and the other trademarks and logos
listed on Schedule 1.83 and any variations thereof. 
 1.84 “U.S.” or “United States” means the United
States of America and its possessions and territories. 
 1.85 “Valid Claim” means any claim of any issued and
unexpired patent or a patent application that has not been disclaimed or held invalid or unenforceable by judgment or decree entered in any judicial proceeding that is not further reviewable through the exhaustion of all permissible applications for
rehearing or review by a superior tribunal, or through the expiration of the time permitted for such applications; provided, that any claim in a pending Patent application that does not issue as a patent claim within [...***...] ([...***...])
years after the earliest priority date of such application will not be a “Valid Claim” until such claim issues as a patent claim. 
 2.
COLLABORATION GOVERNANCE 
 2.1 Establishment. 

2.1.1 Product Team. Within twenty (20) days after the Amended and Restated Effective Date, the Parties will appoint representatives
to the PT in accordance with the terms of this Section 2.1 and convene the first PT meeting. The PT will coordinate and oversee the Commercialization of the Initial POZEN Product hereunder. The purposes of the PT will be, with respect to the
Initial POZEN Product only, to develop Licensee’s marketing plans for the Initial POZEN Product in the Territory. The PT will have the membership and will operate by the procedures set forth in Section 2.2 (Membership and Procedures). 

  
  

***Confidential Treatment Requested 

- 11 - 

 2.1.2 Joint Steering Committee Promptly following the Amended and Restated Effective Date,
the Parties will create a joint steering committee (the “JSC”) to provide strategic guidance to the PT in decisions pertaining to the Initial POZEN Product in the Territory. The purposes of the JSC will be to resolve disputes of the
PT. The JSC will have the membership and will operate by the procedures set forth in Section 2.2 (Membership and Procedures). 
 2.2
Membership and Procedures. 
 2.2.1 PT. 

(a) Membership. In addition to members designated by Licensee, the PT shall have up to three (3) representatives designated by
POZEN, attending, observing and participating in meetings of the PT at POZEN’s expense, such representatives having the relevant experience and skill appropriate for service on such team. Attendance of POZEN representatives at PT meetings shall
be agenda-driven, as determined in the sole discretion of Licensee. Licensee shall be entitled to have as many representatives serve as members of the PT as it desires. POZEN may replace its representatives on the PT at any time upon written notice
to Licensee. Licensee shall provide POZEN with office space at its facilities for such representatives to facilitate such participation; provided, that such representatives shall comply with all policies and reasonable restrictions imposed by
Licensee and provided to POZEN in writing. Upon prior written consent of Licensee, which consent will not be unreasonably withheld, a reasonable number of employees, consultants, representatives or advisors of POZEN who are not POZEN’s PT
representatives may attend PT meetings as observers; provided, that such persons shall comply with all policies and reasonable restrictions imposed by Licensee and provided to POZEN in writing. 

(b) Chairpersons. The product director designated by Licensee for the Initial POZEN Product will chair the PT (“PT
Chair”). 
 (c) Meetings. The PT will hold meetings when called by the PT Chair. Meetings may be held in person or by means
of telecommunication (telephone, video, or web conference). Face-to-face PT meetings that require POZEN attendance will be convened on an as-needed basis as mutually agreed by Licensee and POZEN, but in any event, at least twice per annum. The
location of these meetings, will be based on business requirements and determined by mutual agreement between Licensee and POZEN. Following any PT meeting, the PT Chair will be responsible for preparing and issuing minutes of such meeting within
fifteen (15) Business Days thereafter. When POZEN has participated in the meeting, such minutes will not be finalized until a representative of the PT designated by each Party has reviewed and confirmed the accuracy of such minutes in writing.
If a disagreement regarding the accuracy of such minutes cannot be resolved, the minutes will reflect such disagreement. 
 2.2.2
JSC. 
 (a) Membership. Each Party will designate an equal number of representatives, but in no event less than three
(3) each, with appropriate expertise to serve as 

  
 - 12 - 

 
members of the JSC. Each Party may replace its representatives on the JSC at any time upon written notice to the other Party. 

(b) Co-Chairpersons. One of each Party’s representatives to the JSC will be designated as a co-chairperson. The co-chairpersons
will be responsible for calling meetings and preparing and circulating an agenda in advance of each meeting, and preparing minutes of each meeting. 

(c) Meetings. The JSC will hold meetings at least once every Calendar Quarter, or more frequently as the Parties may agree with at
least two meetings held in person annually. Subject to the preceding sentence, meetings may be held in person at locations to be determined by the mutual agreement of the Parties or by means of telecommunication (telephone, video, or web
conferences). Following any JSC meeting, the co-chairpersons will be responsible for preparing and issuing minutes of such meeting within fifteen (15) Business Days thereafter. Such minutes will not be finalized until a representative of each
Party has reviewed and confirmed the accuracy of such minutes in writing. If a disagreement regarding the accuracy of such minutes cannot be resolved, the minutes will reflect such disagreement. 

2.2.3 Limitations of Powers. The PT and JSC will have only such powers as are specifically delegated to them hereunder and will not be a
substitute for the rights of the Parties. Without limiting the generality of the foregoing, the PT and JSC will not have any power to amend this Agreement. Any amendment to the terms and conditions of this Agreement may only be implemented pursuant
to Section 15.6 (Entire Agreement; Modifications) below. 
 2.2.4 Expenses. Each Party will be responsible for all of its own
expenses of participating in the PT and JSC. 
 2.3 Decision-Making. 

2.3.1 PT Decisions. Subject to the terms of this Section 2.3 (Decision-Making), the PT will act by decision of the PT Chair. If a
POZEN representative objects to any decision, then such dispute will be referred to the JSC. 
 2.3.2 JSC Decisions. Subject to the
terms of this Section 2.3 (Decision-Making), the JSC will take action by unanimous vote with each Party having a single vote, irrespective of the number of representatives actually in attendance at a meeting, or by a written resolution signed
by the designated representatives of each of the Parties. If the JSC fails to reach unanimous consent on a particular matter within [...***...] ([...***...]) Business Days of POZEN
having requested a formal vote on such matter (or any earlier period mutually agreed to by the Parties if a delay may reasonably be anticipated to have an adverse effect on the Commercialization of the Initial POZEN Product in the Territory), then
such dispute will be subject to the resolution procedures described in Section 2.3.3 (Dispute Resolution) below. 
 2.3.3 Dispute
Resolution. In the event of any dispute in the JSC that is not resolved pursuant to the terms of Section 2.3.2 (JSC Decisions), either Party may provide written notice of such failure (a “Notice of Disagreement”) to the
Chief Executive Officer of the other Party (or his or her designee). The Chief Executive Officers or designees of each of the Parties will meet at least once in person or by means of live telecommunication (telephone, video, or 

  
  

***Confidential Treatment Requested 

- 13 - 

 
web conferences) to discuss the matter on which the JSC failed to reach unanimous consent and use their good faith efforts to resolve the matter within [...***...] ([...***...])
Business Days after receipt of the Notice of Disagreement by the applicable Chief Executive Officer of a Party. If any such disagreement is not resolved by the Chief Executive Officers or designees within such [...***...] ([...***...])
Business Day period, then the Chief Executive Officer or designee of Licensee will have the final decision-making authority with respect to disagreement relating to any and all matters. 

2.3.4 Limitation. Notwithstanding this Section 2.3 (Decision-Making), any dispute regarding the interpretation of this Agreement,
the performance or alleged nonperformance of a Party’s obligations under this Agreement, or any alleged breach of this Agreement will be resolved in accordance with the terms of Section 15.4 (Governing Law; Dispute Resolution). 

2.4 Operating Principles. Promptly after the Amended and Restated Effective Date, the Parties will agree in writing on operating
principles to guide the conduct of the PT and JSC. To the extent there is any conflict between such operating principles and the terms and conditions of the Agreement, then the Agreement will control. 

3. [INTENTIONALLY OMITTED] 
 4. REGULATORY MATTERS

 4.1 Responsibilities. Licensee shall have the sole right at its own expense to (a) seek any Marketing Approval for Products
in the Territory, including Marketing Approval for claims not obtained in the initial NDA Approval for the Initial POZEN Product, and (b) prepare or make any filings or submissions to, or otherwise communicate with, any Regulatory Authority in
the Territory regarding Products. For clarity, Licensee shall own all Marketing Approvals and Regulatory Materials pertaining to Products in the Territory. Without limiting the foregoing, as owner of the NDA Approval for the Initial POZEN Product,
Licensee will be the sole owner of all data exclusivity protection related to the Initial POZEN Product in the Territory as provided by Applicable Law. 

4.2 Access to Filings. Licensee and its Affiliates will have the right of cross-reference to all NDAs or other filings made by or on
behalf of POZEN for the purpose of prosecuting Marketing Approval applications for Products in the Territory, and POZEN and its Affiliates will, or will use reasonable efforts to cause their licensees to, take all such reasonable actions to allow
such cross-reference. 
 4.3 Interactions with Regulatory Authorities. 

4.3.1 Consultation. Each Party will consult with the other Party regarding (and provide copies of materials prior to any submission to a
Regulatory Authority and materials after receipt from a Regulatory Authority), and keep such other Party reasonably and regularly informed of, the status of the preparation of all Regulatory Materials in the Territory, review of such materials by
the relevant Regulatory Authority in the Territory, and Marketing Approvals received for the Initial POZEN Product in the Territory. 

  
  

***Confidential Treatment Requested 

- 14 - 

 4.3.2 Communications. Except as may be required by Applicable Law, only Licensee will
communicate regarding POZEN Products, including the Initial POZEN Product, with any Regulatory Authority in the Territory. If POZEN is required to make such a communication by a Regulatory Authority, then POZEN will [...***...]. 

4.4 Exchange of Know-How; Information Sharing. As of the Amended and Restated Effective Date, each Party has provided to the other
Party copies of all Know-How in its possession relating to the Initial POZEN Product, including, without limitation, procedures, formulations, manufacturing reports, pre-clinical and clinical protocols and data, regulatory filings, and toxicology
reports with respect to the Initial POZEN Product, including any final versions of any study reports and any drafts outstanding of any study reports, all to the extent reasonably required for a Party to perform its obligations under this Agreement.
Each Party will provide to the other Party copies of any Know-How that comes into its possession on or after the Amended and Restated Effective relating to the Initial POZEN Product, including, without limitation, procedures, formulations,
manufacturing reports, pre-clinical and clinical protocols and data, regulatory filings, and toxicology reports with respect to the Initial POZEN Product, including any final versions of any study reports and any drafts then-outstanding of any study
reports, all to the extent reasonably required for a Party to perform its obligations under this Agreement. In addition, each Party will provide the other Party, in a timely manner, with copies of, and all information received by it pertaining to,
notices, questions, actions and requests from or by Regulatory Authorities with respect to the Initial POZEN Product in the Territory, or the testing, Manufacture, packaging, distribution or facilities in relation thereto, including any notices of
non-compliance with laws in connection with the Initial POZEN Product (e.g., warning letters or other notices of alleged non-compliance), audit notices, notices of initiation by Regulatory Authorities of investigations,
inspections, detentions, seizures or injunctions concerning the Initial POZEN Product (or its manufacture, distribution, or facilities connected thereto), notice of violation letters (i.e., an untitled letter), warning letters,
service of process or other inquiries. Except as otherwise set forth in this Agreement or to comply with Applicable Law, [...***...]. 

4.5 Regulatory Audits. If a Regulatory Authority in the Territory desires to conduct an inspection or audit of a Party’s facility,
or a facility under contract with a Party, with regard to a POZEN Product, then such Party will promptly notify the other Party and permit and cooperate with such inspection or audit, and will cause the contract facility to permit and cooperate with
such Regulatory Authority and such other Party during such inspection or audit. Licensee will have the right upon request (which request shall not be unreasonably withheld) to have a representative observe such inspection or audit with respect to a
POZEN facility, or a facility under contract with POZEN. Following receipt of the inspection or audit observations of such Regulatory Authority (a copy of which the audited Party will immediately provide to the other Party), the audited Party will
prepare the response to any such observations, and will provide a copy of such response to the other Party. The audited Party agrees to conform its activities under this Agreement to any commitments made in such a response, except to the extent it
believes in good faith that such commitments violate Applicable Laws. 
 4.6 Adverse Event Reporting. 

  
  

***Confidential Treatment Requested 

- 15 - 

 4.6.1 Licensee will maintain and will be the recognized holder of the safety database for
AE and SAE reports related to POZEN Products in the Territory. Direct access to this database will not be granted to POZEN. Upon request, all reasonable assistance will be provided by either Party in responding to safety inquiries in the Territory.

 4.6.2 Each Party shall keep the other Party informed of notification of any action by, or notification or other information which
it receives (directly or indirectly) from any Regulatory Authority in the Territory which: (i) raises any material concerns regarding the safety or efficacy of the Initial POZEN Product; (ii) indicates or suggests a potential material
liability for either Party to Third Parties arising in connection with the Initial POZEN Product; (iii) is reasonably likely to lead to a “Dear Doctor” letter, recall or market withdrawal of the Initial POZEN Product;
(iv) relates to the Initial POZEN Product, Regulatory Materials, Promotional Materials, samples, package inserts, the indications, labeling, expedited and periodic Adverse Event Reports, medical inquiries, Initial POZEN Product complaints, this
Agreement, or (v) is otherwise important to the Development and/or Commercialization of the Initial POZEN Product. 
 4.7 Records
and Reports. Each Party will retain all records required by Applicable Law to be maintained in connection with such Party’s performance of Development activities under this Agreement.  

5. DEVELOPMENT AND COMMERCIALIZATION 

5.1 Development and Commercialization. As between the Parties, Licensee will be solely responsible for the Development and
Commercialization of POZEN Products in the Territory during the Term. 
 5.2 Regulatory Obligations. Licensee will own and
maintain all regulatory filings and Marketing Approvals in the Territory for POZEN Products, including all INDs and NDAs for the Initial POZEN Product. As between the Parties, but subject to
[...***...], Licensee will be solely responsible for all activities in connection with maintaining Marketing Approvals required for the Commercialization and manufacture of POZEN Products in the
Territory, including communicating and preparing and filing all reports (including Adverse Event reports) with the applicable Regulatory Authorities in the Territory.  

5.3 Performance; Diligence. Licensee will use Diligent Efforts to Commercialize a POZEN Product in the Territory. The foregoing
Diligent Efforts requirement will apply only to one POZEN Product in the Territory, irrespective of the number of POZEN Products Licensee elects to Develop and Commercialize, and Licensee may elect to fulfill its Diligent Efforts obligation in the
Territory in respect to any POZEN Product of its choice in the exercise of its reasonable and good faith judgment. Licensee will have the right to Develop and Commercialize Products during the Term in the Territory, for so long as Licensee is using
Diligent Efforts to Commercialize at least one POZEN Product in accordance with this Section 5.3, it being understood that the Parties intend for Licensee to focus its initial efforts on the Commercialization of the Initial POZEN Product in the
Territory. 

  
  

***Confidential Treatment Requested 

- 16 - 

 5.4 Threatened Removal. In the event that any governmental authority threatens or
initiates any action to remove any POZEN Product from the market in the Territory, Licensee will promptly notify POZEN of such communication. Any voluntary recall or withdrawal of any POZEN Product in the Territory will be at Licensee’s sole
discretion and expense. Before Licensee initiates a recall or withdrawal in the Territory, the Parties will promptly and in good faith discuss the reasons therefor; provided, that such discussions do not delay the recall or withdrawal. In the event
of any recall or withdrawal of any POZEN Product in the Territory, Licensee will implement any necessary action, with assistance from POZEN as reasonably requested by Licensee. 

5.5 Compliance. Each Party will comply with all Applicable Laws relating to activities performed or to be performed by such Party (or
its Affiliates or contractors) under or in relation to the Commercialization of the Initial POZEN Product in the Territory pursuant to this Agreement. Each Party represents, warrants and covenants to the other Party that as of the Effective Date and
during the Term, such Party and its Affiliates have adequate policies and procedures in place: (i) to ensure their compliance with such laws; (ii) to bring any non-compliance therewith by any of the foregoing entities to its attention; and
(iii) to promptly remedy any such non-compliance.  
 5.6 Branding; Trademarks; Domain Names; Trade Dress; Logos. 

5.6.1 Responsibilities. As between the Parties, Licensee will select all Product Trademarks for use on or in connection with POZEN
Products in the Territory, will be the sole owner of the Product Trademarks in the Territory and, except with respect to the Vimovo Trademarks, which are addressed in the last sentence of this Section 5.6.1, will be responsible for the filing,
prosecution, maintenance and defense of all registrations of the Product Trademarks in the Territory, and will be responsible for the payment of any costs relating to filing, prosecution, maintenance and defense of the Product Trademarks in the
Territory. The Parties acknowledge and agree that AstraZeneca AB (or its Affiliate) is the sole owner of any Vimovo Trademark that may be used by Licensee in connection with POZEN Products in the Territory pursuant to a separate agreement between
Licensee and AstraZeneca AB, and that the filing, prosecution, maintenance and defense of all registrations of the Vimovo Trademarks in the Territory shall be governed by the terms of such separate agreement. 

5.6.2 Use. Licensee will use the Product Trademarks in connection with the Commercialization of POZEN Products hereunder. The packaging,
Promotional Materials and Product Labeling for POZEN Products will carry the POZEN House Marks only if and to the extent required by Applicable Law. 

5.6.3 Licensee Marks. Licensee reserves all rights in the Licensee House Marks. POZEN acknowledges Licensee’s exclusive right,
title and interest in and to such trademarks and acknowledges that nothing herein will be construed to accord to POZEN any rights in such trademarks. POZEN agrees not to use or file any application to register any trademark or trade name that is
confusingly similar to any Product Trademarks or Licensee House Mark. 

  
 - 17 - 

 5.6.4 POZEN Marks. POZEN reserves all rights in the POZEN House Marks not expressly
granted to Licensee in this Agreement. Licensee acknowledges POZEN’s exclusive right, title and interest in and to the POZEN House Marks and acknowledges that nothing herein will be construed to accord to Licensee any rights in such trademarks
except as expressly provided herein. Licensee further acknowledges that its use of the POZEN House Marks will not create in Licensee any right, title or interest in such trademarks, and that all use of such trademarks and the goodwill generated
thereby will inure solely to the benefit of POZEN. Licensee agrees not to use or file any application to register any trademark or trade name that is confusingly similar to any POZEN House Mark. 

5.6.5 Promotional Materials. As between the Parties, Licensee will own all right, title and interest in and to any Promotional Materials
created by or on behalf of Licensee (or its Affiliates) relating to POZEN Product in the Territory, but excluding the POZEN House Marks. The PT will approve a standard template for use of the POZEN House Marks in Promotional Materials, and Licensee
will use the POZEN House Marks in accordance with approved template. 
 5.7 Commercial Supply. Licensee will be solely responsible,
at its own expense, for the Manufacture and supply of Licensee’s entire requirements of supplies of POZEN Product for Commercialization in the Territory.  

6. [INTENTIONALLY OMITTED] 
 7. LICENSES 

7.1 Licensed Technology. Subject to the terms and conditions of this Agreement, POZEN hereby grants to Licensee an exclusive (including
with regard to POZEN and its Affiliates), royalty-bearing license, with the right to grant sublicenses as described in Section 7.3 (Sublicenses), under the Licensed Technology to make, use, have made, sell, offer for sale, import and export
Products in the Field of Use in the Territory. For the avoidance of doubt, Licensee shall have no license or other right under the Licensed Technology to make, use, have made, sell, offer for sale, import, and export any product containing acetyl
salicylic acid (including salts and derivatives thereof). 
 7.2 Trademarks. Subject to the terms and conditions set forth in
this Agreement, POZEN hereby grants to Licensee a license to use the POZEN House Marks in connection with the Commercialization of POZEN Products in the Field of Use in the Territory. 

7.3 Sublicenses. Licensee may grant a sublicense, option to sublicense, or any other right relating to any Licensed Technology to any
of its Affiliates without the right to grant further sublicense rights to any Third Party. Licensee may grant a sublicense, option to sublicense, or any other right relating to any Licensed Technology to any Third Party solely as provided in this
Section 7.3 (Sublicenses). Licensee may enter into Sublicense Agreements only with POZEN’s prior consent. In order for rights under Licensed Technology to be validly granted to a Sublicensee, the Sublicense Agreement with such Sublicensee
must be consistent with the following terms and conditions of this Agreement, and will include provisions for the benefit of POZEN corresponding to Section 11 (Confidentiality), 14 (Limitation of Liability), 8.2

  
 - 18 - 

 
(Payments and Sales Reporting), and 8.3 (Records; Audit). Except as set forth in that certain side letter agreement between POZEN and AstraZeneca AB dated September 16, 2013,
(a) Licensee will use Diligent Efforts to (i) procure the performance by any Sublicensee of the terms of each such Sublicense Agreement, and (ii) ensure that any Sublicensee will comply with the applicable terms and conditions of this
Agreement and (b) Licensee hereby guarantees the performance of its Affiliates and Sublicensees that are sublicensed as permitted herein, and the grant of any such sublicense will not relieve Licensee of its obligations under this Agreement,
except to the extent they are satisfactorily performed by such Affiliate or Sublicensee. Notwithstanding the foregoing, Licensee will have the right to sell POZEN Products through any distributors or sub-distributors of its choice, without the need
to obtain prior consent from POZEN, in carrying out its Commercialization activities under this Agreement. 
 7.4 Reservation of Rights;
No Implied Licenses.  
 (a) POZEN retains rights under the Licensed Technology to the extent necessary to perform its
obligations under this Agreement. Except for the rights specifically granted in this Agreement, POZEN reserves all rights to the Licensed Technology. No implied licenses are granted under this Agreement. In particular POZEN is not by this Agreement,
by implication or otherwise, granted any license or other right relating to Esomeprazole, Nexium or the Nexium Business or any Esomeprazole based products or any products containing acetyl salicylic acid (including salts and derivatives thereof) or
any right in relation to any patent, trademark or other intellectual property right belonging to Licensee or any of its Affiliates, and likewise Licensee is not by this Agreement, by implication or otherwise, granted any license or other right under
the Licensed Technology relating to any products containing acetyl salicylic acid (including salts and derivatives thereof) or any right in relation to any patent, trademark or other intellectual property right belonging to POZEN or any of its
Affiliates, in each case, except as expressly set forth in this Agreement. 
 (b) Licensee understands that POZEN has retained rights
to the Products outside the Territory and has licensed such rights to a Person under the ROW Agreement (the “ROW Party”). 

7.5 Restrictive Covenant. Licensee hereby covenants and agrees not to use any Licensed Technology, nor grant any Third Party any
license or right under any Licensed Technology, other than as expressly permitted in this Agreement. The Parties agree that nothing in this Agreement restricts or prohibits Licensee from by itself or with Third Parties exploiting any products,
including without limitation any products containing non-steroidal anti-inflammatory drugs (e.g., acetyl salicylic acid and esters and derivatives thereof); provided, that Licensee shall not use or practice Licensed Technology
in connection with the development, manufacture or commercialization of any product that is not a Product, and nothing requires Licensee to compensate POZEN if Licensee so exploits such products. 

8. FINANCIAL TERMS 
 8.1
Royalties. 

  
 - 19 - 

 8.1.1 Royalty Rate. Subject to the terms and conditions of this Agreement, Licensee will
pay to POZEN royalties based on the aggregate annual Net Sales of Products sold by Licensee, its Affiliates or Sublicensees, at the rate of 10% of aggregate Net Sales of Products sold in the Territory.  

8.1.2 Royalty Term. Licensee acknowledges that it will continue to enjoy substantial benefit from its license under, and the transfer
to Licensee of certain elements of, the Licensed Technology pursuant to this Agreement (including the Licensed Know-How and the regulatory data to be provided to Licensee pursuant to this Agreement) as well as from Licensee’s own development of
technology derived from the practice of such license and Licensee’s use of such Licensed Technology, even after expiration of all Valid Claims of the Licensed Patents covering the composition of matter, manufacture, use or sale of POZEN Product
in the Territory. Accordingly, subject to the terms of Section 8.1.3 (Rate Step Down for Competing Product Entrants), Licensee’s royalty payment obligations under this Section 8.1 (Royalties) will commence upon First Commercial Sale
of a Product in the Territory and will expire upon the later of: (i) expiration of the last-to-expire Valid Claim of the Licensed Patents that, but for the licenses granted in this Agreement, would be infringed by the sale of such Product in
the Territory, and (ii) ten (10) years after the First Commercial Sale of such Product in the Territory (such period ending at the later of the periods set forth in clause (i) and (ii) above, the “Royalty Term”).

 8.1.3 Rate Step Down For Competing Product Entrants. With respect to any particular Product in the Territory, if in any
Calendar Quarter there is a Market Reduction of such Product (based on prescription market data published by IMS Health, Scott-Levin, or such other industry standard source as the Parties may agree), then the royalty rates which would otherwise
apply to Net Sales of such Product during such Calendar Quarter will be reduced to [...***...] percent ([...***...]%). Such reduced royalty rates will continue in effect, on a
Product-by-Product basis, until expiration of the applicable Royalty Term. As used in this Section 8.1.3, the term “Market Reduction” of a Product in a Calendar Quarter occurs when (i) the cumulative share achieved by
Competing Products for such Product commercialized by Third Parties in such [...***...] of the [...***...] in the Territory of the Product and Competing Products and (ii) the sales of the Product(s) in such [...***...] are
reduced by [...***...] to the [...***...] in which the [...***...] of a Competing Product occurred. The example set forth in Schedule 8.1.3 illustrates the application of this Section 8.1.3. 

8.1.4 Third Party Payments. If Licensee or a Sublicensee determines that a license to certain Third Party technology is reasonably
necessary for the successful Development, Manufacture or Commercialization of a Product in the Territory, then Licensee will notify POZEN in writing of such determination. The Parties will consult in good faith regarding the need for such Third
Party technology and, subject to POZEN’s consent (not to be unreasonably withheld, conditioned or delayed), Licensee (or Sublicensee, if applicable) will negotiate the terms on which such a Third Party license would be granted to Licensee and
will serve as the primary point of contact with the applicable Third Party licensor following the execution of the license agreement. The royalties required to be paid by Licensee with respect to a Product pursuant to Section 8.1 (Royalties)
shall be subject to a reduction by Licensee in an 

  
  

***Confidential Treatment Requested 

- 20 - 

 
amount equal to [...***...] ([...***...]%) of the amount of [...***...] that are [...***...] under such
[...***...] in the [...***...] for the [...***...] of such [...***...] during the [...***...]; provided, that (i) [...***...] of the [...***...] of such [...***...] pursuant to [...***...]
for such [...***...], and (ii) if such [...***...] is a [...***...] (i.e., [...***...] for such [...***...]). For clarity, and notwithstanding anything to the contrary in this Agreement, AstraZeneca AB and
its Affiliates shall be solely responsible for any Third Party payment obligations it may have to Merck & Co., Inc. or its affiliates, without any offset or deduction. Any amount of Third Party Royalties that may, pursuant to the preceding
paragraph be used to reduce royalties due hereunder, in any Calendar Quarter, but are not so used as a result of the limitation described in clause (i) of this paragraph may be carried over and used for further reduction in any succeeding
royalty payment due for such Product. 
 8.1.5 [...***...]. 

8.2 Payments and Sales Reporting. 

8.2.1 Sales Reporting. Licensee will provide POZEN, within [...***...] ([...***...]) of the end of each Calendar Quarter,
with a report setting forth, on a Product-by-Product basis, the amount of gross sales of each Product in the Territory, a calculation of Net Sales and a calculation of the amount of royalty payment due on such Net Sales, provided that Licensee shall
use reasonable efforts to provide such report as soon as practicable to accommodate POZEN’s SEC filing requirements and to provide such reports in a shorter time period than the periods specified above if Licensee has such reports available for
its own internal purposes. If any payment reduction is claimed by Licensee under this Agreement from the full royalty rates set forth in Section 8.1 (Royalties), then the report will set forth in detail the claimed reduction and the related
facts.  
 8.2.2 Payment Timing. Licensee will make royalty payments to POZEN within [...***...] ([...***...])
days of the last day of each Calendar Quarter for which such payments are due under Section 8.1 (Royalties). 
 8.2.3 Payment
Method. All amounts due hereunder will be paid in United States Dollars by wire transfer in immediately available funds to the following account, or such other account as may be designated in writing by POZEN: 

 

			
	Receiving bank name:	  	[...***...]
	Receiving bank address:	  	[...***...]
	ABA routing number (1):	  	[...***...] (1)—required for domestic transfers
	SWIFT BIC address (2):	  	[...***...] (2)—required for international transfers
	For credit to the account of:	  	POZEN Inc.

  
  

***Confidential Treatment Requested 

- 21 - 

			
	For credit to account number:	  	[...***...]

 8.2.4 Currency. All payments required under this Article 8 shall be made in U.S. Dollars. 

8.2.5 Late Payments. If a Party does not receive payment of any sum due to it on or before the due date, simple interest will
thereafter accrue on the sum due to such Party until the date of payment at the per annum rate of [...***...] percent ([...***...]%) over the then-current [...***...] quoted by Citibank in New York City, or the maximum rate
allowable by Applicable Law, whichever is lower. 
 8.3 Records; Audit. Licensee will maintain complete and accurate records
in sufficient detail to permit POZEN to confirm the accuracy of the calculation of payments under this Agreement. Upon reasonable prior notice, such records will be available during regular business hours of Licensee for a period of
[...***...] ([...***...]) calendar years following the year in which such records were created, for examination at POZEN’s expense, and not more often than once each calendar year, by an independent certified public accountant
selected by POZEN and reasonably acceptable to Licensee, for the sole purpose of verifying the accuracy of the financial reports furnished by Licensee pursuant to this Agreement. Any such auditor will not disclose Licensee’s Confidential
Information, except to the extent such disclosure is necessary to verify the accuracy of the financial reports furnished by Licensee or the amount of payments due by Licensee under this Agreement. Any amounts shown to be owed but unpaid will be paid
within [...***...] ([...***...]) days from the accountant’s report, plus interest (as set forth in Section 8.2.5 (Late Payments)) from the original due date. Any amounts determined to be overpaid will be refunded within
[...***...] ([...***...]) days from the accountant’s report. POZEN will bear the full cost of such audit unless such audit discloses an underpayment of the amount actually owed during the applicable calendar year of more than
[...***...] percent ([...***...]%), in which case Licensee will bear the full cost of such audit. 
 8.4 Taxes.

 8.4.1 General. The royalties, milestones and other amounts payable by one Party to the other Party pursuant to this Agreement
or the Three-Party Agreement (“Payments”) shall not be reduced on account of any taxes unless required by Applicable Law. The Party receiving any Payment shall be responsible for paying any and all taxes (other than withholding
taxes or deduction of tax at source required by Applicable Law to be paid by the paying Party) levied on account of, or measured in whole or in part by reference to, any Payments it receives. The paying Party shall deduct or withhold from the
Payments any taxes that it is required by Applicable Law to deduct or withhold. Notwithstanding the foregoing, if the Party receiving payment is entitled under any applicable tax treaty to a reduction of rate of, or the elimination of, applicable
withholding tax, it may deliver to the paying Party or the appropriate governmental authority (with the assistance of the paying Party to the extent that this is reasonably required and is expressly requested in writing) the prescribed forms
necessary to reduce the applicable rate of withholding tax or to relieve the paying Party of its obligation to withhold tax, and the paying Party shall apply the reduced rate of withholding tax, or dispense with withholding tax, as the case may be,
provided that the paying Party has received evidence, in a form satisfactory to the paying Party, of the other Party’s delivery of all applicable forms (and, if necessary, its receipt of 

  
  

***Confidential Treatment Requested 

- 22 - 

 
appropriate governmental authorization) at least [...***...] ([...***...]) days prior to the time that the Payments are due. If,
in accordance with the foregoing, the paying Party withholds any amount, it shall pay to the other Party the balance when due, make timely payment to the proper taxing authority of the withheld amount, and send to the other Party proof of such
payment within [...***...] ([...***...]) days following that payment. 
 8.4.2 Indirect Taxes. Notwithstanding anything
contained in Section 8.4.1 (General), this Section 8.4.2 (Indirect Taxes) shall apply with respect to Indirect Taxes. All Payments are exclusive of Indirect Taxes. If any Indirect Taxes are chargeable in respect of any Payments, the paying
Party shall pay the Indirect Taxes at the applicable rate in respect of any such Payments following the receipt of an Indirect Taxes invoice in the appropriate form issued by the Party receiving Payments in respect of those Payments, such Indirect
Taxes to be payable on the due date of the payment of the Payments to which such Indirect Taxes relate. 
 9. INTELLECTUAL PROPERTY 

9.1 Prosecution and Maintenance of Licensed Patents. POZEN will be responsible for the preparation, filing, prosecution and maintenance
of the Licensed Patents (other than Joint Patents), at its own expense. POZEN will provide a copy of all proposed filings at least [...***...] ([...***...]) days in advance of the filing date and will consider in good faith the requests
and suggestions of Licensee with respect to filing and prosecuting the Licensed Patents and will keep Licensee promptly informed of progress with regard to the preparation, filing, prosecution and maintenance of Licensed Patents. In the event that
POZEN desires to abandon any Licensed Patent, POZEN will provide reasonable prior written notice to Licensee of such intention to abandon (which notice will, in any event, be given no later than [...***...] ([...***...]) days prior to
the next deadline for any action that may be taken with respect to such Licensed Patent with the U.S. Patent & Trademark Office), and Licensee will have the right to assume responsibility for such Licensed Patent. For clarity, any Patent
with Valid Claims solely directed to any product containing acetyl salicylic acid (including salts and derivatives thereof) is not a Licensed Patent; therefore, Licensee will have no right to assume responsibility for such Patent as provided under
this Section 9.1 should Pozen decide to abandon such Patent. 
 9.2 Prosecution and Maintenance of Joint Patents.
Licensee will be responsible for the preparation, filing, prosecution and maintenance of Joint Patents, at its own expense. Licensee will provide to POZEN a copy of all proposed filings at least [...***...] ([...***...]) days in advance
of the filing date and will consider in good faith the requests and suggestions of POZEN with respect to filing and prosecuting the Joint Patents and will keep POZEN promptly informed of progress with regard to the preparation, filing, prosecution
and maintenance of Joint Patents. In the event that Licensee desires to abandon any Joint Patent, Licensee will provide reasonable prior written notice to POZEN of such intention to abandon (which notice will, in any event, be given no later than
[...***...] ([...***...]) days prior to the next deadline for any action that may be taken with respect to such Joint Patent with the U.S. Patent & Trademark Office), and POZEN will have the right to assume responsibility for
such Joint Patent.  
 9.3 Ownership of Inventions. Inventorship of Inventions will be determined in accordance with the rules
of inventorship under United States patent laws. Subject to the licenses granted under this Agreement, as between the Parties, Licensee will own all Licensee 

  
  

***Confidential Treatment Requested 

- 23 - 

 
Inventions, POZEN will own all POZEN Inventions, and Joint Inventions will be owned jointly by Licensee and POZEN; provided, however, that during the Term of this Agreement:
(i) neither POZEN nor Licensee shall [...***...] other than as expressly provided in this Agreement, including Section 7.1 (Licensed Technology), without the consent of the other
Party, which consent shall not be unreasonably withheld, conditioned or delayed, and (ii) neither Party shall assign, pledge, encumber, license or otherwise transfer any of its rights in any Joint Invention or Joint Patent without the other
Party’s prior written consent, which consent shall not be unreasonably withheld, conditioned or delayed. Upon any expiration or termination of this Agreement, each Party will have the right to exploit, license and grant rights to sublicense
each such Joint Invention and Joint Patent, without any duty of accounting to the other Party, and each Party hereby consents, and agrees to consent, without payment of any further consideration or royalty, to the Joint Party’s exploitation and
licensing of said Joint Party’s interest in such Joint Invention or Joint Patent to Third Parties; provided, that nothing in this Section 9.3 gives either Party any right or license under any intellectual property rights Controlled by the
other Party other than Joint Inventions and Joint Patents, regardless of whether such rights are necessary in order to exploit the Joint Inventions and Joint Patents pursuant to this Section 9.3. The Parties acknowledge and agree that
AstraZeneca AB owns all AstraZeneca Inventions (as defined in the Original Agreement) conceived under the Original Agreement in the performance of activities undertaken pursuant to the Original Agreement solely by employees, agents, or independent
contractors of AstraZeneca AB, its Affiliates or sublicensees prior to the Amended and Restated Effective Date. 
 9.4
Disclosure. Each Party will promptly disclose to the other Party in writing, and will cause its Affiliates, agents, and independent contractors to so disclose to the other Party, the conception and reduction to practice of any Invention.

 9.5 Cooperation. Each Party acknowledges the importance of securing and maintaining effective patent protection for the
Licensed Technology and Joint Patents. Each Party agrees to cooperate fully in the preparation, filing, prosecution and maintenance of the Licensed Patents and Joint Patents and in the obtaining and maintenance of any patent extensions,
supplementary protection certificates and the like with respect to the Licensed Patents and Joint Patents. Such cooperation includes, but is not limited to: (a) executing all papers and instruments, or requiring its employees or contractors, to
execute such papers and instruments, so as to effectuate the ownership of Inventions set forth in Section 9.3 (Ownership of Inventions), and Patents in the Territory claiming or disclosing such Inventions, and to enable the other Party to apply
for and to prosecute patent applications in the Territory; and (b) promptly informing the other Party of any matters coming to such Party’s attention that may affect the preparation, filing, prosecution or maintenance of any such patent
applications. 
 9.6 Enforcement of Licensed Patents. 

9.6.1 Infringement by Third Parties. Licensee and POZEN will each, within [...***...] ([...***...]) Business Days of
learning of any alleged or threatened infringement of the Licensed Patents or Joint Patents, notify the other Party in writing. [...***...] will have the first right, but not the obligation, to prosecute any such infringement. If
[...***...] does not commence an infringement action against the alleged or threatened infringement (i) within [...***...] ([...***...]) days following the detection of the of alleged infringement, or
(ii) [...***...] ([...***...]) Business Days before the 

  
  

***Confidential Treatment Requested 

- 24 - 

 
time limit, if any, set forth in appropriate laws and regulations for filing of such actions, whichever comes first, then [...***...]
will so notify [...***...] promptly, and [...***...] may commence litigation with respect to the alleged or threatened infringement at its own expense. For clarity, any Patent with Valid Claims solely directed to any product containing
acetyl salicylic acid (including salts and derivatives thereof) is not a Licensed Patent; therefore, [...***...] will have no right to prosecute any infringement of such Patent under this Section 9.6.1. Notwithstanding anything in this
Section 9.6.1 to the contrary, [...***...] shall not have the right to prosecute an infringement action under this Section 9.6.1 unless such action involves a Product. 

9.6.2 Challenge by Third Parties. Licensee and POZEN will each notify the other Party in writing within [...***...]
([...***...]) Business Days of learning of any alleged or threatened opposition, reexamination request, action for declaratory judgment, nullity action, interference or other attack upon the validity, title or enforceability of the Licensed
Patents or Joint Patents by a Third Party. [...***...] will have the first right, but not the obligation, to defend any such challenge. If [...***...] does not commence Diligent Efforts to defend against the alleged or threatened
challenge (i) within [...***...] ([...***...]) days following the detection of the alleged challenge, or (ii) [...***...] ([...***...]) Business Days before the time limit, if any, set forth in appropriate laws and
regulations for making a filing in defense of such a challenge, whichever comes first, then [...***...] will so notify [...***...] promptly, and [...***...] may take action with respect to the alleged or threatened challenge at its
own expense. For clarity, any Patent with Valid Claims solely directed to any product containing acetyl salicylic acid (including salts and derivatives thereof) is not a Licensed Patent; therefore, [...***...] will have no right to defend any
challenge of such Patent under this Section 9.6.2. 
 9.6.3 Cooperation. In the event a Party brings an infringement
action pursuant to Section 9.6.1 (Infringement by Third Parties), the other Party will cooperate fully, including, if required to bring such action, the furnishing of a power of attorney or to join such action as a necessary party, executing
all papers and instruments, or requiring its employees or contractor, to execute such papers and instruments, so as to successfully prosecute any such actions. Neither Party will have the right to settle any patent infringement litigation under this
Section 9.6.3 (Cooperation) in a manner that could be reasonably expected to diminish the rights or interest of the other Party, or adversely effect the validity or enforceability of such other Party’s Patents, without the express written
consent of such other Party. The Party commencing the litigation will provide the other Party with copies of all pleadings and other documents filed with the court and will consider reasonable input from the other Party during the course of the
proceedings. 
 9.6.4 Recovery. Except as otherwise agreed by the Parties in connection with a cost sharing arrangement, any
recovery realized as a result of such litigation described in Section 9.6.1 (Infringement by Third Parties) (whether by way of settlement or otherwise) will be first allocated to reimbursement of unreimbursed legal fees and all litigation
expenses incurred by the Party initiating the proceeding, then toward reimbursement of any of unreimbursed legal fees and all litigation expenses of the other Party, and then the remainder will be divided between the Parties as follows:
(a) settlements, damages or other monetary awards recovered pursuant to a suit, action or proceeding brought by [...***...] will be [...***...] and subject to [...***...] set forth in [...***...];

  
  

***Confidential Treatment Requested 

- 25 - 

 
and (b) settlements, damages or other monetary awards recovered pursuant to a suit, action or proceeding brought by [...***...]
will be [...***...]. 
 9.7 Defense of Infringement Claims. If the manufacture, sale or use of a POZEN Product pursuant to this
Agreement results in any claim, suit, or proceeding by a Third Party alleging that such activities infringe a Third Party patent, or if a Third Party threatens such a claim, suit or proceeding, each Party will promptly notify the other Party
thereof. [...***...] will have the exclusive right to defend and control the defense of any such claim, suit or proceeding at its own expense, using counsel of its own choice; provided, that if any such proceedings involve
matters relating to the validity or enforceability of the Licensed Patents or Joint Patents, then the provisions of Section 9.6.3 (Cooperation) above shall apply. In any claim, suit or proceeding under this Section 9.7, [...***...]
will keep [...***...] reasonably informed of all material developments in connection with any such claim, suit, or proceeding; provided, that if [...***...] is named as a defendant in any such claim, suit or
proceeding, that [...***...] shall have the right to participate in the defense using counsel of its choice at its own expense. In any claim, suit or proceeding under this Section 9.7, [...***...] agrees to provide [...***...]
with copies of all pleadings filed in such action and to allow [...***...] reasonable opportunity to participate in the defense of the claims. 

9.8 Patent Term Extension and Supplementary Protection Certificate. Upon receiving Marketing Approval for a POZEN Product, the Parties
agree to coordinate the application for any patent term extension or supplementary protection certificates that may be available. The primary responsibility of applying for any extension or supplementary protection certificate will be the Party
having the right to make the application under the Applicable Law. The Party responsible for filing the application will keep the other Party fully informed of its efforts to obtain such extension or supplementary protection certificate. Each Party
will provide prompt and reasonable assistance, without additional compensation, to obtain such patent extension or supplementary protection certificate. The Party filing such request will pay all expenses in regard to obtaining the extension or
supplementary protection certificate. 
 9.9 Consequence of Patent Challenge. If Licensee or its Affiliates challenge the
validity or enforceability of any of the Licensed Patents by any opposition, reexamination request, action for declaratory judgment, nullity action, interference or other attack upon the validity, title or enforceability thereof before any
governmental agency, court or other similar adjudicative forum (any such proceeding, a “Patent Challenge”), such Patent Challenge shall give POZEN the right to terminate this Agreement as provided in Section 12.3 (Termination
for Material Breach) or to terminate all licenses granted under any of the Licensed Patents subject to such Patent Challenge; provided, that the foregoing provisions of this Section 9.9 (Consequence of Patent Challenge) will not apply in the
event that, prior to such Patent Challenge, POZEN or any of its licensees or assignees initiates or threatens litigation against, or makes claims or assertions against, Licensee or its Affiliates, Sublicensees or Third Party contractors, that allege
that any of such parties infringe a Licensed Patent. 
 9.10 Patent Certifications. 

9.10.1 Orange Book Listings. To the extent required or permitted by Applicable Law, Licensee will use Diligent Efforts to promptly list
and maintain with the applicable 

  
  

***Confidential Treatment Requested 

- 26 - 

 
Regulatory Authorities in the Territory during the Term correct and complete listings of applicable Licensed Patents for such POZEN Product, including all so called “Orange Book”
listings required under the Hatch-Waxman Act. [...***...]. 
 9.10.2
Hatch-Waxman Act. Notwithstanding Section 9.6.1 (Infringement by Third Parties) above, each Party will immediately give notice to the other Party of any notice it receives of certification filed under the Hatch-Waxman Act claiming that any
of the Licensed Patents is invalid, unenforceable or that any infringement will not arise from the manufacture, use or sale of the POZEN Product by a Third Party. If Licensee decides not to bring infringement proceedings against the entity making
such a certification with respect to any such Licensed Patents, Licensee will give notice to POZEN of its decision not to bring suit within [...***...] ([...***...]) Business Days after receipt of notice of such certification (or, if the
time period permitted by law is less than [...***...] ([...***...]) Business Days, within [...***...] of the time period permitted by law for Licensee to commence such action). POZEN may then, but is not required to, bring suit
against the Third Party that filed the certification. Any suit by either Party may be in the name of either or both Parties, as may be required by law. For this purpose, the Party not bringing suit will execute such legal papers necessary for the
prosecution of such suit as may be reasonably requested by the Party bringing suit. For clarity, any Patent with Valid Claims solely directed to any product containing acetyl salicylic acid (including salts and derivatives thereof) is not a Licensed
Patent; therefore, Licensee will have no right to bring infringement proceedings of such Patent under this Section 9.10.2. Notwithstanding anything in this Section 9.10.2 to the contrary, Licensee shall not have the right to bring an
infringement proceeding under this Section 9.10.2 unless such proceeding involves a POZEN Product.  
 9.11 Patent
Marking. Any POZEN Product marketed and sold by Licensee under this Agreement will be marked with appropriate patent numbers or indicia as permitted or required by law. The Parties agree to cooperate to reach a decision on the marking
requirements. 
 10. REPRESENTATIONS, WARRANTIES; COVENANTS 

10.1 POZEN Representations and Warranties. POZEN hereby warrants and represents to Licensee as of the Amended and Restated Execution
Date and the Amended and Restated Effective Date that POZEN is the sole and exclusive owner of the Licensed Patents and has the right to perform its obligations hereunder and to grant to Licensee the rights and licenses set forth in this Agreement
in and to the Licensed Technology. 
 10.2 Reciprocal Representations and Warranties. Each Party represents and warrants to
the other Party that: (a) this Agreement is a legal and valid obligation binding upon its execution and enforceable against it in accordance with its terms and conditions; and (b) the

  
  

***Confidential Treatment Requested 

- 27 - 

 
execution, delivery and performance of this Agreement by such Party has been duly authorized by all necessary corporate action, and the person executing this Agreement on behalf of
such Party has been duly authorized to do so by all requisite corporate actions. 
 10.3 DISCLAIMER OF WARRANTY. EXCEPT FOR THE
EXPRESS REPRESENTATIONS AND WARRANTIES SET FORTH IN SECTIONS 10.1 (POZEN WARRANTIES) AND 10.2 (RECIPROCAL REPRESENTATIONS AND WARRANTIES),EACH PARTY MAKES NO REPRESENTATIONS AND GRANTS NO WARRANTIES, EXPRESS OR IMPLIED, EITHER IN FACT OR BY
OPERATION OF LAW, BY STATUTE OR OTHERWISE, AND POZEN AND LICENSEE EACH SPECIFICALLY DISCLAIMS ANY OTHER WARRANTIES, WHETHER WRITTEN OR ORAL, OR EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF QUALITY OR MERCHANTABILITY, OR ANY WARRANTY AS TO THE
VALIDITY OR ENFORCEABILITY OF ANY PATENTS OR THE NON-INFRINGEMENT OF ANY INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES. 
 10.4 POZEN
Non-Compete. POZEN covenants that it will not at any time prior to the expiration of the Royalty Term, and will ensure that its Affiliates do not, directly or indirectly, develop or commercialize or license any Third Party to develop or
commercialize any product having a [...***...]. Without limiting Licensee’s rights under this Agreement or otherwise, in case of any breach of this 10.4 (POZEN Non-Compete), Licensee
will notify POZEN and, if such breach is not cured by POZEN within [...***...] ([...***...]) days after receipt of such notice, [...***...]. 

10.5 Other Covenants. 

10.5.1 POZEN will not enter into any agreement, whether written or oral with respect to, or otherwise assign, transfer, license, convey
or otherwise encumber its rights, title or interest in the Licensed Technology (including by granting any covenant not to sue with respect thereto) to any Person in a manner that is inconsistent with the rights and licenses granted to Licensee under
this Agreement. 
 10.5.2 Each Party will obtain from each of its Affiliates, sublicensees, employees and agents and from the
employees and agents of its Affiliates, sublicensees and agents who are or will be involved in the Development of the POZEN Products or of the Licensed Technology, rights to any and all inventions, information, and intellectual property rights
conceived in the course of performance of this Agreement, necessary to enable such Party to grant the licenses and other rights granted to the other Party under this Agreement. 

11. CONFIDENTIALITY. 
 11.1 Definition.
“Confidential Information” means information, including scientific and manufacturing information and plans, marketing and business plans, and financial and personnel matters relating to a Party or its present or future products, sales,
suppliers, customers, employees, investors or business, communicated by a Party (a “Disclosing Party”) to the other 

  
  

***Confidential Treatment Requested 

- 28 - 

 
Party (a “Receiving Party”) (a) after the Amended and Restated Effective Date in connection with this Agreement or the performance of its obligations hereunder or
(b) in connection with (i) that certain confidentiality agreement between POZEN and AstraZeneca AB dated as of March 27, 2006, (ii) that certain confidentiality agreement between POZEN and AstraZeneca AB dated as of June 15,
2006 or (iii) the Original Agreement, in each case ((i), (ii) and (iii)), except to the extent that such information relates exclusively to the exploitation of Products outside the Territory. Notwithstanding the foregoing or any other
provision of this Agreement to the contrary, during the Term, the Licensed Know-How will be deemed to be the Confidential Information of both Parties. 

11.2 Exclusions. Notwithstanding the foregoing, information of a Disclosing Party will not be deemed Confidential Information with
respect to a Receiving Party for purposes of this Agreement to the extent the Receiving Party can demonstrate by competent evidence that such information: 

11.2.1 was already known to the Receiving Party or its Affiliates, as evidenced by their written records, other than under an obligation
of confidentiality or non-use, at the time of disclosure to the Receiving Party; 
 11.2.2 was generally available or was
otherwise part of the public domain at the time of its disclosure to the Receiving Party; 
 11.2.3 became generally available
or otherwise became part of the public domain after its disclosure to the Receiving Party, through no fault of or breach of its obligations under this Section 11 (Confidentiality) by the Receiving Party; 

11.2.4 was disclosed to the Receiving Party or any of its Affiliates, other than under an obligation of confidentiality or non-use, by a
Third Party who had no obligation to the Party that controls such information and know-how not to disclose such information or know-how to others; or 

11.2.5 was independently discovered or developed by the Receiving Party or its Affiliates, as evidenced by their written records,
without the use of, and by personnel who had no access to, Confidential Information belonging to the Party that controls such information and know-how. 

11.3 Disclosure and Use Restriction. Except to the extent expressly authorized by this Agreement or otherwise agreed in writing by the
parties, the parties agree that, during the Term and for [...***...] ([...***...]) years thereafter, the Receiving Party will keep confidential and will not publish or otherwise disclose and
will not use for any purpose other than as expressly provided for in this Agreement any Confidential Information of the Disclosing Party. The Receiving Party may use such Confidential Information only to the extent required to accomplish the
purposes of this Agreement or in connection with the exercise of its rights hereunder. The Receiving Party will use at least the same standard of care as it uses to protect proprietary or confidential information of its own to ensure that its
employees, agents, consultants and other representatives do not disclose or make any unauthorized use of the Confidential Information. The Receiving 

  
  

***Confidential Treatment Requested 

- 29 - 

 
Party will promptly notify the other upon discovery of any unauthorized use or disclosure of the Confidential Information. 

11.4 Authorized Disclosure. A Receiving Party may disclose Confidential Information of a Disclosing Party to the extent that such
disclosure is: 
 11.4.1 made in response to a valid order of a court of competent jurisdiction or other governmental or regulatory
body of competent jurisdiction; provided, however, that such Receiving Party will have given notice to the Disclosing Party within [...***...] ([...***...]) Business Days of
receipt of such order and given the Disclosing Party a reasonable opportunity to quash such order and to obtain a protective order requiring that the Confidential Information and documents that are the subject of such order be held in confidence by
such court or governmental or regulatory body or, if disclosed, be used only for the purposes for which the order was issued; and provided, further, that if a disclosure order is not quashed or a protective order is not obtained, the
Confidential Information disclosed in response to such court or governmental order will be limited to that information which is legally required to be disclosed in response to such court or governmental order; 

11.4.2 otherwise required by law; provided, that the Disclosing Party will provide the Receiving Party with notice of such
disclosure at least [...***...] ([...***...]) days in advance thereof to the extent practicable and take reasonable steps as requested by the Disclosing Party to protect the Disclosing Party’s rights; 

11.4.3 made by a Receiving Party, in connection with the performance of this Agreement, (a) to Affiliates, employees, consultants,
representatives or agents, each of whom prior to disclosure must be bound by obligations of confidentiality and non-use at least equivalent in scope to those set forth in this Section 11 (Confidentiality) or (b) to Regulatory Authorities
in the Territory (provided, that in the case of disclosures to Regulatory Authorities, the Receiving Party will, to the extent practicable, provide the Disclosing Party with notice of such disclosure at least [...***...]
([...***...]) days in advance thereof and will reasonably consider any comments received from the Disclosing Party); 
 11.4.4
made by a Receiving Party to existing or potential acquirers or merger candidates; potential sublicensees or collaborators (to the extent contemplated hereunder); investment bankers; existing or potential investors, venture capital firms or
other financial institutions or investors for purposes of obtaining financing; or Affiliates, each of whom prior to disclosure must be bound by obligations of confidentiality and non-use at least equivalent in scope to those set forth in this
Section 11 (Confidentiality); or 
  
 11.4.5made by
the Receiving Party with the prior written consent of the Disclosing Party. 
 11.5 Use of Name. Neither Party may make public use of
the other Party’s name except (a) in connection with announcements and other disclosures relating to this Agreement and the activities contemplated hereby as permitted in Section 11.6 (Press Releases), (b) as required by
Applicable Law, and (c) otherwise as agreed in writing by such other Party. 
 11.6 Press Releases. 

  
  

***Confidential Treatment Requested 

- 30 - 

 11.6.1 On or after the Amended and Restated Effective Date of this Agreement at a mutually
agreed time, each Party (including, for clarity, Horizon as assignee of Licensee in connection with the Divestiture) will issue a mutually agreed press release announcing the existence of this Agreement each in the form and substance to be mutually
agreed upon in advance. For subsequent press releases and other written public disclosures relating to this Agreement or the Parties’ relationship hereunder (each, a “Public Disclosure”), each Party will use reasonable efforts
to submit to the other Party a draft of such Public Disclosures for review and comment by the other Party at least [...***...] ([...***...]) Business Days prior to the date on which such
Party plans to release such Public Disclosure, and in any event will submit such drafts at least [...***...] prior to the release of such Public Disclosure, and will review and consider in good faith any comments provided in response.

 11.6.2 If a Party is unable to comply with the foregoing [...***...] notice requirement because of a legal obligation or
stock exchange requirement to make more rapid disclosure, such Party will not be in breach of this Agreement but will in that case provide notice as promptly as practicable under the circumstances. 

11.6.3 A Party may publicly disclose, without regard to the preceding requirements of this Section 11.6 (Press Releases),
information that was previously disclosed in a Public Disclosure that was in compliance with such requirements. 
 11.7 Terms of
Agreement to be Maintained in Confidence. The Parties agree that the terms of this Agreement are confidential and will not be disclosed by either Party to any Third Party (except to a Party’s professional advisors, including without
limitation accountants, financial advisors, and attorneys) without prior written permission of the other Party; provided, however, that (a) either Party may make any filings of this Agreement required by law or regulation in any country so long
as such Party uses its reasonable efforts to obtain confidential treatment for portions of this Agreement as available, consults with the other Party, and permits the other Party to participate, to the greatest extent practicable, in seeking a
protective order or other confidential treatment; (b) either Party may disclose this Agreement on a confidential basis to existing or potential Third Party investors, lenders or acquirors or, in the case of Licensee, to existing or potential
Sublicensees, in each case in connection with due diligence or similar investigations; and (c) a Party may publicly disclose, without regard to the preceding requirements of this Section 11.7, information that was previously disclosed in
compliance with such requirements. 
 12. TERM AND TERMINATION 

12.1 Amended and Restated Effective Date. This Agreement (other than this Section 12.1, which is binding and effective as of the
Amended and Restated Execution Date), shall not become effective unless and until the closing of a Divestiture occurs (the date of such closing, the “Amended and Restated Effective Date”), and upon the Amended and Restated Effective
Date this Agreement and all of its terms and provisions shall be automatically effective and binding on both Parties. The Original Agreement shall not be amended and restated or otherwise superseded by this Agreement until the Amended and Restated
Effective Date. If the Amended and Restated Effective Date has not occurred by December 31, 2013, then this Agreement, including this Section 12.1, shall terminate and be of no further force and effect. For

  
  

***Confidential Treatment Requested 

- 31 - 

 
clarity, such termination will not give rise to any of the effects or consequences set forth in Section 12.5. 

12.2 Term. The term of this Agreement will commence as of the Effective Date and, unless earlier terminated in accordance with
this Section 12 (Term and Termination), will expire upon the expiration of the Royalty Term for all POZEN Products in the Territory (the “Term”).  

12.3 Termination for Material Breach. In the event that either Party (the “Breaching Party”) shall be in material
default of any of its material obligations under this Agreement, in addition to any other right and remedy the other Party (the “Non-Breaching Party”) may have, the Non-Breaching Party may terminate this Agreement in its entirety by
ninety (90) days prior written notice (the “Notice Period”) to the Breaching Party, specifying the breach and its claim of right to terminate; provided, that the termination shall not become effective at the end of the Notice
Period if the Breaching Party cures the breach complained about during the Notice Period (or, if such default cannot be cured within such Notice Period, if the Breaching Party commences actions to cure such default within the Notice Period and
thereafter diligently continues such actions). It is understood that termination pursuant to this Section 12.3 (Termination for Material Breach) shall be a remedy of last resort and may be invoked only in the case where the breach cannot be
reasonably remedied by the payment of money damages or other remedy under applicable law. If either Party initiates a dispute resolution procedure as permitted under this Agreement prior to the end of the Notice Period to resolve the dispute for
which termination is being sought and is diligently pursuing such procedure, including any litigation following therefrom, the termination shall become effective only if and when such dispute is finally resolved through such dispute resolution
procedure. This Section 12.3 (Termination for Material Breach) defines exclusively the Parties’ right to terminate in case of any material breach of this Agreement. 

12.4 Termination for Cause. If a Post-Approval Failure occurs in the Territory, Licensee may, at its option, terminate the Agreement in
its entirety; provided, that written notice of termination must be delivered to POZEN within sixty (60) days following such Post-Approval Failure.  
  

	12.5	Consequences of Expiration and Termination. 

 12.5.1 Effect of Expiration.
Upon expiration (but not earlier termination) of the Term pursuant to Section 12.2 (Term), Licensee will have a non exclusive, irrevocable, perpetual, fully-paid license, with the right to sublicense, under the Licensed Technology to research,
develop, make, use, sell, offer for sale, and import the POZEN Product in the Field of Use in the Territory. 
 12.5.2 Effect of
Termination. The use by either party hereto of a termination right provided for under this Agreement and in accordance with this Agreement shall not give rise to the payment of damages or any other form of compensation or relief to the other
party with respect thereto. Subject to the preceding sentence, termination of this Agreement shall not preclude either party from claiming any other damages, compensation or relief that it may be entitled to upon such termination or for any breach
of this Agreement. If either Party terminates 

  
 - 32 - 

 
this Agreement, all rights and licenses granted by POZEN to Licensee and all obligations of Licensee and POZEN under this Agreement will terminate immediately. 

12.6 Termination for Insolvency. This Agreement may be terminated by written notice by either Party at any time during the Term upon
the declaration by a court of competent jurisdiction that the other Party is bankrupt and, pursuant to the U.S. Bankruptcy Code such other Party’s assets are to be liquidated; upon the filing or institution of bankruptcy, liquidation or
receivership proceedings (other than reorganization proceedings under Chapter 11 of the U.S. Bankruptcy Code); or upon an assignment of a substantial portion of the assets for the benefit of creditors by the other Party; or in the event a receiver
or custodian is appointed for such Party’s business; provided, however, that in the case of any involuntary proceeding, such right to terminate shall only become effective if the proceeding is not dismissed within 60 days after the filing
thereof (each of the foregoing, a “Bankruptcy Event”). 
 12.7 Effect of Bankruptcy. All rights and licenses
with respect to Patents and Know-How granted under or pursuant to this Agreement by one Party to the other Party are, for all purposes of Section 365(n) of Title 11 of the United States Code (“Title 11”), licenses of rights to
“intellectual property” as defined in Title 11. Each Party agrees that the other Party, as licensee of such rights under this Agreement shall retain and may fully exercise all of its rights and elections under Title 11. POZEN hereby grants
to Licensee and all Affiliates of Licensee, effective upon any breach of this Agreement caused by the rejection of this Agreement by POZEN under Section 365 of Title 11 or otherwise, a right of access and to obtain possession of and to benefit
from the following items to the extent Controlled by POZEN relating to the Licensed Technology or POZEN Products: (i) copies of research data, (ii) laboratory samples, (iii) formulas, (iv) laboratory notes and notebooks,
(v) data and results related to clinical trials, (vi) clinical and pre-clinical research data and results, and (vii) any IND, NDA or other regulatory filing or approval related to a POZEN Product in the Territory, all of which
constitute “embodiments” of intellectual property pursuant to Section 365(n) of Title 11, and (viii) copies or examples of all other embodiments of the Licensed Technology. POZEN agrees not to interfere with Licensee and its
Affiliates’ exercise of rights and licenses to intellectual property licensed hereunder and embodiments thereof in accordance with this Agreement and agrees to use commercially reasonable efforts to assist Licensee and its Affiliates to obtain
such intellectual property and embodiments thereof in the possession or control of Third Parties as reasonably necessary or desirable for Licensee or its Affiliates to exercise such rights and licenses in accordance with this Agreement. Each party
agrees and acknowledges that all payments by Licensee to POZEN payable under this Agreement other than royalty payments pursuant to Section 8.1 (Royalties) and commercialization milestone payments under the Three-Party Agreement do not
constitute “royalties” within the meaning of Section 365(n) of Title 11 or relate to licenses of intellectual property hereunder. 

12.8 Formulation Technology. If Licensee terminates this Agreement for any reason other than for material breach by POZEN under
Section 12.3 or as a result of POZEN’s insolvency under Section 12.7, then, subject to the terms and conditions of this Agreement, Licensee agrees to grant to POZEN, and does hereby grant effective automatically upon such termination,
(a) a perpetual, irrevocable, non-exclusive license or sublicense under the Formulation Technology, with the right to grant sublicenses and authorize the grant of sublicenses to the extent provided in this Section 12.8, to make, have made,
use, sell, offer for 

  
 - 33 - 

 
sale, and import POZEN Products in the Territory and (b) a perpetual, irrevocable, non-exclusive license or sublicense, as applicable, under the Formulation Technology, with the
right to grant sublicenses and authorize the grant of sublicenses to the extent provided in this Section 12.8, to Develop and Manufacture (but not sell or otherwise Commercialize) POZEN Products outside the Territory solely in support of the
Development or Commercialization of the POZEN Products in the Territory; provided, that nothing herein gives POZEN any right or license under any other intellectual property rights Controlled by Licensee, regardless of whether such rights are
necessary in order to exploit the Formulation Technology pursuant to this Section 12.8. POZEN may grant sublicenses and the right to grant further sublicenses under the foregoing license only as follows: (i) for any sublicense relating to
the development or commercialization of a POZEN Product Commercialized by Licensee in the Territory at the time of such termination (a “Commercialized POZEN Product”) in the Territory, POZEN may grant such sublicense upon notice to
Licensee, but without obtaining Licensee’s consent, and (ii) for any sublicense relating to POZEN Products other than Commercialized POZEN Products in the Territory, POZEN may grant such sublicense with Licensee’s prior written
consent (such consent not to be unreasonably withheld, conditioned or delayed). 
 12.9 Survival. Expiration or termination of
this Agreement will not relieve the Parties of any obligation accruing prior to such expiration or termination. The provisions of Sections 8.1 (Royalties), 8.2 (Payments and Sales Reporting), 8.3 (Records; Audits), 9.2 (Prosecution and Maintenance
of Joint Patents), 9.3 (Ownership of Inventions), 10.3 (Disclaimer of Warranty), 11 (Confidentiality), 12.5 (Consequences of Expiration and Termination), 12.7 (Effect of Bankruptcy), 12.8 (Formulation Technology), 12.9 (Survival), 13
(Indemnification and Insurance), 14 (Limitation of Liability), and 15 (Miscellaneous) will survive any termination or expiration of this Agreement (other than a termination pursuant to Section 12.1).  

13. INDEMNIFICATION AND INSURANCE 

13.1 Indemnification by POZEN. POZEN hereby agrees to save, defend and hold Licensee and its Affiliates and their respective directors,
officers, employees and agents (each, a “Licensee Indemnitee”) harmless from and against any and all claims, suits, actions, demands, liabilities, expenses and/or loss, including reasonable legal expense and attorneys’ fees
(collectively, “Losses”), to which any Licensee Indemnitee may become subject as a result of any claim, demand, action or other proceeding by any Third Party to the extent such Losses arise directly or indirectly out of:
(i) the gross negligence or willful misconduct of any POZEN Indemnitee or (ii) the breach by POZEN of any warranty, representation, covenant or agreement made by POZEN in this Agreement; except, in each case, to the extent such Losses
result from the gross negligence or willful misconduct of any Licensee Indemnitee or the breach by Licensee of any warranty, representation, covenant or agreement made by Licensee in this Agreement. 

13.2 Indemnification by Licensee. Licensee hereby agrees to save, defend and hold POZEN and its Affiliates and their respective
directors, officers, employees and agents (each, an “POZEN Indemnitee”) harmless from and against any and all Losses to which any POZEN Indemnitee may become subject as a result of any claim, demand, action or other proceeding by
any Third Party to the extent such Losses arise directly or indirectly out of: (i) the development, manufacture, use, handling, storage, sale or other disposition of any Product by Licensee, its Affiliates or any of their respective
Sublicensees, (ii) the gross negligence or willful misconduct 

  
 - 34 - 

 
of any Licensee Indemnitee, or (iii) the breach by Licensee of any warranty, representation, covenant or agreement made by Licensee in this Agreement, in each case ((i),
(ii) and (iii)), after the Amended and Restated Effective Date; except, in each case, to the extent such Losses result from the gross negligence or willful misconduct of any POZEN Indemnitee or the breach by POZEN of any warranty,
representation, covenant or agreement made by POZEN in this Agreement. 
 13.3 Indemnification Procedure. 

13.3.1 Notice of Claim. The indemnified Party will give the indemnifying Party (the “Indemnifying Party”) prompt
written notice (an “Indemnification Claim Notice”) of any Losses or discovery of fact upon which such Indemnified Party intends to base a request for indemnification under Section 13.1 (Indemnification by POZEN) or
Section 13.2 (Indemnification by Licensee); provided, however, that the failure to give such prompt written notice will not relieve Indemnifying Party of its indemnification obligation under this Agreement except and only
to the extent that the Indemnifying Party is actually prejudiced as a result of such failure. In no event will the Indemnifying Party be liable for any Losses that result from any delay in providing such notice. Each Indemnification Claim Notice
must contain a description of the claim and the nature and amount of such Loss (to the extent that the nature and amount of such Loss are known at such time). The indemnified Party will furnish promptly to the indemnifying Party copies of all papers
and official documents received in respect of any Losses. All indemnification claims in respect of a Party, its Affiliates or their respective directors, officers, employees and agents (collectively, the “Indemnitees” and each an
“Indemnitee”) will be made solely by such Party to this Agreement (the “Indemnified Party”). 

13.3.2 Control of Defense. At its option, the Indemnifying Party may assume the defense of any claim for which indemnification is
sought (a “Third Party Claim”) by giving written notice to the Indemnified Party within [...***...] ([...***...]) days after the Indemnifying Party’s receipt of
an Indemnification Claim Notice. Upon assuming the defense of a Third Party Claim, the Indemnifying Party may appoint as lead counsel in the defense of the Third Party Claim any legal counsel selected by the Indemnifying Party. In the event the
Indemnifying Party assumes the defense of a Third Party Claim, the Indemnified Party will immediately deliver to the Indemnifying Party all original notices and documents (including court papers) received by any Indemnitee in connection with the
Third Party Claim. Should the Indemnifying Party assume the defense of a Third Party Claim, the Indemnifying Party will not be liable to the Indemnified Party or any other Indemnitee for any legal expenses subsequently incurred by such Indemnified
Party or other Indemnitee in connection with the analysis, defense or settlement of the Third Party Claim. 
 13.3.3 Right to Participate
in Defense. Without limiting Section 13.3.2 (Control of Defense) above, any Indemnitee will be entitled to participate in, but not control, the defense of such Third Party Claim and to employ counsel of its choice for such purpose;
provided, however, that such employment will be at the Indemnitee’s own expense unless (i) the employment thereof has been specifically authorized by the Indemnifying Party in writing, or (ii) the Indemnifying
Party has failed to assume the defense and employ counsel in accordance with Section 13.3.2 (Control of Defense) (in which case the Indemnified Party will control the defense). 

  
  

***Confidential Treatment Requested 

- 35 - 

 13.3.4 Settlement. With respect to any Losses relating solely to the payment of money
damages in connection with a Third Party Claim and that will not result in the Indemnitee’s becoming subject to injunctive or other relief or otherwise adversely affect the business of the Indemnitee in any manner, and as to which the
Indemnifying Party will have acknowledged in writing the obligation to indemnify the Indemnitee hereunder, the Indemnifying Party will have the sole right to consent to the entry of any judgment, enter into any settlement or otherwise dispose of
such Loss, on such terms as the Indemnifying Party, in its sole discretion, will deem appropriate, and will transfer to the Indemnified Party all amounts which said Indemnified Party will be liable to pay prior to the time prior to the entry of
judgment. With respect to all other Losses in connection with Third Party Claims, where the Indemnifying Party has assumed the defense of the Third Party Claim in accordance with Section 13.3.2 (Control of Defense), the Indemnifying Party will
have authority to consent to the entry of any judgment, enter into any settlement or otherwise dispose of such Loss provided it obtains the prior written consent of the Indemnified Party (which consent will be at the Indemnified Party’s sole
and absolute discretion). The Indemnifying Party will not be liable for any settlement or other disposition of a Loss by an Indemnitee that is reached without the written consent of the Indemnifying Party. Regardless of whether the Indemnifying
Party chooses to defend or prosecute any Third Party Claim, no Indemnitee will admit any liability with respect to, or settle, compromise or discharge, any Third Party Claim without the prior written consent of the Indemnifying Party. 

13.3.5 Cooperation. The Indemnified Party will, and will cause each other Indemnitee to, cooperate in the defense or prosecution
thereof and will furnish such records, information and testimony, provide such witnesses and attend such conferences, discovery proceedings, hearings, trials and appeals as may be reasonably requested in connection with the defense or prosecution of
any Third Party Claim. Such cooperation will include access during normal business hours afforded to the Indemnifying Party to, and reasonable retention by the Indemnified Party of, records and information that are reasonably relevant to such Third
Party Claim, and making Indemnitees and other employees and agents available on a mutually convenient basis to provide additional information and explanation of any material provided hereunder, and the Indemnifying Party will reimburse the
Indemnified Party for all its reasonable out-of-pocket expenses in connection therewith. 
 13.4 Expenses. Except as provided
above, the reasonable and verifiable costs and expenses, including fees and disbursements of counsel, incurred by the Indemnified Party in connection with any claim will be reimbursed on a Calendar Quarter basis by the Indemnifying Party, without
prejudice to the Indemnifying Party’s right to contest the Indemnified Party’s right to indemnification and subject to refund in the event the Indemnifying Party is ultimately held not to be obligated to indemnify the Indemnified Party.

 13.5 Insurance. Each Party will have and maintain such types and amounts of liability insurance as is normal and customary in
the industry generally for parties similarly situated, and will upon request provide the other Party with a copy of its policies of insurance in that regard, along with any amendments and revisions thereto. 

14. LIMITATION OF LIABILITY 

  
 - 36 - 

 IN NO EVENT WILL EITHER PARTY BE LIABLE FOR LOST PROFITS, LOSS OF DATA, OR FOR ANY SPECIAL,
INDIRECT, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, HOWEVER CAUSED, ON ANY THEORY OF LIABILITY AND WHETHER OR NOT SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, ARISING UNDER ANY CAUSE OF ACTION AND ARISING IN ANY WAY OUT OF
THIS AGREEMENT. THE FOREGOING LIMITATIONS WILL NOT APPLY TO AN AWARD OF ENHANCED DAMAGES AVAILABLE UNDER THE PATENT LAWS FOR WILLFUL PATENT INFRINGEMENT AND WILL NOT LIMIT EITHER PARTY’S LIABILITY TO THE OTHER PARTY UNDER SECTIONS 7.5
(RESTRICTIVE COVENANT), 10.4 (POZEN NON-COMPETE), 11 (CONFIDENTIALITY), AND 13 (INDEMNIFICATION AND INSURANCE) OF THIS AGREEMENT. 
 15. MISCELLANEOUS

 15.1 Assignment.  

15.1.1 Without the prior written consent of the other Party hereto (which may be granted at the other Party’s
discretion), neither Party will sell, transfer, assign, delegate, pledge or otherwise dispose of, whether voluntarily, involuntarily, by operation of law or otherwise, this Agreement or any of its rights or duties hereunder; provided,
however, that either Party hereto may assign or transfer this Agreement or any of its rights or obligations hereunder without the consent of the other Party (a) to any Affiliate of such Party; or (b) in connection with the transfer
or sale of all or substantially all of the business of such party to which this Agreement relates to a Third Party, whether by merger, sale of stock, sale of assets or otherwise. Except as set forth in that certain side letter agreement between
POZEN and AstraZeneca AB dated September 16, 2013, the assigning Party (except if it is not the surviving entity) will remain jointly and severally liable with the relevant Affiliate or Third Party assignee under this Agreement, and the
relevant Affiliate assignee, Third Party assignee or surviving entity will assume in writing all of the assigning Party’s obligations under this Agreement. Any purported assignment or transfer in violation of this Section 15.1 (Assignment)
will be void ab initio and of no force or effect. 
 15.1.2 In the event that POZEN desires to sell all or a part of
its rights to receive payments under this Agreement, then upon POZEN’s written request, Licensee shall enter into a consent in substantially the form of the Consent Agreement attached hereto as Schedule 15.1.2 with respect to such
transaction. 
 15.2 Termination of Certain Rights Upon POZEN Change of Corporate Control. POZEN shall promptly notify
Licensee in writing following consummation of a Change of Corporate Control of POZEN. Notwithstanding anything else in this Agreement to the contrary, in the event of a Change of Corporate Control of POZEN, then Licensee will have the right,
exercisable by written notice to POZEN or its successor in interest given within [...***...] ([...***...]) days after Licensee receives written notice from POZEN of the completion of such
Change of Corporate Control: (a) to terminate [...***...] established pursuant to this Agreement; and (b) to terminate its obligation to make [...***...] to POZEN pursuant to this Agreement other than [...***...] and as
reasonably required to [...***...] 

  
  

***Confidential Treatment Requested 

- 37 - 

 
[...***...]; subject, in each case, to Licensee’s continued compliance with all applicable provisions of this Agreement (including, without limitation, Articles 8, 9 and 11). POZEN shall
cooperate in providing to Licensee all information, assistance, assignments and other support reasonably requested to assist Licensee in assuming such control. For purposes of clarification, all Confidential Information of Licensee in POZEN’s
or its successor’s possession following Licensee’s exercise of its rights under this Section 15.2 shall continue to be subject to all applicable provisions of this Agreement (including, without limitation, Articles 7 and 11).

 15.3 Severability. If any provision of this Agreement is held to be illegal, invalid or unenforceable under any present or
future law, and if the rights or obligations of either Party under this Agreement will not be materially and adversely affected thereby, (a) such provision will be fully severable, (b) this Agreement will be construed and enforced as if
such illegal, invalid or unenforceable provision had never comprised a part hereof, (c) the remaining provisions of this Agreement will remain in full force and effect and will not be affected by the illegal, invalid or unenforceable provision
or by its severance herefrom, and (d) in lieu of such illegal, invalid or unenforceable provision, there will be added automatically as a part of this Agreement a legal, valid and enforceable provision as similar in terms to such illegal,
invalid or unenforceable provision as may be possible and reasonably acceptable to the Parties herein. To the fullest extent permitted by Applicable Law, each Party hereby waives any provision of law that would render any provision prohibited or
unenforceable in any respect. 
 15.4 Governing Law; Dispute Resolution. 

15.4.1 This Agreement, and any disputes between the Parties related to or arising out of this Agreement, including the Parties’
relationship created hereby, the negotiations for and entry into this Agreement, its conclusion, binding effect, amendment, coverage, termination, or the performance or alleged non-performance of a Party of its obligations under this Agreement (each
a “Dispute”), will be governed by the laws of the State of New York without reference to any choice of law principles thereof that would cause the application of the laws of a different jurisdiction. 

15.4.2 In the event of any Dispute, a Party may notify the other Party in writing of such Dispute, and the Parties will try to settle
such Dispute amicably between themselves. If the Parties are unable to resolve the Dispute within [...***...] Business Days of receipt of the written notice by the other Party, such Dispute will be referred to the Chief Executive Officers of
each of the Parties (or their respective designees) who will use their good faith efforts to resolve the Dispute within [...***...] Business Days after it was referred to the Chief Executive Officers. 

15.4.3 Any Dispute that is not resolved as provided in Section 15.4.2, whether before or after termination of this Agreement, will
be resolved by litigation in the courts of competent jurisdiction located in New York, New York. Each Party hereby agrees to the exclusive jurisdiction of such courts and waives any objections as to the personal jurisdiction or venue of such
courts. 
 15.4.4 Notwithstanding the foregoing, nothing in this Section 15.4 (Governing Law; Dispute Resolution) will
limit either Party’s right to seek immediate temporary injunctive 

  
  

***Confidential Treatment Requested 

- 38 - 

 
or other temporary equitable relief whenever the facts or circumstances would permit a Party to seek such relief in a court of competent jurisdiction. 

15.5 Notices. All notices or other communications that are required or permitted hereunder will be in writing and delivered personally,
sent by facsimile (and promptly confirmed by personal delivery or overnight courier as provided herein), or sent by internationally-recognized overnight courier addressed as follows: 

If to POZEN, to: 

POZEN Inc. 

1414 Raleigh Road, Suite 400 

Chapel Hill, NC 27517 

USA 

Attention: President and CEO 

Facsimile: (919) 913-1039 

With a copy to: 

DLA Piper LLP (US) 

51 John F. Kennedy Parkway, Suite 120 

Short Hills, New Jersey 07078 

USA 

Attention: Andrew P. Gilbert 

Facsimile: (973) 520-2575 

If to Licensee, to: 

AstraZeneca AB 

SE-431 83 

Mölndal 

Sweden 

Attention: Manager Legal Department Mölndal 

Facsimile: +46 31 776 38 71 
 or
to such other address as the Party to whom notice is to be given may have furnished to the other Party in writing in accordance herewith. Any such communication will be deemed to have been given (i) when delivered, if personally delivered or
sent by facsimile on a Business Day, and (ii) on the second Business Day after dispatch, if sent by nationally-recognized overnight courier. It is understood and agreed that this Section 15.5 (Governing Law; Dispute Resolution) is not
intended to govern the day-to-day business communications necessary between the Parties in performing their duties, in due course, under the terms of this Agreement. 

15.6 Entire Agreement; Modifications. This Agreement including the Exhibits attached hereto, each of which is hereby incorporated and
made part of in this Agreement by reference, together with that certain side letter between POZEN and AstraZeneca AB, dated 

  
 - 39 - 

 
September 16, 2013, and the Three-Party Agreement, sets forth and constitutes the entire agreement and understanding between the Parties with respect to the subject matter hereof
and supersedes all prior agreements, understandings, promises and representations, whether written or oral, with respect thereto. Each Party confirms that it is not relying on any representations or warranties of the other Party except as
specifically set forth herein. No amendment or modification of this Agreement will be binding upon the Parties unless in writing and duly executed by authorized representatives of both Parties. 

15.7 Relationship of the Parties. It is expressly agreed that the Parties’ relationship under this Agreement is strictly one of
licensor-licensee, and that this Agreement does not create or constitute a partnership, joint venture, or agency. Neither Party will have the authority to make any statements, representations or commitments of any kind, or to take any action, which
will be binding (or purport to be binding) on the other. 
 15.8 Waiver. Any term or condition of this Agreement may be waived
at any time by the Party that is entitled to the benefit thereof, but no such waiver will be effective unless set forth in a written instrument duly executed by or on behalf of the Party waiving such term or condition. The waiver by either Party
hereto of any right hereunder or of claims based on the failure to perform or a breach by the other Party will not be deemed a waiver of any other right hereunder or of any other breach or failure by said other Party whether of a similar nature or
otherwise. 
 15.9 Counterparts. This Agreement may be executed in two or more counterparts, each of which will be deemed an
original, but all of which together will constitute one and the same instrument. 
 15.10 No Benefit to Third Parties. The
representations, warranties, covenants and agreements set forth in this Agreement are for the sole benefit of the Parties hereto and their successors and permitted assigns (including Horizon), and they will not be construed as conferring any rights
on any Third Party.  
 15.11 Further Assurance. Each Party will duly execute and deliver, or cause to be duly executed and
delivered, such further instruments and do and cause to be done such further acts and things, including the filing of such assignments, agreements, documents and instruments, as may be necessary or as the other Party may reasonably request in
connection with this Agreement or to carry out more effectively the provisions and purposes, or to better assure and confirm unto such other Party its rights and remedies under this Agreement. 

15.12 No Drafting Party. This Agreement has been submitted to the scrutiny of, and has been negotiated by, both Parties and their
counsel, and will be given a fair and reasonable interpretation in accordance with its terms, without consideration or weight being given to any such terms having been drafted by any Party or its counsel. No rule of strict construction will be
applied against either Party. 
 15.13 Construction. Except where the context otherwise requires, wherever used, the use of
any gender will be applicable to all genders and the word “or” is used in the inclusive sense (and/or). The captions of this Agreement are for convenience of reference only and in no 

  
 - 40 - 

 
way define, describe, extend or limit the scope or intent of this Agreement or the intent of any provision contained in this Agreement. The term “including” as used herein means
including, without limiting the generality of any description preceding such term. Unless the context indicates otherwise, the singular will include the plural and the plural will include the singular. Unless the context requires otherwise,
(a) any definition of or reference to any agreement, instrument or other document refer to such agreement, instrument or other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such
amendments, supplements or modifications set forth herein or therein), (b) any reference to any laws refer to such laws as from time to time enacted, repealed or amended, (c) the words “herein”, “hereof” and
“hereunder”, and words of similar import, refer to this Agreement in its entirety and not to any particular provision hereof, and (d) all references herein to Sections and Exhibits, unless otherwise specifically provided, refer to the
Sections and Exhibits of this Agreement. 
 15.14 Assignment to Horizon. POZEN acknowledges that, in connection with the Divestiture,
AstraZeneca AB will assign this Agreement to Horizon, effective as of the Amended and Restated Effective Date, and that, notwithstanding Section 15.1, AstraZeneca AB may assign this Agreement to Horizon in connection with the Divestiture
without the prior written consent of POZEN. Without limiting any provision of the Three-Party Agreement, from and after the Amended and Restated Effective Date, all references to “Licensee” in this Agreement, other than references to
Licensee in connection with anticipated actions to be taken by AstraZeneca AB as Licensee in connection with the Divestiture, shall automatically be deemed references to Horizon. 

15.15 Amendment and Restatement. This Agreement, together with the ROW Agreement, constitutes an amendment and restatement of the
Original Agreement effective from and after the Amended and Restated Effective Date. All rights or obligations owing under the Original Agreement, or based on facts or events occurring or existing prior to the Amended and Restated Effective Date,
shall be governed by the Original Agreement. As of the Amended and Restated Effective Date, the Original Agreement is hereby amended, supplemented, modified and restated in its entirety as described herein and in the ROW Agreement. For clarity, in
no event shall this Section 15.15 or any other provision in this Agreement be deemed to limit or otherwise affect the agreements made by AstraZeneca AB, Horizon and POZEN in the Three-Party Agreement or that certain side letter agreement
between POZEN and AstraZeneca AB dated September 16, 2013 with respect to each party’s respective liability in connection with the Original Agreement, this Agreement or the ROW Agreement. 

[Remainder of page intentionally left blank. Signature page follows.] 

  
 - 41 - 

 IN WITNESS WHEREOF, the Parties have executed this Amended and Restated Collaboration and License
Agreement for the United States by their respective authorized representatives as of the date first written above. 
  

			
	POZEN INC.
		
	By:	 	/s/ John R. Plachetka
	Name:	 	John R. Plachetka
	Title:	 	Chairman, President and CEO
	
	ASTRAZENECA AB (publ)
		
	By:	 	/s/ Jan-Olof Jacke
	Name:	 	Jan-Olof Jacke
	Title:	 	President

 [Signature Page to Pozen US Agreement] 

 Schedule 1.43 

Licensed Patents 
  

							
	 SERIAL NUMBER/

FILING DATE
	  	 PUBLICATION NUMBER/ DATE
	  	 TITLE
	  	 TERRITORY

	 10/158,216
 May 31, 2002
	  	 US2003069255 A1
 US6926907 B2 / 2005-08-09

Expires 2023-02-28
	  	Pharmaceutical Compositions for the Coordinated Delivery of NSAIDs	  	U.S.
				
	 11/129,320
 May 16, 2005
	  	US2005249811 A1 / 2005-11-10	  	Pharmaceutical Compositions for the Coordinated Delivery of NSAIDs	  	U.S.

 Schedule 1.83 

Vimovo Trademarks 
  

											
	 Country
	  	 Mark
	  	 App Date /

Reg Date
	  	 App No /

Reg No
	  	 Goods
	  	 Status

	United States	  	 VIMOVO & Design
 

	  	 App 01-MAY-2009

Reg 01-FEB-2011
	  	 App 77726998
 Reg
3914867
	  	(Class 5) pharmaceutical preparations and substances for the treatment of pain and inflammation	  	REGISTERED
						
	United States	  	VIMOVO	  	 App 13-FEB-2009

Reg 05-APR-2011
	  	 App 77670350
 Reg 3941225
	  	(Class 5) pharmaceutical preparations and substances for the treatment of pain and inflammation	  	REGISTERED

 Schedule 8.1.3 

Market Reduction Example 
 For Products
sold in the Territory: 
 [...***...] 

  
  

***Confidential Treatment Requested 

 Schedule 15.1.2 

Form of Consent Agreement 

CONSENT AGREEMENT 

This Consent Agreement (this “Consent”) is made and entered into as of
[            ] the Effective Date by and between POZEN Inc., a Delaware corporation (“Sponsor”), and [AstraZeneca AB, a corporation organized under the laws of
Sweden][Horizon Pharma USA, Inc., a Delaware corporation] (“Counterparty”). Sponsor and Counterparty are parties to the Amended and Restated Collaboration and License Agreement for [Outside] the United States effective as of
November         , 2013, and any amendments thereto (collectively, the “Agreement”). As of the Effective Date, Sponsor is considering a transaction to sell all or part of its rights to receive
payments under Sections [8.2, 9.6.4 and 12.6.4(b)(i) of the Agreement and paragraph 5 of that certain letter agreement by and among Sponsor, Counterparty and Horizon Pharma USA dated November         , 2013,
as well as certain related information rights under Sections 8.3 and 8.4 of the Agreement and certain recovery rights under Section 8.5 of the Agreement] [8.1 and 9.6.4 of the Agreement and paragraph 5 of that certain letter agreement by and
among Sponsor, Counterparty and AstraZeneca AB dated November         , 2013, as well as certain related information rights under Sections 8.2 and 8.3 of the Agreement and certain recovery rights under
Section 8.4 of the Agreement] (collectively, “Rights”; such contemplated transaction, the “Transaction”). In connection with the Transaction, Sponsor is requesting Counterparty to give its consent under the
Agreement to certain matters, as set forth below. Capitalized terms not otherwise defined herein shall have the meaning ascribed to them in the Agreement. 

1. Assignability. Notwithstanding Section 15.1 of the Agreement, Counterparty hereby consents and agrees that in connection the
Transaction, Sponsor may sell, assign, pledge as security, contribute, convey, grant or otherwise transfer (collectively, “assign”) all or any part of the Rights to any one person or entity (whether or not an affiliate of Sponsor)
other than a Competitor without the prior written consent of Counterparty in accordance with the terms of this Consent. In addition, such person or entity (an “Assignee”) of Sponsor may likewise assign such Assignee’s Rights to
any one person or entity (whether or not Sponsor or an affiliate of Sponsor) other than a Competitor without the prior written consent of Counterparty, it being understood and agreed that, all times, there shall only be one single person or entity
that holds the Rights (other than Sponsor) and constitutes an “Assignee.” “Competitor” shall mean any Person, other than Sponsor or its subsidiaries and affiliates, that is in the business of researching, developing or
commercializing therapeutics primarily for rheumatoid arthritis and osteoarthritis pain indications or any company ranked in the top 10 pharmaceutical companies in the United States based on IMS-reported pharmaceutical sales for the preceding
calendar year (or any of such company’s subsidiaries or controlled affiliates). 
 2. Payment Direction; Reports. Following the
consummation of the Transaction, Sponsor shall remain responsible for the performance of its obligations and the exercise of its rights under the Agreement, however, Counterparty agrees that, upon written notice from Sponsor (or any direct or
indirect permitted Assignee contemplated by Section 1 above), Counterparty shall deliver any future payments contemplated by the Agreement, together with 

 
any royalty or other reports or statements contemplated by the Agreement (“Reports”) to the Assignee, in accordance with the directions in such written notice; provided copies of
Reports are also simultaneously sent to the Sponsor. 
 3. Prospective Assignee Confidentiality. Notwithstanding Section 11 of
the Agreement, Counterparty consents and agrees that Sponsor, in connection with the Transaction, may disclose Confidential Information to its advisors, affiliates, agents, assignees, auditors, bankers,
co-investors, contractors, counsel, directors, employees, financing parties, insurance providers, investors, lenders, managers, members, officers, partners, sublicensees, trustees or other representatives or
any third party that has, or proposes to have, an interest (whether direct or indirect) in the Rights (each, a “Recipient”), provided that each such Recipient (a) is not a Competitor and (b) shall agree to keep such
Confidential Information confidential on reasonable and customary terms pursuant to a non-disclosure agreement between Sponsor (or an affiliate of Sponsor) and such Recipient, which non-disclosure agreement shall, among other things, provide that
(i) if such Recipient is not a prospective Assignee identified by the Company or a holder of a debt or equity interests therein (a “Prospective Assignee”), the term of such non-disclosure agreement shall extend for a period of
24 months from the date of such nondisclosure agreement, (ii) if such Recipient is a Prospective Assignee, the term of such non-disclosure agreement shall extend for a period of 24 months from the date such Prospective Assignee notifies Sponsor
that it ceases to have an interest in the Transaction, (iii) such Recipient shall use any Confidential Information so disclosed only to evaluate, enter into, monitor or enforce the Transaction, (iv) upon expiration of such non-disclosure
agreement, such Recipient promptly shall destroy the Confidential Information or return the Confidential Information to Sponsor, as directed by Sponsor, provided that in each case an appropriate person within such Recipient’s organization may
retain one copy of such Confidential Information subject to the provisions hereof if required to comply with internal record retention policies or regulatory considerations, and (v) Counterparty shall be treated as a third party beneficiary of
such non-disclosure agreement and shall have the right to enforce any provision of such non-disclosure agreement against such Recipient. For the avoidance of doubt, the term “Confidential Information” shall include unredacted copies
of the Agreement, all royalty reports provided by Counterparty pursuant to Section [8.3.1][8.2.1] of the Agreement, and material notices and correspondence received by Sponsor relating to or involving the Agreement that affect the Rights. 

4. Final Assignee Confidentiality. If Sponsor consummates the Transaction, Sponsor shall cause the Assignee to agree, pursuant to the
definitive documentation for the Transaction, to be bound by confidentiality provisions in substantially the same form and substance as those confidentiality provisions contained in Section 11 of the Agreement (with such Counterparty being
treated as a third party beneficiary of such provisions to the same extent as is contemplated by clause (v) of Paragraph 3 hereof). 

5. Consent Concerning Additional Disclosures. Counterparty hereby consents to and agrees that Sponsor may disclose to its advisors,
including its consulting firm, L.E.K. Consulting (“LEK”), and the Sponsor, its advisors and/or LEK may in turn disclose to Prospective Assignees (who are not Competitors and who have agreed to the confidentiality obligations set forth in
Paragraph 3 hereof) , the following information provided to Sponsor by Counterparty: [(i) the anticipated launch dates of commercial sales of Vimovo by Counterparty in countries outside the United States;][ (ii) information pertaining to the
Counterparty’s new US 

 
sales model for Vimovo implemented in 2012;] (iii) historical information relating to the ratio of Vimovo gross sales to net sales[; and (iv) information relating to Counterparty’s
promotional plan for Vimovo and strategy regarding Medicare Part D]. 
 6. Termination. Unless a definitive agreement with respect to
the Transaction has been executed prior to the first anniversary of the Effective Date, this Consent shall automatically terminate as of the first anniversary of the Effective Date. 

Except as supplemented hereby, all terms and provisions of the Agreement shall remain in full force and effect. This Consent may be executed
in any number of counterparts, each of which shall be deemed an original, and all of which, taken together, shall constitute one and the same agreement. An executed signature page of this Consent delivered by facsimile transmission or in PDF format
via email shall be as effective as an original executed signature page. This Consent shall be governed by the laws of the State of New York without regard to any choice of law principles thereof that would cause the application of the laws of a
different jurisdiction. 
  

			
	POZEN INC.
		
	 By:
	 	 
	 Name:
	 	
	 Title:
	 	
	
	 [ASTRAZENECA AB (publ)][HORIZON PHARMA USA, INC.]

		
	 By:
	 	 
	 Name:
	 	
	 Title:EX-10.49

 Exhibit 10.49 

***Text Omitted and Filed Separately with the Securities and Exchange Commission. 

Confidential Treatment Requested Under 

17 C.F.R. Sections 200.80(b)(4) and 240.24b-2 

Master Manufacturing Services Agreement 

Master Manufacturing Services Agreement 

October 31, 2013 

 Master Manufacturing Services Agreement 

 

 Table of Contents 

 

							
	 ARTICLE 1
	  	 	1	  
		
	 STRUCTURE OF AGREEMENT AND INTERPRETATION
	  	 	1	  
			
	 1.1
	    	MASTER AGREEMENT	  	 	1	  
	 1.2
	    	PRODUCT AGREEMENTS	  	 	1	  
	 1.3
	    	DEFINITIONS	  	 	2	  
	 1.4
	    	CURRENCY	  	 	6	  
	 1.5
	    	SECTIONS AND HEADINGS	  	 	6	  
	 1.6
	    	SINGULAR TERMS	  	 	7	  
	 1.7
	    	APPENDIX 1 AND EXHIBITS	  	 	7	  
		
	 ARTICLE 2 
	  	 	8	  
		
	 PATHEON’S MANUFACTURING SERVICES
	  	 	8	  
			
	 2.1
	    	MANUFACTURING SERVICES	  	 	8	  
	 2.2
	    	ACTIVE MATERIAL YIELD	  	 	10	  
		
	 ARTICLE 3 
	  	 	11	  
		
	 CLIENT’S OBLIGATIONS
	  	 	11	  
			
	 3.1
	    	PAYMENT	  	 	11	  
	 3.2
	    	ACTIVE MATERIALS AND QUALIFICATION OF ADDITIONAL SOURCES OF SUPPLY	  	 	11	  
		
	 ARTICLE 4
	  	 	12	  
		
	 CONVERSION FEES AND COMPONENT COSTS
	  	 	12	  
			
	 4.1
	    	FIRST YEAR PRICING	  	 	12	  
	 4.2
	    	PRICE ADJUSTMENTS – SUBSEQUENT YEARS’ PRICING	  	 	12	  
	 4.3
	    	PRICE ADJUSTMENTS – CURRENT YEAR PRICING	  	 	14	  
	 4.4
	    	ADJUSTMENTS DUE TO TECHNICAL CHANGES	  	 	14	  
	 4.5
	    	MULTI-COUNTRY PACKAGING REQUIREMENTS	  	 	15	  
		
	 ARTICLE 5
	  	 	15	  
		
	 ORDERS, SHIPMENT, INVOICING, PAYMENT
	  	 	15	  
			
	 5.1
	    	ORDERS AND FORECASTS	  	 	15	  
	 5.2
	    	RELIANCE BY PATHEON	  	 	16	  
	 5.3
	    	MINIMUM ORDERS	  	 	16	  
	 5.4
	    	SHIPMENTS	  	 	16	  
	 5.5
	    	LATE DELIVERY	  	 	17	  
	 5.6
	    	INVOICES AND PAYMENT	  	 	17	  

  
 - i - 

 Master Manufacturing Services Agreement 

 

							
	 ARTICLE 6
	  	 	17	  
		
	 PRODUCT CLAIMS AND RECALLS
	  	 	17	  
			
	 6.1
	    	PRODUCT CLAIMS	  	 	17	  
	 6.2
	    	PRODUCT RECALLS AND RETURNS	  	 	18	  
	 6.3
	    	PATHEON’S RESPONSIBILITY FOR DEFECTIVE AND RECALLED PRODUCTS	  	 	18	  
	 6.4
	    	DISPOSITION OF DEFECTIVE OR RECALLED PRODUCTS	  	 	19	  
	 6.5
	    	HEALTHCARE PROVIDER OR PATIENT QUESTIONS AND COMPLAINTS	  	 	19	  
	 6.6
	    	SOLE REMEDY	  	 	20	  
		
	 ARTICLE 7
	  	 	20	  
		
	 CO-OPERATION
	  	 	20	  
			
	 7.1
	    	QUARTERLY REVIEW	  	 	20	  
	 7.2
	    	GOVERNMENTAL AGENCIES	  	 	20	  
	 7.3
	    	RECORDS AND ACCOUNTING BY PATHEON	  	 	20	  
	 7.4
	    	INSPECTION	  	 	20	  
	 7.5
	    	ACCESS	  	 	21	  
	 7.6
	    	NOTIFICATION OF REGULATORY INSPECTIONS	  	 	21	  
	 7.7
	    	REPORTS	  	 	21	  
	 7.8
	    	REGULATORY FILINGS	  	 	21	  
		
	 ARTICLE 8
	  	 	22	  
		
	 TERM AND TERMINATION
	  	 	22	  
			
	 8.1
	    	INITIAL TERM	  	 	22	  
	 8.2
	    	TERMINATION FOR CAUSE	  	 	22	  
	 8.3
	    	PRODUCT DISCONTINUATION	  	 	23	  
	 8.4
	    	OBLIGATIONS ON TERMINATION	  	 	23	  
		
	 ARTICLE 9
	  	 	24	  
		
	 REPRESENTATIONS, WARRANTIES AND COVENANTS
	  	 	24	  
			
	 9.1
	    	AUTHORITY	  	 	24	  
	 9.2
	    	CLIENT WARRANTIES	  	 	24	  
	 9.3
	    	PATHEON WARRANTIES	  	 	25	  
	 9.4
	    	DEBARRED PERSONS	  	 	25	  
	 9.5
	    	PERMITS	  	 	26	  
	 9.6
	    	NO WARRANTY	  	 	26	  
		
	 ARTICLE 10
	  	 	26	  
		
	 REMEDIES AND INDEMNITIES
	  	 	26	  
			
	 10.1
	    	CONSEQUENTIAL DAMAGES	  	 	26	  
	 10.2
	    	LIMITATION OF LIABILITY	  	 	26	  

  
 - ii - 

 Master Manufacturing Services Agreement 

 

							
	 10.3
	    	PATHEON	  	 	26	  
	 10.4
	    	CLIENT	  	 	27	  
	 10.5
	    	REASONABLE ALLOCATION OF RISK	  	 	27	  
		
	 ARTICLE 11
	  	 	27	  
		
	 CONFIDENTIALITY
	  	 	27	  
			
	 11.1
	    	CONFIDENTIALITY	  	 	27	  
		
	 ARTICLE 12
	  	 	28	  
		
	 DISPUTE RESOLUTION
	  	 	28	  
			
	 12.1
	    	COMMERCIAL DISPUTES	  	 	28	  
	 12.2
	    	TECHNICAL DISPUTE RESOLUTION	  	 	28	  
		
	 ARTICLE 13
	  	 	28	  
		
	 MISCELLANEOUS
	  	 	28	  
			
	 13.1
	    	CORPORATE RESPONSIBILITY	  	 	28	  
	 13.2
	    	INVENTIONS	  	 	29	  
	 13.3
	    	INTELLECTUAL PROPERTY	  	 	29	  
	 13.4
	    	INSURANCE	  	 	29	  
	 13.5
	    	INDEPENDENT CONTRACTORS	  	 	30	  
	 13.6
	    	NO WAIVER	  	 	30	  
	 13.7
	    	ASSIGNMENT	  	 	30	  
	 13.8
	    	FORCE MAJEURE	  	 	30	  
	 13.9
	    	ADDITIONAL PRODUCT	  	 	31	  
	 13.10
	    	NOTICES	  	 	31	  
	 13.11
	    	SEVERABILITY	  	 	32	  
	 13.12
	    	ENTIRE AGREEMENT	  	 	32	  
	 13.13
	    	OTHER TERMS	  	 	32	  
	 13.14
	    	NO THIRD PARTY BENEFIT OR RIGHT	  	 	32	  
	 13.15
	    	EXECUTION IN COUNTERPARTS	  	 	32	  
	 13.16
	    	USE OF CLIENT NAME	  	 	32	  
	 13.17
	    	GOVERNING LAW	  	 	33	  

  
 - iii - 

 Master Manufacturing Services Agreement 

 

 MASTER MANUFACTURING SERVICES AGREEMENT 

THIS MASTER MANUFACTURING SERVICES AGREEMENT (the “Agreement”) is made as of October 31, 2013 (the “Effective
Date”) 
 B E T W E E N: 
 PATHEON
PHARMACEUTICALS INC., 
 a corporation existing under the laws of the State of Delaware 

(“Patheon”), 
 -
and - 
 Horizon Pharma Inc., 

a corporation existing under the laws of the State of Delaware 

(“Client”). 

THIS AGREEMENT WITNESSES THAT in consideration of the rights conferred and the obligations assumed herein, and for other good and valuable
consideration (the receipt and sufficiency of which are acknowledged by each party), and intending to be legally bound the parties agree as follows: 

ARTICLE 1 
 STRUCTURE
OF AGREEMENT AND INTERPRETATION 
 1.1 Master Agreement.  

This Agreement establishes the general terms and conditions under which Patheon or any Affiliate of Patheon may perform Manufacturing Services
for Client or any Affiliate of Client, at the manufacturing site where the Affiliate of Patheon resides. This “master” form of agreement is intended to allow the parties, or any of their Affiliates, to contract for the manufacture of
multiple Products through Patheon’s global network of manufacturing sites through the issuance of site specific Product Agreements without having to re-negotiate the basic terms and conditions contained herein. 

1.2 Product Agreements. 

This Agreement is structured so that a Product Agreement may be entered into by the parties for the manufacture of a particular Product or
multiple Products at a Patheon manufacturing site. Each Product Agreement will be governed by the terms and conditions of this Agreement unless the parties to the Product Agreement expressly modify the terms and conditions of this Agreement in the
Product Agreement. Unless otherwise agreed by the parties, each Product Agreement will be in the general form and contain the information set forth in Appendix 1 hereto. 

  
 - 1 - 

 Master Manufacturing Services Agreement 

 

 1.3 Definitions. 

The following terms will, unless the context otherwise requires, have the respective meanings set out below and grammatical variations of these
terms will have corresponding meanings: 
 “Active Materials”, “Active Pharmaceutical Ingredients” or
“API” means the materials listed in a Product Agreement on Schedule D; 
 “Active Materials Credit Value”
means the value of the Active Materials for certain purposes of this Agreement, as set forth in a Product Agreement on Schedule D; 

“Actual Annual Yield” or “AAY” has the meaning specified in Section 2.2(a); 

“Affiliate” means: 
  

	 	(a)	a business entity which owns, directly or indirectly, a controlling interest in a party to this Agreement, by stock ownership or otherwise; or 

 

	 	(b)	a business entity which is controlled by a party to this Agreement, either directly or indirectly, by stock ownership or otherwise; or 

 

	 	(c)	a business entity, the controlling interest of which is directly or indirectly common to the majority ownership of a party to this Agreement; 

For this definition, “control” means the ownership of shares carrying at least a majority of the votes for the election of the
directors of a corporation; 
 “Annual Product Review Report” means the annual product review report prepared by Patheon as
described in Title 21 of the United States Code of Federal Regulations, Section 211.180(e); 
 “Annual Report” means
the annual report to the FDA prepared by Client regarding the Product as described in Title 21 of the United States Code of Federal Regulations, Section 314.81(b)(2); 

“Annual Volume” means the minimum volume of Product to be manufactured in any Year of this Agreement as set forth in Schedule
B; 
 “Applicable Laws” means (i) for Patheon, the Laws of the State of Ohio [or local jurisdiction for Patheon
Affiliate], being the jurisdiction where the Manufacturing Site is located; and (ii) for Client and the Products, the Laws of all jurisdictions where the Products are manufactured, distributed, and marketed as these are agreed and understood by
the parties in this Agreement; 
 “Authority” means any governmental or regulatory authority, department, body or agency or
any court, tribunal, bureau, commission or other similar body, whether federal, state, provincial, county or municipal; 
 “Bill Back
Items” means the expenses for all third party supplier fees for the purchase or use of columns, standards, tooling, non-standard pallets, PAPR or PPE suits (where applicable), RFID tags and supporting equipment, and other project-specific
items necessary for Patheon to perform the Manufacturing Services, and which are not included as Components; 
 “Breach
Notice” will have the meaning specified in Section 8.2(a); 

  
 - 2 - 

 Master Manufacturing Services Agreement 

 

 “Business Day” means a day other than a Saturday, Sunday or a day that is a
statutory holiday in the United States; 
 “cGMPs” means, as applicable, current good manufacturing practices as described
in: 
  

	 	(a)	Division 2 of Part C of the Food and Drug Regulations (Canada); 

  

	 	(b)	Parts 210 and 211 of Title 21 of the United States’ Code of Federal Regulations; and 

  

	 	(c)	EC Directive 2003/94/EC, 

 together with the latest Health Canada, FDA and EMEA guidance
documents pertaining to manufacturing and quality control practice, all as updated, amended and revised from time to time; 
 “Client
Intellectual Property” means Intellectual Property generated or derived by Client before entering into this Agreement or during any Term of this Agreement, or by Patheon while performing any Manufacturing Services or otherwise generated or
derived by Patheon in its business which Intellectual Property is specific to, integral or dependent upon, Client’s Active Material or Product; 

“Client Property” will have the meaning specified in Section 8.4(e); 

“Client-Supplied Components” means those Components to be supplied by Client or that have been supplied by Client; 

“CMC” has the meaning specified in Section 7.8(c); 

“Components” means, collectively, all packaging components, raw materials, ingredients, and other materials (including labels,
product inserts and other labelling for the Products) required to manufacture the Products in accordance with the Specifications, other than the Active Materials; 

“Confidentiality Agreement” means the agreement about the non-disclosure of confidential information between Patheon and
Client dated September 27, 2013; 
 “Deficiencies” has the meaning specified in Section 7.8(d); 

“Deficiency Notice” has the meaning specified in Section 6.1(a); 

“Delivery Date” means the date scheduled for shipment of Product under a Firm Order as set forth in Section 5.1(d); 

“EMA” means the European Medicines Agency; 

[”Equipment” will have the meaning ascribed to it in {the Capital Equipment Agreement related to this MSA if any}] 

“FDA” means the United States Food and Drug Administration; 

“Firm Orders” has the meaning specified in Section 5.1(b); 

  
 - 3 - 

 Master Manufacturing Services Agreement 

 

 “Force Majeure” will have the meaning specified in Section 13.7; 

“Health Canada” means the section of the Canadian Government known as Health Canada and includes, among other departments, the
Therapeutic Products Directorate and the Health Products and Food Branch Inspectorate; 
 “Initial Product Term” has the
meaning specified in Section 8.1; 
 “Initial Set Exchange Rate” means as of the Effective Date of a Product Agreement,
the initial exchange rate set forth in the Product Agreement to convert one unit of the billing currency into the Patheon Manufacturing Site local currency, calculated as the daily average interbank exchange rate for conversion of one unit of the
billing currency into the Patheon Manufacturing Site local currency during the 90 day period immediately preceding the Effective Date as published by OANDA.com “The Currency Site” under the heading “FxHistory: historical currency
exchange rates” at www.OANDA.com/convert/fxhistory; 
 “Initial Term” has the meaning specified in
Section 8.1; 
 “Intellectual Property” includes, without limitation, rights in patents, patent applications, formulae,
trademarks, trademark applications, trade-names, Inventions, copyrights, industrial designs, trade secrets, and know how; 

“Invention” means information about any innovation, improvement, development, discovery, computer program, device, trade
secret, method, know-how, process, technique or the like, whether or not written or otherwise fixed in any form or medium, regardless of the media on which it is contained and whether or not patentable or copyrightable; 

“Inventory” means all inventories of Components and work-in-process produced or held by Patheon for the manufacture of the
Products but, for greater certainty, does not include the Active Materials; 
 “Late Delivery” has the meaning specified in
Section 5.5; 
 “Laws” means all laws, statutes, ordinances, regulations, rules, by-laws, judgments, decrees or orders
of any Authority; 
 “Manufacturing Services” means the manufacturing, quality control, quality assurance, stability
testing, bulk packaging and finished product packaging (if agreed between the parties in the relevant Product Agreement), and related services, as set forth in this Agreement, required to manufacture Product or Products using the Active Materials,
Components, and Bill Back Items; 
 “Manufacturing Site” means the facility owned and operated by Patheon where the
Manufacturing Services will be performed as identified in a Product Agreement; 
 “Materials” means all Components and Bill
Back Items required to manufacture the Products in accordance with the Specifications, other than the Active Materials; 
 “Maximum
Credit Value” means the maximum value of Active Materials that may be credited by Patheon under this Agreement, as set forth in a Product Agreement on Schedule D; 

  
 - 4 - 

 Master Manufacturing Services Agreement 

 

 “Minimum Order Quantity” means the minimum number of batches of a Product to
be produced during the same cycle of manufacturing as set forth in a Product Agreement on Schedule B; 
 “Patheon
Competitor” means an entity that generates greater than [...***...]% of its gross revenues from performing contract pharmaceutical commercial manufacturing services pursuant to
arrangements with unrelated third party companies; 
 “Patheon Intellectual Property” means Intellectual Property generated
or derived by Patheon before performing any Manufacturing Services, or generated or derived by Patheon in its business which Intellectual Property is not specific to, integral to, or dependent upon, Client’s Active Material or Product
including, without limitation, Inventions and Intellectual Property which may apply to manufacturing processes or the formulation or development of drug products, drug product dosage forms or drug delivery systems unrelated to the specific
requirements of the Product(s); 
 “Price” means the price measured in US Dollars to be charged by Patheon for performing
the Manufacturing Services, and includes the cost of Components (other than Client-Supplied Components), certain cost items as set forth in a Product Agreement on Schedule B, and annual stability testing costs as set forth in Schedule C; 

“Product(s)” means the product(s) listed in a Product Agreement on Schedule A; 

“Product Agreement” means the agreement between Patheon and Client issued under this Agreement in the form set forth in
Appendix 1 (including Schedules A to D) under which Patheon will perform Manufacturing Services at a particular Manufacturing Site; 

“Quality Agreement” means the agreement (the general form of which is set forth in Exhibit B) between the parties entering a
Product Agreement that sets out the quality assurance standards for the Manufacturing Services to be performed by Patheon for Client; 

“Recall” has the meaning specified in Section 6.2(a); 

“Regulatory Authority” means the FDA, EMA, and Health Canada and any other foreign regulatory agencies competent to grant
marketing approvals for pharmaceutical products including the Products in the Territory; 
 “RFID” means Radio Frequency
Identification Devices which (at present or in the future) may be affixed to Products or Materials to assist in inventory control, tracking, and identification; 

“Remediation Period” has the meaning specified in Section 8.2(a); 

“Set Exchange Rate” means the exchange rate to convert one unit of the billing currency into the Patheon Manufacturing Site
local currency for each Year, calculated as the average daily interbank exchange rate for conversion of one unit of the billing currency into the Patheon Manufacturing Site local currency during the full year period (October 1st [preceding year] to September 30th) .as published by OANDA.com “The Currency Site” under the heading “FxHistory: historical
currency exchange rates” at www.OANDA.com/convert/fxhistory; 
 “Shortfall” has the meaning specified in
Section 2.2(b); 

  
  

***Confidential Treatment Requested 

- 5 - 

 Master Manufacturing Services Agreement 

 

 “Specifications” means the file, for each Product, which is given by Client
to Patheon in accordance with the procedures listed in a Product Agreement on Schedule A and which contains documents relating to each Product, including, without limitation: 

(a) specifications for Active Materials and Components; 

(b) manufacturing and testing specifications, directions, and processes; 

(c) storage requirements; 
 (d)
all environmental, health and safety information for each Product including material safety data sheets; and 
 (e) the finished Product
specifications, packaging specifications and shipping requirements for each Product; 
 all as updated, amended and revised from time to
time by Client in accordance with the terms of this Agreement; 
 “Target Yield” has the meaning specified in
Section 2.2(a); 
 “Target Yield Determination Batches” has the meaning specified in Section 2.2(a); 

“Technical Dispute” has the meaning specified in Section 12.2; 

“Territory” means the geographic area described in a Product Agreement where Products manufactured by Patheon will be
distributed by Client; 
 “Third Party Rights” means the Intellectual Property of any third party; and 

“Year” means in the first year of this Agreement or in the first year of a Product Agreement, the period from the Effective
Date up to and including December 31 of the same calendar year, and thereafter will mean a calendar year. 
 1.4 Currency.  

Unless otherwise agreed in a Product Agreement, all monetary amounts expressed in this Agreement are in United States Dollars (USD). 

1.5 Sections and Headings.  

The division of this Agreement into Articles, Sections, Subsections, an Appendix, and Exhibits and the insertion of headings are for
convenience of reference only and will not affect the interpretation of this Agreement. Unless otherwise indicated, any reference in this Agreement to a Section, Appendix or Exhibit refers to the specified Section, Appendix, or Exhibit to this
Agreement. In this Agreement, the terms “this Agreement”, “hereof”, “herein”, “hereunder” and similar expressions refer to this Agreement and not to any particular part, Section,
Appendix or Exhibit of this Agreement. 

  
 - 6 - 

 Master Manufacturing Services Agreement 

 

 1.6 Singular Terms. 

Except as otherwise expressly stated or unless the context otherwise requires, all references to the singular will include the plural and vice
versa. 
 1.7 Appendix 1 and Exhibits. 

Appendix 1 and the following Exhibits are attached to, incorporated in, and form part of this Agreement: 

 

							
	 Appendix 1
	  	 	—  	  	  	Form of Product Agreement (Including Schedules A to D)
			
	 Exhibit A
	  	 	—  	  	  	Technical Dispute Resolution
	 Exhibit B
	  	 	—  	  	  	Commercial Quality Agreement
	 Exhibit C
	  	 	—  	  	  	Quarterly Active Materials Inventory Report
	 Exhibit D
	  	 	—  	  	  	Report of Annual Active Materials Inventory Reconciliation and Calculation of Actual Annual Yield
	 Exhibit E
	  	 	—  	  	  	Example of Price Adjustment Due to Currency Fluctuation

  
 - 7 - 

 Master Manufacturing Services Agreement 

 

 ARTICLE 2 

PATHEON’S MANUFACTURING SERVICES 

2.1 Manufacturing Services. 

Patheon will perform the Manufacturing Services for the Territory for the fees specified in a Product Agreement in Schedules B and C to
manufacture Products for Client. Schedule B to a Product Agreement sets forth a list of cost items that are included in the Price for Products; all cost items that are not included in this list are excluded from the Price and are subject to
additional fees to be paid by the Client. Patheon may amend the fees set out in Schedules B and C to a Product Agreement as set forth in Article 4. Patheon may change the Manufacturing Site for the Products only with the prior written consent of
Client, this consent not to be unreasonably withheld. Unless otherwise agreed in a Product Agreement, Patheon will manufacture at least [...***...]% of the Products offered for sale by
Client in the Territory if Patheon remains in material compliance with its obligations under this Agreement and the Product Agreement. In performing the Manufacturing Services, Patheon and Client agree that: 

 

	 	(a)	Conversion of Active Materials and Components. Patheon will convert Active Materials and Components into Products. 

  

	 	(b)	Quality Control and Quality Assurance. Patheon will perform the quality control and quality assurance testing specified in the Quality Agreement. Batch review and release to Client will be the responsibility of
Patheon’s quality assurance group. Patheon will perform its batch review and release responsibilities in accordance with Patheon’s standard operating procedures. Each time Patheon ships Products to Client, it will give Client a certificate
of analysis and certificate of compliance, including deviations as specified by the Quality Agreement, including a statement that the batch has been manufactured and tested in accordance with Specifications and cGMPs. Client will have sole
responsibility for the release of Products to the market. The form and style of batch documents, including, but not limited to, batch production records, lot packaging records, equipment set up control, operating parameters, and data printouts, raw
material data, and laboratory notebooks are the exclusive property of Patheon. Specific Product related information contained in those batch documents is Client property. 

 

	 	(c)	Components. Patheon will purchase and test all Components (with the exception of Client-Supplied Components) at Patheon’s expense and as required by the Specifications. 

 

	 	(d)	Stability Testing. Patheon will conduct stability testing on the Products in accordance with the protocols set out in the Specifications for the separate fees and during the time periods set out in
Schedule C to a Product Agreement. Patheon will not make any changes to these testing protocols without prior written approval from Client. If a confirmed stability test failure occurs, Patheon will notify Client within [...***...], after
which Patheon and Client will jointly determine the proceedings and methods to be undertaken to investigate the cause of the failure, including which party will bear the cost of the investigation. Patheon will not be liable for these costs unless it
has failed to perform the Manufacturing Services in accordance with the Specifications, cGMPs, and Applicable Laws. Patheon will give Client all stability test data and results at Client’s request. 

 

	 	(e)	 Packaging. Patheon will package the Products as set out in the Specifications. Client will be responsible for the cost of artwork development.
Patheon will determine and imprint the batch numbers and expiration dates for each Product shipped. The batch numbers 

  
  

***Confidential Treatment Requested 

- 8 - 

 Master Manufacturing Services Agreement 

 

	 	
and expiration dates will be affixed on the Products and on the shipping carton of each Product as outlined in the Specifications and as required by cGMPs. Client may, in its sole discretion,
make changes to labels, product inserts, and other packaging for the Products. Those changes will be submitted by Client to all applicable governmental agencies and other third parties responsible for the approval of the Products. Client will be
responsible for the cost of labelling obsolescence when changes occur, as contemplated in Section 4.4. Patheon’s name will not appear on the label or anywhere else on the Products unless: (i) required by any Laws; or (ii) Patheon
consents in writing to the use of its name. 

  

	 	(f)	Active Materials and Client-Supplied Components. At least [...***...] days before the scheduled production date, Client will deliver the Active
Materials and any Client-Supplied Components to the Manufacturing Site [...***...] (Incoterms 2010), at no cost to Patheon, in sufficient quantity to enable Patheon to manufacture the desired quantities of Product and to ship Product on the
Delivery Date. If the Active Materials and/or Client-Supplied Components are not received [...***...] days before the scheduled production date, Patheon may delay the shipment of Product by the same number of days as the delay in receipt of
the Active Materials and/or Client-Supplied Components. But if Patheon is unable to manufacture Product to meet this new shipment date due to prior third party production commitments, Patheon may delay the shipment until a later date as agreed to by
the parties. All shipments of Active Material will be accompanied by certificate(s) of analysis from the Active Material manufacturer and the Client, confirming the identity and purity of the Active Materials and its compliance with the Active
Material specifications. At a minimum, Patheon will perform identity testing on each incoming lot of API and a full testing will be performed at least for one batch per year. Additional incoming tests to be performed on the API will be defined in
the respective Product Agreement. 

  

	 	(g)	Bill Back Items. Bill Back Items will be charged to Client at Patheon’s cost plus a [...***...]% handling fee for an item costing $[...***...] or less or, for an item costing in excess of
$[...***...], a handling fee of [...***...]%. 

  

	 	(h)	Validation Activities. Patheon may assist in the development and approval of the validation protocols for analytical methods and manufacturing procedures (including packaging procedures) for the Products. The
fees associated with Patheon’s assistance in providing validation development assistance are set out in Schedule C to a Product Agreement. 

  

	 	(i)	Product Rejection for Finished Product Specification Failure. Internal process specifications will be defined and agreed upon. If it is determined by a quality investigation that Patheon manufactured Product in
accordance with the agreed upon process specifications, the batch production record, and Patheon’s standard operating procedures for manufacturing, but a batch or portion of batch of Product does not meet a Finished Product Specification,
Client will pay Patheon the applicable fee per unit for the non-conforming Product. The API in the non-conforming Product will be included in the “Quantity Converted” for purposes of calculating the “Actual Annual Yield” under
Section 2.2(a). 

  
  

***Confidential Treatment Requested 

- 9 - 

 2.2 Active Material Yield.
  

	 	(a)	Reporting. Patheon will give Client a quarterly inventory report of the Active Materials held by Patheon using the inventory report form set out in Exhibit C, which will contain the following information for the
quarter: 

 Quantity Received: The total quantity of Active Materials that complies with the Specifications and is
received at the Manufacturing Site during the applicable period. 
 Quantity Dispensed: The total quantity of Active Materials
dispensed at the Manufacturing Site during the applicable period. The Quantity Dispensed is calculated by [...***...]. The Quantity Dispensed will only include Active Materials received and
dispensed in commercial manufacturing of Products and, for certainty, will not include any (i) Active Materials that must be retained by Patheon as samples, (ii) Active Materials contained in Product that must be retained as samples,
(iii) Active Materials used in testing (if applicable), and (iv) Active Materials received or dispensed in technical transfer activities or development activities during the applicable period, including without limitation, any regulatory,
stability, validation or test batches manufactured during the applicable period. 
 Quantity Converted: The total amount of Active
Materials contained in the Products manufactured with the Quantity Dispensed (including any additional Products produced in accordance with Section 6.3(a) or 6.3(b)), delivered by Patheon, and not rejected, recalled or returned in accordance
with Section 6.1 or 6.2 because of Patheon’s failure to perform the Manufacturing Services in accordance with Specifications, cGMPs, and Applicable Laws. 

Within [...***...] days after the end of each Year, Patheon will prepare an annual reconciliation of Active Materials on the
reconciliation report form set forth in Exhibit D including the calculation of the “Actual Annual Yield” or “AAY” for the Product at the Manufacturing Site during the Year. AAY is the percentage of the Quantity
Dispensed that was converted to Products and is calculated as follows: 
 Quantity Converted during the Year x 100% 

Quantity Dispensed during the Year 

Unless otherwise agreed in a Product Agreement, after Patheon has produced a minimum of [...***...] successful commercial production
batches of Product and has produced commercial production batches for at least [...***...] months at the Manufacturing Site (collectively, the “Target Yield Determination Batches”), the parties will agree on the target yield
for the Product at the Manufacturing Site (each, a “Target Yield”); The Target Yield will be revised annually to reflect the actual manufacturing experience as agreed to by the parties. 

 

	 	(b)	Shortfall Calculation. If the Actual Annual Yield falls more than [...***...]% below the respective Target Yield in a Year, then the shortfall for the Year (the “Shortfall”) will be
calculated as follows: 

  
 - 10 - 

 Master Manufacturing Services Agreement 

 

 [...***...] 

 

	 	(c)	Credit for Shortfall. If there is a Shortfall for a Product in a Year, then Patheon will credit Client’s account for the amount of the Shortfall not later than [...***...] days after the end of the
Year. 

 Each credit under this Section 2.2(c) will be summarized on the reconciliation report form set forth in Exhibit
D. Upon expiration or termination of a Product Agreement, any remaining credit owing under this Section 2.2 will be paid to Client. The Annual Shortfall, if any, will be disclosed by Patheon on the reconciliation report form. 

 

	 	(d)	Maximum Credit. Patheon’s liability for Active Materials calculated in accordance with this Section 2.2 [for any Product] in a Year will not exceed, in the aggregate, the Maximum Credit Value set
forth in Schedule D to a Product Agreement. 

  

	 	(e)	No Material Breach. It will not be a material breach of this Agreement by Patheon under Section 8.2(a) if the Actual Annual Yield is less than the Target Yield. 

ARTICLE 3 

CLIENT’S OBLIGATIONS 
 3.1
Payment. 
 Client will pay Patheon for performing the Manufacturing Services according to the Prices specified in
Schedules B and C in a Product Agreement. These Prices may be subject to adjustment under other parts of this Agreement. Client will also pay Patheon for any Bill Back Items. 

3.2 Active Materials and Qualification of Additional Sources of Supply. 

Client will at its sole cost and expense, deliver the Active Materials to Patheon (in accordance with Section 2.1(f)) sufficient for
Patheon to manufacture the desired quantities of Product and to ship Product on the Delivery Date. If applicable, Patheon and the Client will reasonably cooperate to permit the import of the Active Materials to the Manufacturing Site. Client’s
obligation will include obtaining the proper release of the Active Materials from the applicable Customs Agency and Regulatory Authority. Client or Client’s designated broker will be the “Importer of Record” for Active Materials
imported to the Manufacturing Site. The Active Materials will be held by Patheon on behalf of Client as set forth in this Agreement. Title to the Active Materials will at all times remain the property of Client. Any Active Materials received by
Patheon will only be used by Patheon to perform the Manufacturing Services. If the Parties mutually determine a need to change the supplier of any Active Material or Component (other than a supplier that is specifically described in an applicable
Product Agreement), they will work together to develop a plan to qualify such additional supplier. 

  
  

***Confidential Treatment Requested 

- 11 - 

 Master Manufacturing Services Agreement 

 

 ARTICLE 4 

CONVERSION FEES AND COMPONENT COSTS 

4.1 First Year Pricing. 
 The
tiered Price and annual stability Price for the Products for the first Year are listed in Schedules B and C in a Product Agreement and are subject to the adjustments set forth in Sections 4.2 and 4.3. Upon Client’s request, Patheon will
provide a breakdown of the manufacturing conversion costs, packaging conversion costs, and the Component costs for a Product. 
 4.2 Price Adjustments
– Subsequent Years’ Pricing. 
 After the first Year of the Product Agreement, but in no case before
[...***...], Patheon may adjust the Price effective January 1st of each Year as follows: 
  

	 	(a)	Manufacturing and Stability Testing Costs. For Products manufactured in the United States or Puerto Rico, Patheon may adjust the Price for inflation, based upon the preliminary number for any increase in the
Producer Price Index pcu325412325412 for Pharmaceutical Preparation Manufacturing (“PPI”) published by the United States Department of Labor, Bureau of Labor Statistics in August of the preceding Year compared to the final number
for the same month of the Year prior to that, unless the parties otherwise agree in writing. On or about November 1st of each Year, Patheon will give Client a statement setting forth the
calculation for the inflation adjustment to be applied in calculating the Price for the next Year. For Products manufactured outside the United States or Puerto Rico, Patheon may similarly adjust the Price for inflation using an inflation index to
be agreed by the parties in a Product Agreement. 

  

	 	(b)	Component Costs. If Patheon incurs an increase in Component costs during the Year, it may increase the Price for the next Year to pass through the additional Component costs. On or about November 1st of each
Year, Patheon will give Client information about the increase in Component costs which will be applied to the calculation of the Price for the next Year to reasonably demonstrate that the Price increase is justified. 

 

	 	(c)	Pricing Basis. Client acknowledges that the Price in any Year is quoted based upon the Minimum Order Quantity and the Annual Volume specified in Schedule B to a Product Agreement. The Price is subject to
change if [...***...]. 

  

	 	(d)	Adjustments Due to Currency Fluctuations. If the parties agree in a Product Agreement to invoice in a currency other than the local currency for the Manufacturing Site, Patheon will adjust the Price to reflect
currency fluctuations. The adjustment will be calculated after all 

  
  

***Confidential Treatment Requested 

- 12 - 

 Master Manufacturing Services Agreement 

 

	 	
other annual Price adjustments under this Section 4.2 have been made. The adjustment will proportionately reflect the increase or decrease, if any, in the Set Exchange Rate compared to the
Set Exchange Rate established for the prior Year or the Initial Set Exchange Rate, as the case may be. An example of the calculation of the price adjustment (for a Canadian Manufacturing Site invoiced in USD) is set forth in Exhibit E.

  

	 	(e)	Tier Pricing (if applicable). The pricing in Schedule B of a Product Agreement is set forth in Annual Volume tiers based upon the Client’s volume forecasts under Section 5.1. The Client will be
invoiced during the Year for the unit price set forth in the Annual Volume tier based on the [...***...] forecast provided in September of the previous Year. Within [...***...] days of the end of each Year or of the termination of
the Agreement, Patheon will send Client a reconciliation of the actual volume of Product ordered by the Client during the Year with the pricing tiers. If Client has overpaid during the Year, Patheon will issue a credit to the Client for the
amount of the overpayment within [...***...] days of the end of the Year or will issue payment to the Client for the overpayment within [...***...] days of the termination of the Agreement. If Client has underpaid during the Year,
Patheon will issue an invoice to the Client under Section 5.6 for the amount of the underpayment within [...***...] days of the end of the Year or termination of the Agreement. If Client disagrees with the reconciliation, the parties
will work in good faith to resolve the disagreement amicably. If the parties are unable to resolve the disagreement within [...***...] days, the matter will be handled under Section 12.1. 

 

	 	(f)	Process Improvement Efforts. Patheon continually works to improve its processes to eliminate waste, improve cost efficiencies, deliver product as promised and adhere to strict quality standards. Patheon believes
in the continuous improvement of its performance, which led Patheon to create the Patheon Advantage program. Patheon Advantage incorporates Lean6Sigma to identify opportunities and implement changes to maximize the efficiency of Patheon’s
processes. If these improvement efforts result in quantifiable reductions in costs in providing the Services contemplated under this Agreement Patheon will promptly notify Client of the reductions, and the Price hereunder will be reduced by
[...***...]% of the cost reduction from and after the date of the notice. 

 For all Price adjustments under this
Section 4.2, Patheon will deliver to Client on or about November 1st of each Year a revised Schedule B to the Product Agreement to be effective for Product delivered on or after the
first day of the next Year. 
 4.2.1 Price Adjustment due to Volume Changes from Yearly Forecast Volumes for Sterile Products.

 On the execution of a Product Agreement, Client will give to Patheon a forecast of the volume of Product required for the first
[...***...] Years of the Product Agreement (the “Yearly Forecast Volume” or “YFV”) that will become part of the Product Agreement. If at the end of the first Year the aggregate actual volume of Product ordered
by Client and invoiced by Patheon under Section 5.6 (“Actual Yearly Volume” or “AYV”) during the Year is less than the YFV as set out in the Product Agreement, then Client will pay Patheon for its non-absorbed
fixed manufacturing costs incurred during the Year in an amount to be determined as follows: 
 Amount due to
Patheon = [...***...] 

  
  

***Confidential Treatment Requested 

- 13 - 

 Master Manufacturing Services Agreement 

 

 On or before June 10 of each Year, the parties will agree on the YFV for the next
[...***...] of the Product Agreement on a rolling forward basis. The forecast of the volume of Product for the second Year may not vary by more than [...***...]% from the original YFV for the second Year. Once agreed, the YFV for the
next Year will become binding on the parties and any amount due to Patheon will be determined as set forth above. 
 4.3 Price Adjustments –
Current Year Pricing. 
 During any Year, the Prices set out in Schedule B of a Product Agreement will be adjusted as
follows: 
 Extraordinary Increases in Component Costs. If, at any time, market conditions result in Patheon’s cost of Components
being materially greater than normal forecasted increases, then Patheon will be entitled to an adjustment to the Price for any affected Product to compensate it for the increased Component costs. Changes materially greater than normal forecasted
increases will have occurred if: (i) the cost of a Component increases by [...***...]% of the cost for that Component upon which the most recent fee quote was based; or (ii) the aggregate cost for all Components required to
manufacture a Product increases by [...***...]% of the total Component costs for the Product upon which the most recent fee quote was based. If Component costs have been previously adjusted to reflect an increase in the cost of one or more
Components, the adjustments set out in (i) and (ii) above will operate based on the last cost adjustment for the Components. 
 For
a Price adjustment under this Section 4.3, Patheon will deliver to Client a revised Schedule B to the Product Agreement and budgetary pricing information, adjusted Component costs or other documents reasonably sufficient to demonstrate that a
Price adjustment is justified. Patheon will have no obligation to deliver any supporting documents that are subject to obligations of confidentiality between Patheon and its suppliers. The revised Price will be effective for any Product delivered on
or after the first day of the month following Client’s receipt of the revised Schedule B to the Product Agreement. 
 4.4 Adjustments Due to
Technical Changes. 
 Amendments to the Specifications or the Quality Agreement requested by Client will only be implemented
following a technical and cost review that Patheon will perform at Client’s cost, and are subject to Client and Patheon reaching agreement on Price changes required because of the amendment. Amendments to the Specifications, the Quality
Agreement, or the Manufacturing Site requested by Patheon will only be implemented following the written approval of Client, the approval not to be unreasonably withheld. If Client accepts a proposed Price change, the proposed change in the
Specifications will be implemented at Client’s cost, and the Price change will become effective, only for those orders of Products that are manufactured under the revised Specifications. In addition, Client agrees to purchase, at Patheon’s
cost (including all costs incurred by Patheon for the purchase and handling of the Inventory), all Inventory used under the “old” Specifications and purchased or maintained by Patheon in order to fill Firm Orders or under Section 5.2,
if the Inventory can no longer be used under the revised Specifications. Open purchase orders for Components no longer required under any revised Specifications that were placed by Patheon with suppliers in order to fill Firm Orders or under
Section 5.2 will be cancelled where possible, and if the orders may not be cancelled without penalty, will be assigned to and satisfied by Client. If an amendment to the Specifications or the Quality Agreement becomes necessary as the result of
changes to a compendia, the Parties will discuss the necessary changes and Client will be solely responsible for the costs associated with these changes. 

  
  

***Confidential Treatment Requested 

- 14 - 

 Master Manufacturing Services Agreement 

 

 4.5 Multi-Country Packaging Requirements. 

If Client decides to have Patheon perform Manufacturing Services for the Product for countries outside the Territory, then Client will inform
Patheon of the packaging requirements for each new country and Patheon will prepare a quotation for consideration by Client of any additional costs for Components (other than Client-Supplied Components) and the change over fees for the Product
destined for each new country. The agreed additional packaging requirements and related packaging costs and change over fees will be set out in a written amendment to this Agreement. 

ARTICLE 5 
 ORDERS,
SHIPMENT, INVOICING, PAYMENT 
 5.1 Orders and Forecasts.  

 

	 	(a)	Rolling [...***...] Month Forecast. When each Product Agreement is executed, Client will give Patheon a non-binding [...***...] month forecast of the volume of Product that Client expects to
order in the first [...***...] months of commercial manufacture of the Product. This forecast will then be updated by Client on or before the [...***...] day of each month on a rolling forward basis. Client will update the forecast
forthwith if it determines that the volumes estimated in the most recent forecast have changed by more than [...***...]%. The most recent [...***...] month forecast will prevail. 

 

	 	(b)	Firm Orders. On a rolling basis during the term of the Product Agreement, Client will issue an updated [...***...] month forecast on or before the [...***...] day of each month. This forecast will
start on the first day of the next month. The first [...***...] months of this updated forecast will be considered binding firm orders. Concurrent with the [...***...] month forecast, Client will issue a new firm written order in the
form of a purchase order or otherwise (“Firm Order”) by Client to purchase and, when accepted by Patheon, for Patheon to manufacture and deliver the agreed quantity of the Products. The Delivery Date will not be less than
[...***...] days following the date that the Firm Order is submitted. Firm Orders submitted to Patheon will specify Client’s purchase order number, quantities by Product type, monthly delivery schedule, and any other elements necessary to
ensure the timely manufacture and shipment of the Products. The quantities of Products ordered in those written orders will be firm and binding on Client and may not be reduced by Client. 

 

	 	(c)	[...***...] Year Forecast. On or before the [...***...] of each Year, Client will give Patheon a written non-binding [...***...]-year forecast, broken down by quarters for the [...***...]
and [...***...] years of the forecast, of the volume of each Product Client then anticipates will be required to be manufactured and delivered to Client during the [...***...]-year period. 

 

	 	(d)	Acceptance of Firm Order. Patheon will accept Firm Orders by sending an acknowledgement to Client within [...***...] Business Days of its receipt of the Firm Order. The acknowledgement will include, subject
to confirmation from the Client, the Delivery Date for the Product ordered. The Delivery Date may be amended by agreement of the parties or as set forth in Section 2.1(f). 

  
  

***Confidential Treatment Requested 

- 15 - 

 Master Manufacturing Services Agreement 

 

 5.2 Reliance by Patheon. 

(a) Client understands and acknowledges that Patheon will rely on the Firm Orders and rolling forecasts submitted under Sections 5.1(a), and
(b) in ordering the Components (other than Client-Supplied Components) required to meet the Firm Orders. In addition, Client understands that to ensure an orderly supply of the Components, Patheon may want to purchase the Components in
sufficient volumes to meet the production requirements for Products during part or all of the forecasted periods referred to in Section 5.1(a) or to meet the production requirements of any longer period agreed to by Patheon and Client.
Accordingly, Client authorizes Patheon to purchase Components to satisfy the Manufacturing Services requirements for Products for the first [...***...] months contemplated in the most recent forecast given by Client under Section 5.1(a).
Patheon may make other purchases of Components to meet Manufacturing Services requirements for longer periods if agreed to in writing by the parties. The Client will give Patheon written authorization to order Components for any launch quantities of
Product requested by Client which will be considered a Firm Order when accepted by Patheon. If Components ordered by Patheon under Firm Orders or this Section 5.2 are not included in finished Products manufactured for Client within
[...***...] months after the forecasted month for which the purchases have been made (or for a longer period as the parties may agree) or if the Components have expired during the period, then Client will pay to Patheon its costs therefor
(including all costs incurred by Patheon for the purchase and handling of the Components). But if these Components are used in Products subsequently manufactured for Client or in third party products manufactured by Patheon, Client will receive
credit for any costs of those Components previously paid to Patheon by Client. 
 (b) If Client fails to take possession or arrange for the
destruction of Components within [...***...] months of purchase or, in the case of finished Product, within [...***...] of manufacture, Client will pay Patheon $[...***...] per pallet, per month thereafter for storing the
Components or finished Product. Storage fees for Components or Product which contain controlled substances or require refrigeration will be charged at $[...***...] per pallet per month. Storage fees are subject to a one pallet minimum charge
per month. Patheon may ship finished Product held by it longer than [...***...] to the Client at Client’s expense on [...***...] days written notice to the Client. 

5.3 Minimum Orders. 
 Client
may only order Manufacturing Services for batches of Products in multiples of the Minimum Order Quantities as set out in Schedule B to a Product Agreement. 

5.4 Shipments. 
 Shipments
of Products will be made [...***...] (Incoterms 2010) Patheon’s shipping point unless otherwise agreed in a Product Agreement. Risk of loss or of damage to Products will remain with Patheon until Patheon loads the Products onto the
carrier’s vehicle for shipment at which time risk of loss or damage will transfer to Client. Patheon will, in accordance with Client’s instructions and as agent for Client, (i) arrange for shipping to be paid by Client and
(ii) obtain any export license or other official authorization necessary to export the Products. Client will arrange for insurance and will select the freight carrier used by Patheon to ship Products and may monitor Patheon’s shipping and
freight practices as they pertain to this Agreement. Products will be transported in accordance with the Specifications. 

  
  

***Confidential Treatment Requested 

- 16 - 

 Master Manufacturing Services Agreement 

 

 5.5 Late Delivery  

If Patheon is unable to deliver the quantity of Product ordered under a Firm Order within [...***...] of the Delivery Date due to an act or omission by
Patheon (a “Late Delivery”), Client will receive a credit from Patheon for the Late Delivery that will be applied against the purchase price under the next Firm Order. The credit will be [...***...]% of the Price of the
quantities of Product not delivered by Patheon under the Firm Order within [...***...] of the Delivery Date [...***...]. An additional credit of [...***...]% of the Price of the quantities of Product not delivered by Patheon under
a Firm Order will accrue for each additional [...***...] of the Late Delivery up to a maximum aggregate credit of [...***...]%. A Late Delivery will not be a material breach of this Agreement by Patheon for the purposes of
Section 8.2(a). For clarity, a Late Delivery will not include any delay in shipment of Product caused by events outside of Patheon’s reasonable control, such as a Force Majeure Event, a delay in delivery of API or Materials, a delay in
Product release approval from Client, inaccurate Client forecasts, receipt of non-conforming API or Client-Supplied Components, or any market driven delays in deliveries from approved vendors. 

5.6 Invoices and Payment. 

Invoices will be sent by fax or email to the fax number or email address given by Client to Patheon in writing. Invoices will be sent when the
Product is manufactured and released by Patheon to the Client. Patheon will also submit to Client, with each shipment of Products, a duplicate copy of the invoice covering the shipment. Patheon will also give Client an invoice covering any Inventory
or Components which are to be purchased by Client under Section 5.2 of this Agreement. Each invoice will, to the extent applicable, identify Client’s Manufacturing Services purchase order number, Product numbers, names and quantities, unit
price, freight charges, and the total amount to be paid by Client. Client will pay all invoices within [...***...] days of the date thereof. If any portion of an invoice is disputed, the Client will pay Patheon for the undisputed amount and
the parties will use good faith efforts to reconcile the disputed amount as soon as practicable. Beginning [...***...] days after the date of the invoice, interest on undisputed past due accounts will accrue at [...***...]% per month
which is equal to an annual rate of [...***...]%. The Late Delivery credits set forth in Section 5.5 are only available to Client if all outstanding undisputed invoices have been paid in full or are within [...***...] days
outstanding from the invoice date when the Late Delivery arose. 
 ARTICLE 6 

PRODUCT CLAIMS AND RECALLS 
 6.1
Product Claims. 
 (a) Product Claims. Client has the right to reject any portion of any shipment of Products that
deviates from the Specifications, cGMPs, or Applicable Laws without invalidating any remainder of the shipment. Client will inspect the Products manufactured by Patheon upon receipt and will give Patheon written notice (a “Deficiency
Notice”) of all claims for Products that deviate from the Specifications, cGMPs, or Applicable Laws within [...***...] days after Client’s receipt thereof (or, in the case of any defects not reasonably susceptible to discovery
upon receipt of the Product, within [...***...] days after discovery by Client, but not after the expiration date of the Product). Should Client fail to give Patheon the Deficiency Notice within the applicable [...***...] day period,
then the delivery will be deemed to have been accepted by Client on the [...***...] day after delivery or discovery, as applicable. Except as set out in Section 6.3, Patheon will have no liability for any deviations for which it has not
received notice within the applicable [...***...] day period. 

  
  

***Confidential Treatment Requested 

- 17 - 

 Master Manufacturing Services Agreement 

 

 (b) Determination of Deficiency. Upon receipt of a Deficiency Notice, Patheon will
have [...***...] days to advise Client by notice in writing that it disagrees with the contents of the Deficiency Notice. If Client and Patheon fail to agree within [...***...] days after Patheon’s notice to Client as to whether
any Products identified in the Deficiency Notice deviate from the Specifications, cGMPs, or Applicable Laws, then the parties will mutually select an independent laboratory to evaluate if the Products deviate from the Specifications, cGMPs, or
Applicable Laws. This evaluation will be binding on the parties. If the evaluation certifies that any Products deviate from the Specifications, cGMPs, or Applicable Laws, Client may reject those Products in the manner contemplated in this
Section 6.1 and Patheon will be responsible for the cost of the evaluation. If the evaluation does not so certify for any of the Products, then Client will be deemed to have accepted delivery of the Products on the [...***...] day after
delivery (or, in the case of any defects not reasonably susceptible to discovery upon receipt of the Product, on the [...***...] day after discovery thereof by Client, but not after the expiration date of the Product) and Client will be
responsible for the cost of the evaluation. 
 (c) Shortages. Claims for shortages in the amount of Products shipped by Patheon will
be dealt with by reasonable agreement of the parties. 
 6.2 Product Recalls and Returns. 

(a) Records and Notice. Patheon and Client will each maintain records necessary to permit a Recall of any Products delivered to Client
or customers of Client. Each party will promptly notify the other by telephone (to be confirmed in writing) of any information which might affect the marketability, safety or effectiveness of the Products or which might result in the Recall or
seizure of the Products. Upon receiving this notice or upon this discovery, each party will stop making any further shipments of any Products in its possession or control until a decision has been made whether a Recall or some other corrective
action is necessary. The decision to initiate a Recall or to take some other corrective action, if any, will be made and implemented by Client. “Recall” will mean any action (i) by Client to recover title to or possession of
quantities of the Products sold or shipped to third parties (including, without limitation, the voluntary withdrawal of Products from the market); or (ii) by any regulatory authorities to detain or destroy any of the Products. Recall will also
include any action by either party to refrain from selling or shipping quantities of the Products to third parties which would have been subject to a Recall if sold or shipped. 

(b) Recalls. If (i) any governmental or regulatory authority issues a directive, order or, following the issuance of a safety
warning or alert about a Product, a written request that any Product be Recalled, (ii) a court of competent jurisdiction orders a Recall, or (iii) Client determines that any Product should be Recalled or that a “Dear Doctor”
letter is required relating the restrictions on the use of any Product, Patheon will co-operate as reasonably required by Client, having regard to all applicable laws and regulations. 

(c) Product Returns. Client will have the responsibility for handling customer returns of the Products. Patheon will give Client any
assistance that Client may reasonably require to handle the returns. 
 6.3 Patheon’s Responsibility for Defective and Recalled Products.

 (a) Defective Product. If Client rejects Products under Section 6.1 and the deviation is determined to have arisen from
Patheon’s failure to provide the Manufacturing Services in accordance with the Specifications, cGMPs, or Applicable Laws, Patheon will credit Client’s account for Patheon’s invoice price for the defective Products. If Client
previously paid for the defective Products, Patheon will promptly, at Client’s election, either: (i) refund the invoice price for the defective Products; (ii) offset the 

  
  

***Confidential Treatment Requested 

- 18 - 

 Master Manufacturing Services Agreement 

 

 
amount paid against other amounts due to Patheon hereunder; or (iii) replace the Products with conforming Products without Client being liable for payment therefor under Section 3.1,
contingent upon the receipt from Client of all Active Materials and Client-Supplied Components required for the manufacture of the replacement Products. For greater certainty, Patheon’s responsibility for any loss of Active Materials in
defective Product will be captured and calculated in the Active Materials Yield under Section 2.2. 
 (b) Recalled Product. If a
Recall or return results from, or arises out of, a failure by Patheon to perform the Manufacturing Services in accordance with the Specifications, cGMPs, or Applicable Laws, Patheon will be responsible for the documented out-of-pocket expenses of
the Recall or return and will use its commercially reasonable efforts to replace the Recalled or returned Products with new Products, contingent upon the receipt from Client of all Active Materials and Client-Supplied Components required for the
manufacture of the replacement Products. For greater certainty, Patheon’s responsibility for any loss of Active Materials in Recalled Product will be captured and calculated in the Active Materials Yield under Section 2.2. If Patheon is
unable to replace the Recalled or returned Products (except where this inability results from a failure to receive the required Active Materials and Client-Supplied Components), then Client may request Patheon to reimburse Client for the price that
Client paid to Patheon for Manufacturing Services for the affected Products. In all other circumstances, Recalls, returns, or other corrective actions will be made at Client’s cost and expense. 

(c) Except as set forth in Sections 6.3(a) and (b) above, Patheon will not be liable to Client nor have any responsibility to Client for
any deficiencies in, or other liabilities associated with, any Product manufactured by it, (collectively, “Product Claims”). For greater certainty, Patheon will have no obligation for any Product Claims to the extent the Product
Claim (i) is caused by deficiencies in the Specifications, the safety, efficacy, or marketability of the Products or any distribution thereof, (ii) results from a defect in a Component that is not reasonably discoverable by Patheon using
the test methods set forth in the Specifications, (iii) results from a defect in the Active Materials or Client-Supplied Components that is not reasonably discoverable by Patheon using the test methods set forth in the Specifications,
(iv) is caused by actions of third parties occurring after the Product is shipped by Patheon under Section 5.4, (v) is due to packaging design or labelling defects or omissions for which Patheon has no responsibility, (vi) is due
to any unascertainable reason despite Patheon having performed the Manufacturing Services in accordance with the Specifications, cGMP’s, and Applicable Laws, or (vii) is due to any other breach by Client of its obligations under this
Agreement. 
 6.4 Disposition of Defective or Recalled Products. 

Client will not dispose of any damaged, defective, returned, or Recalled Products for which it intends to assert a claim against Patheon
without Patheon’s prior written authorization to do so. Alternatively, Patheon may instruct Client to return the Products to Patheon. Patheon will bear the cost of disposition for any damaged, defective, returned or Recalled Products for which
it bears responsibility under Section 6.3. In all other circumstances, Client will bear the cost of disposition, including all applicable fees for Manufacturing Services, for any damaged, defective, returned, or Recalled Products. 

6.5 Healthcare Provider or Patient Questions and Complaints. 

Client will have the sole responsibility for responding to questions and complaints from its customers. Questions or complaints received by
Patheon from Client’s customers, healthcare providers or patients will be promptly referred to Client. Patheon will co-operate as reasonably required to allow Client to determine the cause of and resolve any questions and complaints. This
assistance will include follow-up investigations, including testing. In addition, Patheon will give Client all agreed upon information that will enable Client to respond properly to questions or complaints about the Products as

  
 - 19 - 

 Master Manufacturing Services Agreement 

 

 
set forth in the Quality Agreement. Unless it is determined that the cause of the complaint resulted from a failure by Patheon to perform the Manufacturing Services in accordance with the
Specifications, cGMPs, and Applicable Laws, all costs incurred under this Section 6.5 will be borne by Client. 
 6.6 Sole Remedy.

 Except for the indemnity set forth in Section 10.3 and subject to the limitations set forth in Sections 10.1 and 10.2, the
remedies described in this Article 6 will be Client’s sole remedy for any failure by Patheon to provide the Manufacturing Services in accordance with the Specifications, cGMPs, and Applicable Laws. 

ARTICLE 7 

CO-OPERATION 
 7.1 Quarterly
Review. 
 Each party will forthwith upon execution of this Agreement appoint one of its employees to be a relationship
manager responsible for liaison between the parties. The relationship managers will meet not less than quarterly to review the current status of the business relationship and manage any issues that have arisen. 

7.2 Governmental Agencies. 

Subject to Section 7.8, each party may communicate with any governmental agency, including but not limited to governmental agencies
responsible for granting regulatory approval for the Products, regarding the Products if, in the opinion of that party’s counsel, the communication is necessary to comply with the terms of this Agreement or the requirements of any law,
governmental order or regulation. Unless, in the reasonable opinion of its counsel, there is a legal prohibition against doing so, a party will permit the other party to accompany and take part in any communications with the agency, and to receive
copies of all communications from the agency. 
 7.3 Records and Accounting by Patheon. 

Patheon will keep records of the manufacture, testing, and shipping of the Products, and retain samples of the Products as are necessary to
comply with manufacturing regulatory requirements applicable to Patheon, as well as to assist with resolving Product complaints and other similar investigations. Copies of the records and samples will be retained for [...***...] following the
date of Product expiry, or longer if required by law, at which time Client will be contacted concerning the delivery and destruction of the documents and/or samples of Products. Client is responsible for retaining samples of the Products necessary
to comply with the legal/regulatory requirements applicable to Client. 
 7.4 Inspection. 

Client may inspect Patheon reports and records relating to this Agreement during normal business hours and with reasonable advance notice, but
a Patheon representative must be present during the inspection. 

  
  

***Confidential Treatment Requested 

- 20 - 

 Master Manufacturing Services Agreement 

 

 7.5 Access. 

Patheon will give Client reasonable access at agreed times to the areas of the Manufacturing Site in which the Products are manufactured,
stored, handled, or shipped to permit Client to verify that the Manufacturing Services are being performed in accordance with the Specifications, cGMPs, and Applicable Laws. But, with the exception of “for-cause” audits, Client will be
limited each Year to one cGMP-type audit, lasting no more than [...***...] days, and involving no more than [...***...] auditors. Client may request additional cGMP-type audits, additional audit days, or the participation of additional
auditors subject to payment to Patheon of a fee of $[...***...] for each additional audit day and $[...***...] per audit day for each additional auditor. The right of access set forth in this Section 7.5 will not include a right to
access or inspect Patheon’s financial records. In addition to any other rights to audit, otherwise described in this Agreement, Client will have the right to have up to [...***...] representatives present for [...***...] days during
the manufacturing campaigns of any Product during normal business hours and upon reasonable advance notice to Patheon. If Client’s representatives are present for more than [...***...] days during the manufacturing campaigns of any
Products, Client will pay Patheon a fee of $[...***...] per day for each additional day. 
 7.6 Notification of Regulatory
Inspections. 
 Patheon will notify Client within [...***...] of any inspections by any governmental agency specifically
involving the Products. Patheon will also notify Client of receipt of any form 483’s or warning letters or any other significant regulatory action which Patheon’s quality assurance group determines could impact the regulatory status of the
Products. 
 7.7 Reports. 

Patheon will supply on an annual basis all Product data in its control, including release test results, complaint test results, and all
investigations (in manufacturing, testing, and storage), that Client reasonably requires in order to complete any filing under any applicable regulatory regime, including any Annual Report that Client is required to file with the FDA. At the
Client’s request, Patheon will provide a copy of the Annual Product Review Report to the Client at no additional cost. Any additional report requested by Client beyond the scope of cGMPs and customary FDA requirements will be subject to an
additional fee to be agreed upon between Patheon and the Client. 
 7.8 Regulatory Filings. 

(a) Regulatory Authority. Client will have the sole responsibility for filing all documents with all Regulatory Authorities and taking
any other actions that may be required for the receipt and/or maintenance of Regulatory Authority approval for the commercial manufacture of the Products. Patheon will assist Client, to the extent consistent with Patheon’s obligations under
this Agreement, to obtain Regulatory Authority approval for the commercial manufacture of all Products as quickly as reasonably possible. 

(b) Verification of Data. Prior to filing any documents with any Regulatory Authority that incorporate data generated by Patheon, Client
will give Patheon a copy of the documents incorporating this data to give Patheon the opportunity to verify the accuracy and regulatory validity of those documents as they relate to Patheon generated data. Patheon requires [...***...] days to
perform this review but the parties may agree to a shorter time for the review as needed. 

  
  

***Confidential Treatment Requested 

- 21 - 

 Master Manufacturing Services Agreement 

 

 (c) Verification of CMC. Prior to filing with any Regulatory Authority any
documentation which is or is equivalent to the FDA’s Chemistry and Manufacturing Controls (all such documentation herein referred to as “CMC”) related to any Marketing Authorization, such as a New Drug Application or
Abbreviated New Drug Application, Client will give Patheon a copy of the CMC as well as all supporting documents which have been relied upon to prepare the CMC. This disclosure will permit Patheon to verify that the CMC accurately describes the work
that Patheon has performed and the manufacturing processes that Patheon will perform under this Agreement. Patheon requires [...***...] days to perform this review but the parties may agree to a shorter time for the review as needed. Client
will give Patheon copies of all FDA filings which contain CMC information regarding the Product within [...***...] days of the approval submission. 

(d) Deficiencies. If, in Patheon’s sole discretion, acting reasonably, Patheon determines that any of the information given by
Client under clauses (b) and (c) above is inaccurate or deficient in any manner whatsoever (the “Deficiencies”), Patheon will notify Client in writing of the Deficiencies. The parties will work together to have the
Deficiencies resolved prior to any pre-approval inspection. 
 (e) Client Responsibility. For clarity, the parties agree that in
reviewing the documents referred to in clause (b) above, Patheon’s role will be limited to verifying the accuracy of the description of the work undertaken or to be undertaken by Patheon. Subject to the foregoing, Patheon will not assume
any responsibility for the accuracy of any application for receipt of an approval by a Regulatory Authority. The Client is solely responsible for the preparation and filing of the application for approval by the Regulatory Authority and any relevant
costs will be borne by the Client. 
 (f) Inspection by Regulatory Authorities. If Client does not give Patheon the documents
requested under clause (b) above within the time specified and if Patheon reasonably believes that Patheon’s standing with a Regulatory Authority may be jeopardized, Patheon may, in its sole discretion, delay or postpone any inspection by
the Regulatory Authority until Patheon has reviewed the requested documents and is satisfied with their contents. 
 ARTICLE 8 

TERM AND TERMINATION 
 8.1
Initial Term. 
 This Agreement will become effective as of the Effective Date and will continue until December 31,
2019 (the “Initial Term”), unless terminated earlier by one of the parties in accordance herewith. This Agreement will automatically renew after the Initial Term for successive terms of three Years each if there is a Product
Agreement in effect, unless either party gives written notice to the other party of its intention to terminate this Agreement at least 24 months prior to the end of the then current term. In any event, the legal terms and conditions of this
Agreement will continue to govern any Product Agreement in effect as provided in Section 1.2. Each Product Agreement will have an initial term of five Years from the start of commercial manufacture at the Manufacturing Site for the Product
unless the parties agree to a different number of Years in the applicable Product Agreement (each, an “Initial Product Term”). Product Agreements will automatically renew after the Initial Product Term for successive terms of three
Years each unless either party gives written notice to the other party of its intention to terminate the Product Agreement at least 24 months prior to the end of the then current term. 

8.2 Termination for Cause. 

(a) Either party at its sole option may terminate this Agreement or a Product Agreement upon written notice where the other party has failed
to remedy a material breach of any of its representations, 

  
  

***Confidential Treatment Requested 

- 22 - 

 Master Manufacturing Services Agreement 

 

 
warranties, or other obligations under this Agreement or the Product Agreement within 60 days following receipt of a written notice (the “Remediation Period”) of the breach
that expressly states that it is a notice under this Section 8.2(a) (a “Breach Notice”). The aggrieved party’s right to terminate this Agreement or a Product Agreement under this Section 8.2(a) may only be exercised
for a period of 60 days following the expiry of the Remediation Period (where the breach has not been remedied) and if the termination right is not exercised during this period then the aggrieved party will be deemed to have waived the breach
of the representation, warranty, or obligation described in the Breach Notice. 
 (b) Either party at its sole option may immediately
terminate this Agreement or a Product Agreement upon written notice, but without prior advance notice, to the other party if: (i) the other party is declared insolvent or bankrupt by a court of competent jurisdiction; (ii) a voluntary
petition of bankruptcy is filed in any court of competent jurisdiction by the other party; or (iii) this Agreement or a Product Agreement is assigned by the other party for the benefit of creditors. 

(c) Client may terminate a Product Agreement upon 30 days’ prior written notice if any Authority takes any action, or raises any
objection, that prevents Client from importing, exporting, purchasing, or selling the Product. But if this occurs, Client must still fulfill all of its obligations under Section 8.4 below and under any Capital Equipment Agreement regarding the
Product. 
 (d) Patheon may terminate this Agreement or a Product Agreement upon six months’ prior written notice if Client assigns
under Section 13.6 any of its rights under this Agreement or a Product Agreement to an assignee that, in the reasonable opinion of Patheon, is: (i) not a credit worthy substitute for Client or (ii) a Patheon Competitor. 

8.3 Product Discontinuation. 

Client will give at least six months’ advance notice if it intends to no longer order Manufacturing Services for a Product due to this
Product’s discontinuance in the market. 
 8.4 Obligations on Termination. 

If a Product Agreement is completed, expires, or is terminated in whole or in part for any reason, then: 

 

	 	(a)	Client will take delivery of and pay for all undelivered Products that are manufactured and/or packaged under a Firm Order, at the price in effect at the time the Firm Order was placed, subject to Client’s right to
reject any such Product as described in Article 6 of this Agreement; 

  

	 	(b)	Client will purchase, at Patheon’s cost (including all costs incurred by Patheon for the purchase and handling of the Inventory), the Inventory applicable to the Products which was purchased, produced or maintained
by Patheon in contemplation of filling Firm Orders or in accordance with Section 5.2, but not including Components which Patheon can use in its other Manufacturing operations and not including any Inventory that has been stored or otherwise
maintained in an environment that a Regulatory Authority has determined, or would reasonably determine, is not cGMP compliant; 

  

	 	(c)	Client will satisfy the purchase price payable under Patheon’s orders with suppliers of Components, if the orders were made by Patheon in reliance on Firm Orders or in accordance with Section 5.2;

  
  

***Confidential Treatment Requested 

- 23 - 

 Master Manufacturing Services Agreement 

 

	 	(d)	Client acknowledges that no Patheon Competitor will be permitted access to the Manufacturing Site; and 

  

	 	(e)	Client will make commercially reasonable efforts, at its own expense, to remove from Patheon site(s), within 30 days, all unused Active Material and Client-Supplied Components, all applicable Inventory and Materials
(whether current or obsolete), supplies, undelivered Product, chattels, [E]equipment or other moveable property owned by Client, related to the Agreement and located at a Patheon site or that is otherwise under Patheon’s care and control
(“Client Property”). If Client fails to remove the Client Property within 30 days following the completion, termination, or expiration of the Product Agreement, Client will pay Patheon $100.00 per pallet, per month, one pallet
minimum (except that Client will pay $200 per pallet, per month, one pallet minimum, for any of the Client Property that contains controlled substances, requires refrigeration or other special storage requirements) thereafter for storing the Client
Property and will assume any third party storage charges invoiced to Patheon regarding the Client Property. Patheon will invoice Client for the storage charges as set forth in Section 5.6 of this Agreement. 

 

	 	(f)	The parties will reasonably cooperate to support the transfer of the manufacture of the Products to a third party manufacturer. 

Any termination or expiration of this Agreement or a Product Agreement will not affect any outstanding obligations or payments due prior to the termination or
expiration, nor will it prejudice any other remedies that the parties may have under this Agreement or a Product Agreement or any related Capital Equipment Agreement. For greater certainty, termination of this Agreement or of a Product Agreement for
any reason will not affect the obligations and responsibilities of the parties under Articles 6, 10 and 11 and Sections 5.4, 5.6, 8.4, 13.1, 13.2, 13.3, and 13.16, all of which survive any termination. 

ARTICLE 9 

REPRESENTATIONS, WARRANTIES AND COVENANTS 

9.1 Authority. 
 Each party
covenants, represents, and warrants that it has the full right and authority to enter into this Agreement and that it is not aware of any impediment that would inhibit its ability to perform its obligations hereunder. 

9.2 Client Warranties. 

Client covenants, represents, and warrants that: 
  

	 	(a)	Non-Infringement. 

  

	 	(i)	the Specifications for each of the Products are its or its Affiliate’s property and that Client may lawfully disclose the Specifications to Patheon; 

 

	 	(ii)	any Client Intellectual Property, used by Patheon in performing the Manufacturing Services according to the Specifications (A) is Client’s or its Affiliate’s unencumbered property, (B) may be
lawfully used as directed by Client, and (C) does not infringe and will not infringe any Third Party Rights; 

  
 - 24 - 

 Master Manufacturing Services Agreement 

 

	 	(iii)	the performance of the Manufacturing Services by Patheon for any Product under this Agreement or any Product Agreement or the use or other disposition of any Product by Patheon as may be required to perform its
obligations under this Agreement or under any Product Agreement does not and will not infringe any Third Party Rights; 

  

	 	(iv)	there are no actions or other legal proceedings, concerning the infringement of Third Party Rights related to any of the Specifications, or any of the Active Materials and the Components, or the sale, use, or other
disposition of any Product made in accordance with the Specifications; 

  

	 	(b)	Quality and Compliance. 

  

	 	(i)	the Specifications for all Products conform to all applicable cGMPs and Applicable Laws; 

  

	 	(ii)	the Products, if labelled and manufactured in accordance with the Specifications and in compliance with applicable cGMPs and Applicable Laws (i) may be lawfully sold and distributed in every jurisdiction in which
Client markets the Products, (ii) will be fit for the purpose intended, and (iii) will be safe for human consumption; 

  

	 	(iii)	on the date of shipment, the API will conform to the specifications for the API that Client has given to Patheon and that the API will be adequately contained, packaged, and labelled and will conform to the affirmations
of fact on the container. 

 9.3 Patheon Warranties. 

Patheon covenants, represents, and warrants that: 
  

	 	(a)	it will perform the Manufacturing Services in accordance with the Specifications, cGMPs, and Applicable Laws; and 

  

	 	(b)	any Patheon Intellectual Property used by Patheon to perform the Manufacturing Services (i) is Patheon’s or its Affiliate’s unencumbered property, (ii) may be lawfully used by Patheon, and
(iii) does not infringe and will not infringe any Third Party Rights. 

 9.4 Debarred Persons. 

Patheon covenants that it will not in the performance of its obligations under this Agreement use the services of any person debarred or
suspended under 21 U.S.C. §335(a) or (b). Patheon represents that it does not currently have, and covenants that it will not hire, as an officer or an employee any person who has been convicted of a felony under the laws of the United States
for conduct relating to the regulation of any drug product under the Federal Food, Drug, and Cosmetic Act (United States). 

  
 - 25 - 

 Master Manufacturing Services Agreement 

 

 9.5 Permits. 

Client will be solely responsible for obtaining or maintaining, on a timely basis, any permits or other regulatory approvals for the Products
or the Specifications, including, without limitation, all marketing and post-marketing approvals. 
 Patheon will maintain at all relevant
times all governmental permits, licenses, approval, and authorities required to enable it to lawfully and properly perform the Manufacturing Services. 

9.6 No Warranty. 

PATHEON MAKES NO WARRANTY OF ANY KIND, EITHER EXPRESSED OR IMPLIED, BY FACT OR LAW, OTHER THAN THOSE EXPRESSLY SET FORTH IN THIS AGREEMENT.
PATHEON MAKES NO WARRANTY OF FITNESS FOR A PARTICULAR PURPOSE NOR ANY WARRANTY OF MERCHANTABILITY FOR THE PRODUCTS. 
 ARTICLE 10

 REMEDIES AND INDEMNITIES 

10.1 Consequential Damages. 

Under no circumstances whatsoever will either party be liable to the other in contract, tort, negligence, breach of statutory duty, or
otherwise for (i) any (direct or indirect) loss of profits, of production, of anticipated savings, of business, or goodwill or (ii) for any other liability, damage, costs, or expense of any kind incurred by the other party of an indirect
or consequential nature, regardless of any notice of the possibility of these damages. 
 10.2 Limitation of Liability. 

(a) Active Materials. Except as expressly set forth in Section 2.2, under no circumstances will Patheon be responsible for any loss
or damage to the Active Materials. Patheon’s maximum responsibility for loss or damage to the Active Materials will not exceed the Maximum Credit Value set forth in Schedule D of a Product Agreement. 

(b) Maximum Liability. Patheon’s maximum liability to Client under this Agreement or any Product Agreement for any reason
whatsoever, including, without limitation, any liability arising under Article 6 hereof or resulting from any and all breaches of its representations, warranties, or any other obligations under this Agreement or any Product Agreement, but excluding
[...***...], will not exceed on a per Product basis [...***...]% of revenues per Year to Patheon under the applicable Product Agreement, up to a maximum of $[...***...] in the aggregate per Year for all Products. 

10.3 Patheon. 
 Patheon
agrees to defend and indemnify Client, its officers, employees, and agents against all losses, damages, costs, claims, demands, judgments and liability to, from and in favour of third parties (other than Affiliates) resulting from, or relating to
any claim of personal injury or property damage to the extent that the injury or damage is the result of a failure by Patheon to perform the Manufacturing Services in accordance with the Specifications, cGMPs, and Applicable Laws except to the
extent that 

  
  

***Confidential Treatment Requested 

- 26 - 

 Master Manufacturing Services Agreement 

 

 
the losses, damages, costs, claims, demands, judgments, and liability are due to the negligence or wrongful act(s) of Client, its officers, employees, agents, or Affiliates. 

If a claim occurs, Client will: (a) promptly notify Patheon of the claim; (b) use commercially reasonable efforts to mitigate the
effects of the claim; (c) reasonably cooperate with Patheon in the defense of the claim; and (d) permit Patheon to control the defense and settlement of the claim, all at Patheon’s cost and expense. 

10.4 Client. 
 Client agrees
to defend and indemnify Patheon, its officers, employees, and agents against all losses, damages, costs, claims, demands, judgments and liability to, from and in favour of third parties (other than Affiliates) resulting from, or relating to any
claim of infringement or alleged infringement of any Third Party Rights in the Products, or any portion thereof, or any claim of personal injury or property damage to the extent that the injury or damage is the result of a breach of this Agreement
by Client, including, without limitation, any representation or warranty contained herein, except to the extent that the losses, damages, costs, claims, demands, judgments, and liability are due to the negligence or wrongful act(s) of Patheon, its
officers, employees, or agents. 
 If a claim occurs, Patheon will: (a) promptly notify Client of the claim; (b) use commercially
reasonable efforts to mitigate the effects of the claim; (c) reasonably cooperate with Client in the defense of the claim; and (d) permit Client to control the defense and settlement of the claim, all at Client’s cost and expense.

 10.5 Reasonable Allocation of Risk. 

This Agreement (including, without limitation, this Article 10) is reasonable and creates a reasonable allocation of risk for the relative
profits the parties each expect to derive from the Products. Patheon assumes only a limited degree of risk arising from the manufacture, distribution, and use of the Products because Client has developed and holds the marketing approval for the
Products, Client requires Patheon to manufacture and label the Products strictly in accordance with the Specifications, and Client, not Patheon, is best positioned to inform and advise potential users about the circumstances and manner of use of the
Products. 
 ARTICLE 11 

CONFIDENTIALITY 
 11.1
Confidentiality. 
 The Confidentiality Agreement will apply to all confidential information disclosed by the parties under
this Agreement or any Product Agreement. If the Confidentiality Agreement expires or is terminated prior to the expiration or termination of this Agreement or any Product Agreement, the terms of the Confidentiality Agreement will continue to govern
the parties’ obligations of confidentiality for any confidential or proprietary information disclosed by the parties hereunder, for the term of this Agreement or any Product Agreement, as though the Confidentiality Agreement remained in full
force and effect. 

  
 - 27 - 

 Master Manufacturing Services Agreement 

 

 ARTICLE 12 

DISPUTE RESOLUTION 
 12.1
Commercial Disputes. 
 If any dispute arises out of this Agreement or any Product Agreement (other than a dispute under
Section 6.1(b) or a Technical Dispute, as defined herein), the parties will first try to resolve it amicably. In that regard, any party may send a notice of dispute to the other, and each party will appoint, within [...***...] Business
Days from receipt of the notice of dispute, a single representative having full power and authority to resolve the dispute. The representatives will meet as necessary in order to resolve the dispute. If the representatives fail to resolve the matter
within [...***...] from their appointment, or if a party fails to appoint a representative within the [...***...] Business Day period set forth above, the dispute will immediately be referred to the Chief Operating Officer (or another
officer as he/she may designate) of each party who will meet and discuss as necessary to try to resolve the dispute amicably. Should the parties fail to reach a resolution under this Section 12.1, the dispute will be referred to a court of
competent jurisdiction in accordance with Section 13.16. 
 12.2 Technical Dispute Resolution. 

If a dispute arises (other than disputes under Sections 6.1(b) or 12.1) between the parties that is exclusively related to technical aspects of
the manufacturing, packaging, labelling, quality control testing, handling, storage, or other activities under this Agreement (a “Technical Dispute”), the parties will make all reasonable efforts to resolve the dispute by amicable
negotiations. In that regard, senior representatives of each party will, as soon as possible and in any event no later than [...***...] Business Days after a written request from either party to the other, meet in good faith to resolve any
Technical Dispute. If, despite this meeting, the parties are unable to resolve a Technical Dispute within a reasonable time, and in any event within [...***...] Business Days of the written request, the Technical Dispute will, at the request
of either party, be referred for determination to an expert in accordance with Exhibit A. If the parties cannot agree that a dispute is a Technical Dispute, Section 12.1 will prevail. For greater certainty, the parties agree that the release of
the Products for sale or distribution under the applicable marketing approval for the Products will not by itself indicate compliance by Patheon with its obligations for the Manufacturing Services and further that nothing in this Agreement
(including Exhibit A) will remove or limit the authority of the relevant qualified person (as specified by the Quality Agreement) to determine whether the Products are to be released for sale or distribution. 

ARTICLE 13 

MISCELLANEOUS 
 13.1
Corporate Responsibility. Patheon, while performing the Manufacturing Services under this Agreement, will comply, in all material respects, with all applicable laws, rules, regulations, and standards that relate to the Agreement
including, but not limited to, those relating to environmental matters, public health, wages, hours and conditions of employment, subcontractor selection, discrimination and occupational health/safety. Without limiting the foregoing, Patheon
covenants that neither Patheon nor any of its subcontractors will utilize child or any form of forced or involuntary labor in while performing the Manufacturing Services under this Agreement. Upon Client’s reasonable written request, Patheon
will certify in writing its compliance with this Section 13.1 and will provide copies of all applicable permits, certificates and licenses that may be required for its performance under this Agreement. Upon Client’s reasonable written
request, Patheon will allow Client or its authorized representatives to audit the Manufacturing Site to verify Patheon’s performance against the requirements 

  
  

***Confidential Treatment Requested 

- 28 - 

 Master Manufacturing Services Agreement 

 

 
in this Section 13.1. This audit right does not include the right to interview any Patheon employee or subcontractor or to review any personnel or medical files of Patheon’s employees,
any Environmental, Health or Safety files of Patheon, any internal audit files of Patheon, or any financial records, including payroll records, of Patheon. Client will have the right to terminate this Agreement in whole or in part, as set forth in
Section 8.2(a), if Patheon fails to materially comply with the requirements of this Section 13.1. 
 13.2 Inventions. 

(a) For the term of this Agreement, Client hereby grants to Patheon a non-exclusive, paid-up, royalty-free, non-transferable license of
Client’s Intellectual Property which Patheon must use in order to perform the Manufacturing Services. 
 (b) All Intellectual Property
generated or derived by Patheon while performing the Manufacturing Services, to the extent it is specific to the development, manufacture, use, and sale of Client’s Product that is the subject of the Manufacturing Services, will be the
exclusive property of Client. 
 (c) All Patheon Intellectual Property will be the exclusive property of Patheon. Patheon hereby grants to
Client a perpetual, irrevocable, non-exclusive, paid-up, royalty-free, transferable license to use the Patheon Intellectual Property used by Patheon to perform the Manufacturing Services to enable Client to manufacture the Product(s). 

(d) Each party will be solely responsible for the costs of filing, prosecution, and maintenance of patents and patent applications on its own
Inventions. 
 (e) Either party will give the other party written notice, as promptly as practicable, of all Inventions which can reasonably
be deemed to constitute improvements or other modifications of the Products or processes or technology owned or otherwise controlled by the party. 

13.3 Intellectual Property. 

Subject to Section 13.1, all Client Intellectual Property will be owned by Client and all Patheon Intellectual Property will be owned by
Patheon. Neither party has, nor will it acquire, any interest in any of the other party’s Intellectual Property unless otherwise expressly agreed to in writing. Neither party will use any Intellectual Property of the other party, except as
specifically authorized by the other party or as required for the performance of its obligations under this Agreement. 
 13.4 Insurance.

 Each party will maintain commercial general liability insurance, including blanket contractual liability insurance covering the
obligations of that party under this Agreement through the term of this Agreement and for a period of three years thereafter. This insurance will have policy limits of not less than (i) $[...***...] for each occurrence for personal injury
or property damage liability; and (ii) $[...***...] in the aggregate per annum for product and completed operations liability. If requested each party will give the other a certificate of insurance evidencing the above and showing the
name of the issuing company, the policy number, the effective date, the expiration date, and the limits of liability. The insurance certificate will further provide for a minimum of [...***...] days’ written notice to the insured of a
cancellation of, or material change in, the insurance. If a party is unable to maintain the insurance policies required under this Agreement through no fault of its own, then the party will forthwith notify the other party in writing and the parties
will in good faith negotiate appropriate amendments to the insurance provision of this Agreement in order to provide adequate assurances. 

  
  

***Confidential Treatment Requested 

- 29 - 

 Master Manufacturing Services Agreement 

 

 13.5 Independent Contractors. 

The parties are independent contractors and this Agreement and any Product Agreement will not be construed to create between Patheon and Client
any other relationship such as, by way of example only, that of employer-employee, principal agent, joint-venturer, co-partners, or any similar relationship, the existence of which is expressly denied by the parties. 

13.6 No Waiver. 
 Either
party’s failure to require the other party to comply with any provision of this Agreement or any Product Agreement will not be deemed a waiver of the provision or any other provision of this Agreement or any Product Agreement, with the
exception of Sections 6.1 and 8.2 of this Agreement. 
 13.7 Assignment. 

 

	 	(a)	Patheon may not assign this Agreement or any Product Agreement or any of its associated rights or obligations without the written consent of Client, this consent not to be unreasonably withheld. But Patheon may arrange
for subcontractors to perform specific testing services arising under any Product Agreement without the consent of Client. Further it is specifically agreed that Patheon may subcontract any part of the Manufacturing Services under a Product
Agreement to any of its Affiliates with Client’s written consent, this consent not to be unreasonably withheld. 

  

	 	(b)	Subject to Section 8.2(d), Client may assign this Agreement or any Product Agreement or any of its associated rights or obligations without approval from Patheon. But Client will give Patheon prior written notice
of any assignment, any assignee will covenant in writing with Patheon to be bound by the terms of this Agreement or the Product Agreement, and Client will remain liable hereunder. Any partial assignment will be subject to Patheon’s cost review
of the assigned Products and Patheon may terminate this Agreement or any Product Agreement or any assigned part thereof, on [...***...] months’ prior written notice to Client and the assignee if good faith discussions do not lead to
agreement on amended Manufacturing Service fees within a reasonable time. 

  

	 	(c)	Despite the foregoing provisions of this Section 13.6, either party may assign this Agreement or any Product Agreement to any of its Affiliates or to a successor to or purchaser of all or substantially all of its
business, but the assignee must execute an agreement with the non-assigning party whereby it agrees to be bound hereunder. 

 13.8 Force
Majeure. 
 Neither party will be liable for the failure to perform its obligations under this Agreement or any Product
Agreement if the failure is caused by an event beyond that party’s reasonable control, including, but not limited to, strikes or other labor disturbances, lockouts, riots, quarantines, communicable disease outbreaks, wars, acts of terrorism,
fires, floods, storms, interruption of or delay in transportation, defective equipment, lack of or inability to obtain fuel, power or components, or compliance with any order or regulation of any government entity acting within colour of right (a
“Force Majeure Event”). A party claiming a right to excused performance under this Section 13.7 will immediately notify the other party in writing of the extent of its inability to perform, which notice will specify the event
beyond its reasonable control that prevents the performance. Neither party will be entitled to rely on a Force Majeure Event to relieve it from an obligation to pay money (including any interest for 

  
  

***Confidential Treatment Requested 

- 30 - 

 Master Manufacturing Services Agreement 

 

 
delayed payment) which would otherwise be due and payable under this Agreement or any Product Agreement. 

13.9 Additional Product. 

Additional Products may be added to, or existing Products deleted from, any Product Agreement by amendments to the Product Agreement including
Schedules A, B, C, and D as applicable. 
 13.10 Notices. 

Unless otherwise agreed in a Product Agreement, any notice, approval, instruction or other written communication required or permitted
hereunder will be sufficient if made or given to the other party by personal delivery, by telecopy, facsimile communication, or confirmed receipt email or by sending the same by first class mail, postage prepaid to the respective addresses, telecopy
or facsimile numbers or electronic mail addresses set forth below: 
 If to Client: 

Horizon Pharm Inc. 
 520 Lake Cook
Road Suite 520 
 Deerfield, IL 60015 

Attention: Jeff Sherman 

Telecopier No.: (224) 383-3001 

Email address: JSherman@horizonpharma.com 

With a copy to: 
 Horizon Pharm
Inc. 
 520 Lake Cook Road Suite 520 

Deerfield, IL 60015 
 Attention:
Brian Beeler 
 Telecopier No.: (224) 383-3001 

Email address: BBeeler@horizonpharma.com 

If to Patheon: 
 Patheon
Pharmaceuticals Inc 
 2110 East Galbraith Road 

Cincinnati, OH 45237-1625 

Attention: [...***...] 

Telecopier No.: [...***...] 

Email address: [...***...] 

With a copy to: 
 Patheon Inc.

 4721 Emperor Boulevard 

Research Triangle Park, 
 NC 27703

  
  

***Confidential Treatment Requested 

- 31 - 

 Master Manufacturing Services Agreement 

 

 given by personal delivery, telecopy, facsimile, or electronic mail will be deemed to have been sufficiently
made or given when sent (receipt acknowledged), or if mailed, five days after being deposited in the United States, Canada, or European Union mail, postage prepaid or upon receipt, whichever is sooner. 

13.11 Severability. 
 If any
provision of this Agreement or any Product Agreement is determined by a court of competent jurisdiction to be invalid, illegal, or unenforceable in any respect, that determination will not impair or affect the validity, legality, or enforceability
of the remaining provisions, because each provision is separate, severable, and distinct. 
 13.12 Entire Agreement. 

This Agreement, together with the applicable Product Agreement, Quality Agreement and the Confidentiality Agreement, constitutes the full,
complete, final and integrated agreement between the parties relating to the subject matter hereof and supersedes all previous written or oral negotiations, commitments, agreements, transactions, or understandings concerning the subject matter
hereof. Any modification, amendment, or supplement to this Agreement or any Product Agreement must be in writing and signed by authorized representatives of both parties. In case of conflict, the prevailing order of documents will be this Agreement,
the Product Agreement, the Quality Agreement, and the Confidentiality Agreement. 
 13.13 Other Terms. 

No terms, provisions or conditions of any purchase order or other business form or written authorization used by Client or Patheon will have
any effect on the rights, duties, or obligations of the parties under or otherwise modify this Agreement or any Product Agreement, regardless of any failure of Client or Patheon to object to the terms, provisions, or conditions unless the document
specifically refers to this Agreement or the applicable Product Agreement and is signed by both parties. 
 13.14 No Third Party Benefit or
Right. 
 For greater certainty, nothing in this Agreement or any Product Agreement will confer or be construed as conferring
on any third party any benefit or the right to enforce any express or implied term of this Agreement or any Product Agreement. 
 13.15 Execution in
Counterparts. 
 This Agreement and any Product Agreement may be executed in two or more counterparts, by original or
facsimile signature, each of which will be deemed an original, but all of which together will constitute one and the same instrument. 
 13.16 Use of
Client Name. 
 Patheon will not make any use of Client’s name, trademarks or logo or any variations thereof, alone or
with any other word or words, without the prior written consent of Client, which consent will not be unreasonably withheld. Despite this, Client agrees that Patheon may include Client’s name and logo in customer lists or related marketing
and promotional material for the purpose of identifying users of Patheon’s Manufacturing Services.

  
 - 32 - 

 Master Manufacturing Services Agreement 

 

 13.17 Governing Law. 

This Agreement and, unless otherwise agreed by the parties, any Product Agreement, will be construed and enforced in accordance with the laws
of the State of New York and the laws of the United States of America applicable therein and subject to the exclusive jurisdiction of the courts thereof. The UN Convention on Contracts for the International Sale of Goods will not apply to this
Agreement. 
 [Signature page to follow] 

  
 - 33 - 

 Master Manufacturing Services Agreement 

 

 IN WITNESS WHEREOF, the duly authorized representatives of the parties have executed this
Agreement as of the Effective Date. 
  

			
	PATHEON PHARMACEUTICALS INC.
		
	By:	 	/s/ Dean Wilson
	Name:	 	Dean Wilson
	Title:	 	Corporate Controller
	
	HORIZON PHARMA INC.
		
	By:	 	/s/ Jeffrey W. Sherman
	Name:	 	Jeffrey W. Sherman, M.D., FACP
	Title:	 	Chief Medical Officer, EVP
	
	HORIZON PHARMA INC.
		
	By:	 	/s/ Todd N. Smith
	Name:	 	Todd N. Smith
	Title:	 	CCO, EVP

  
 - 34 - 

 Master Manufacturing Services Agreement 

 

 APPENDIX 1 

FORM OF PRODUCT AGREEMENT 

(Includes Schedules A to D) 

PRODUCT AGREEMENT 

This Product Agreement (this “Product Agreement”) is issued under the Master Manufacturing Services Agreement dated
October 31, 2013 between Patheon Pharmaceuticals Inc., and Horizon Pharma Inc., (the “Master Agreement”), and is entered into [insert effective date] (the “Effective Date”), between Patheon
Pharmaceuticals Inc., [or applicable Patheon Affiliate], a corporation existing under the laws of the State of Delaware [or applicable founding jurisdiction for Patheon Affiliate], having a principal place of business at 2110 East
Galbraith Road, Cincinnati, OH 45237-1625 [or Patheon Affiliate address] (“Patheon”) and [insert Client name, legal entity, founding jurisdiction and address] (“Client”). 

The terms and conditions of the Master Agreement are incorporated herein except to the extent this Product Agreement expressly references the
specific provision in the Master Agreement to be modified by this Product Agreement. All capitalized terms that are used but not defined in this Product Agreement will have the respective meanings given to them in the Master Agreement. 

The Schedules to this Product Agreement are incorporated into and will be construed in accordance with the terms of this Product Agreement.

  

	 	1.	Product List and Specifications (See Schedule A attached hereto) 

  

	 	2.	Minimum Order Quantity, Annual Volume, and Price (See Schedule B attached hereto) 

  

	 	3.	Annual Stability Testing and Validation Activities (if applicable) (See Schedule C attached hereto) 

  

	 	4.	Active Materials, Active Materials Credit Value, and Maximum Credit Value (See Schedule D attached hereto) 

  

	 	5.	Yearly Forecasted Volume: (insert for sterile products in Italy if applicable under section 4.2.1) 

  

	 	6.	Territory: (insert the description of the Territory here) 

  

	 	7.	Manufacturing Site: (insert address of Patheon Manufacturing Site where the Manufacturing Services will be performed) 

  

	 	8.	Governing Law: (if applicable under Section 13.16 of the Master Agreement) 

  

	 	9.	Inflation Index: (if applicable under Section 4.2(a) of the Master Agreement for Products manufactured outside of the Unites States or Puerto Rico) 

 

	 	10.	Currency: (if applicable under Section 1.4 of the Master Agreement) 

  
 - 1 - 

 Master Manufacturing Services Agreement 

 

	 	11.	Initial Set Exchange Rate: (if applicable under Section 4.2(d) of the Master Agreement) 

  

	 	12.	Initial Product Term: (if applicable under Section 8.1 of the Master Agreement) 

  

	 	13.	Notices: (if applicable under Section 13.9 of the Master Agreement) 

  

	 	14.	Other Modifications to the Master Agreement: (if applicable under Section 1.2 of the Master Agreement) 

  

 
 IN WITNESS
WHEREOF, the duly authorized representatives of the parties have executed this Product Agreement as of the Effective Date set forth above. 
  

			
	PATHEON PHARMACEUTICALS INC. [or applicable Patheon Affiliate]
		
	By:	 	 
	 Name:
	 	 
	 Title:
	 	 
	
	HORIZON PHARMA INC. [or applicable Horizon Affiliate]
		
	By:	 	 
	 Name:
	 	 
	 Title:
	 	 

  
 - 2 - 

 Master Manufacturing Services Agreement 

 

 SCHEDULE A 

PRODUCT LIST AND SPECIFICATIONS 

[...***...] 

  
  

***Confidential Treatment Requested 

- 3 - 

 Master Manufacturing Services Agreement 

 

 SCHEDULE B 

MINIMUM ORDER QUANTITY, ANNUAL VOLUME, AND PRICE 

[...***...] 

  
  

***Confidential Treatment Requested 

- 1 - 

 Master Manufacturing Services Agreement 

 

 SCHEDULE C 

ANNUAL STABILITY TESTING [and VALIDATION ACTIVITIES (if applicable)] 

[...***...] 

  
  

***Confidential Treatment Requested 

- 1 - 

 Master Manufacturing Services Agreement 

 

 SCHEDULE D 

ACTIVE MATERIALS 
  

			
	 Active Materials
	 	 Supplier

	—	 	—
		
	—	 	—

 ACTIVE MATERIALS CREDIT VALUE 

The Active Materials Credit Value will be as follows: 
  

					
	 PRODUCT
	  	 ACTIVE MATERIALS
	  	 ACTIVE MATERIALS

CREDIT VALUE

		  		  	[...***...]

 MAXIMUM CREDIT VALUE 

Patheon’s liability for Active Materials calculated in accordance with Section 2.2 of the Master Agreement [for any Product] in a Year will
not exceed, in the aggregate, the maximum credit value set forth below: 
  

			
	 PRODUCT
	  	 MAXIMUM CREDIT VALUE

		  	[            ]% of revenues per Year to Patheon under this Product Agreement, up to a maximum of
$[            ] in the aggregate per Year.

 [End of Product Agreement] 

  
  

***Confidential Treatment Requested 

- 1 - 

 Master Manufacturing Services Agreement 

 

 EXHIBIT A 

TECHNICAL DISPUTE RESOLUTION 

Technical Disputes which cannot be resolved by negotiation as provided in Section 12.2 will be resolved in the following manner: 

1. Appointment of Expert. Within [...***...] Business Days after a party requests under Section 12.2 that an expert be appointed to
resolve a Technical Dispute, the parties will jointly appoint a mutually acceptable expert with experience and expertise in the subject matter of the dispute. If the parties are unable to so agree within the [...***...] Business Day period, or
in the event of disclosure of a conflict by an expert under Paragraph 2 hereof which results in the parties not confirming the appointment of the expert, then an expert (willing to act in that capacity hereunder) will be appointed by an experienced
arbitrator on the roster of the American Arbitration Association. 
 2. Conflicts of Interest. Any person appointed as an expert will be
entitled to act and continue to act as an expert even if at the time of his appointment or at any time before he gives his determination, he has or may have some interest or duty which conflicts or may conflict with his appointment if before
accepting the appointment (or as soon as practicable after he becomes aware of the conflict or potential conflict) he fully discloses the interest or duty and the parties will, after the disclosure, have confirmed his appointment. 

3. Not Arbitrator. No expert will be deemed to be an arbitrator and the provisions of the American Arbitration Act or of any other applicable
statute (foreign or domestic) and the law relating to arbitration will not apply to the expert or the expert’s determination or the procedure by which the expert reaches his determination under this Exhibit A. 

4. Procedure. Where an expert is appointed: 
  

	 	(a)	Timing. The expert will be so appointed on condition that (i) he promptly fixes a reasonable time and place for receiving representations, submissions or information from the parties and that he issues the
authorizations to the parties and any relevant third party for the proper conduct of his determination and any hearing and (ii) he renders his decision (with full reasons) within [...***...] Business Days (or another other date as the
parties and the expert may agree) after receipt of all information requested by him under Paragraph 4(b) hereof. 

  

	 	(b)	Disclosure of Evidence. The parties undertake one to the other to give to any expert all the evidence and information within their respective possession or control as the expert may reasonably consider necessary
for determining the matter before him which they will disclose promptly and in any event within [...***...] Business Days of a written request from the relevant expert to do so. 

 

	 	(c)	Advisors. Each party may appoint any counsel, consultants and advisors as it feels appropriate to assist the expert in his determination and so as to present their respective cases so that at all times the
parties will co-operate and seek to narrow and limit the issues to be determined. 

  

	 	(d)	Appointment of New Expert. If within the time specified in Paragraph 4(a) above the expert will not have rendered a decision in accordance with his appointment, a new expert may (at the request of either party)
be appointed and the appointment of the 

  
  

***Confidential Treatment Requested 

- 1 - 

 Master Manufacturing Services Agreement 

 

	 	
existing expert will thereupon cease for the purposes of determining the matter at issue between the parties save this if the existing expert renders his decision with full reasons prior to the
appointment of the new expert, then this decision will have effect and the proposed appointment of the new expert will be withdrawn. 

  

	 	(e)	Final and Binding. The determination of the expert will, except for fraud or manifest error, be final and binding upon the parties. 

 

	 	(f)	Costs. Each party will bear its own costs for any matter referred to an expert hereunder and, in the absence of express provision in the Agreement to the contrary, the costs and expenses of the expert will be
shared equally by the parties. 

 For greater certainty, the release of the Products for sale or distribution under the applicable marketing
approval for the Products will not by itself indicate compliance by Patheon with its obligations for the Manufacturing Services and further that nothing in this Agreement (including this Exhibit A) will remove or limit the authority of the relevant
qualified person (as specified by the Quality Agreement) to determine whether the Products are to be released for sale or distribution. 

  
 - 2 - 

 Master Manufacturing Services Agreement 

 

 EXHIBIT B 

COMMERCIAL QUALITY AGREEMENT 

  
 - 2 - 

  
 

 
 QUALITY AGREEMENT 

Commercial Product 
 Between

 Horizon Pharma Inc., 

a corporation existing under the laws of the State of Delaware 

(“Client”) 
 -and-

 PATHEON PHARMACEUTICALS INC., 

a corporation existing under the laws of the State of Delaware. 

Specific sites covered by this Agreement: 

2110 E. Galbraith Rd. Cincinnati OH 45237-1625 

(“Patheon”) 

Effective Date: December 9, 2013 

Version: QG01-05-T001-01 

 

 
  

 TABLE OF CONTENTS 

 

							
			
	SECTION 1:	 	BACKGROUND AND AGREEMENT	  	 	3	  
			
	SECTION 2:	 	RESPONSIBILITIES TABLE	  	 	4	  
			
	SECTION 3:	 	GENERAL	  	 	6	  
			
	SECTION 4:	 	DESCRIPTION OF RESPONSIBILITIES	  	 	7	  
			
	SECTION 5:	 	APPENDICES	  	 	20	  
			
		 	APPENDIX A: PRODUCT(S)	  			
			
		 	APPENDIX B: QUALITY CONTACTS	  			
			
		 	APPENDIX C: PATHEON APPROVED VENDOR LIST	  			
			
		 	APPENDIX D: CLIENT APPROVED VENDOR LIST	  			
			
		 	APPENDIX E: PATHEON APPROVED CONTRACT LABORATORIES LIST	  			

  

  

					
	 Quality Agreement
 QG01-05-T001-01
	  	

	  	Page 2 of 20

 

 
  

 SECTION 1: BACKGROUND AND AGREEMENT 

BACKGROUND. Under a Master Manufacturing Services Agreement dated October 31, 2013 (the “Master Agreement”)
and a Product Agreement issued under the Master Agreement dated October 31, 2013 between Patheon and the Client (collectively, the “MSA”), Patheon agreed to perform pharmaceutical manufacturing services (the
“Manufacturing Services”) for certain Products (as described in Appendix A hereto) and the Client is required to give certain information to Patheon in order for Patheon to perform the Manufacturing Services (the
“Specifications”). Under the MSA, Patheon is required to operate within the Specifications. The parties desire to allocate the responsibility for procedures and Specifications impacting on the identity, strength, quality, and purity
of the Products. 
 AGREEMENT. NOW THEREFORE in consideration of rights conferred and the obligations assumed under the MSA
and herein, and for other good and valuable consideration (the receipt and sufficiency of which are acknowledged by each party), and intending to be legally bound, the parties agree as follows: 

  

					
	 Quality Agreement
 QG01-05-T001-01
	  	

	  	Page 3 of 20

 

 
  

 SECTION 2: RESPONSIBILITIES TABLE 

Patheon will be responsible for all the operations that are marked with “X” in the column titled “Patheon” and the Client will be
responsible for all the operations that are marked with “X” in the column titled “Client”. If marked with “(X)”, cooperation is required from the designated party. 

 

							
				
	 Section
No.
	  	 Subject / Terms
	  	Client	 	Patheon
	
	 4.1 Quality Management

				
	 4.1.1
	  	GMP, Health and Safety Compliance	  	X	 	X
				
	 4.1.2
	  	Client Audit Rights; rights to have a man in plant during mfg campaigns	  	X	 	
				
	 4.1.3
	  	Subcontracting	  	(X)	 	X
				
	 4.1.4
	  	Self-Inspection	  		 	X
	
	 4.2 Regulatory Requirements

				
	 4.2.1
	  	Permits	  	X	 	
				
	 4.2.2
	  	Regulatory Filing / Registration Change Control	  	X	 	(X)
				
	 4.2.3
	  	Regulatory Compliance	  		 	X
				
	 4.2.4
	  	Government Agency Inspections, Communications and Requisitions	  	(X)	 	X
	
	 4.3 Material Control

				
	 4.3.1
	  	Test Methods and Specifications	  	X	 	X
				
	 4.3.2
	  	Material Destruction	  	(X)	 	X
				
	 4.3.3
	  	Vendor Audit Responsibility	  	X	 	X
				
	 4.3.4
	  	Client Furnished Materials	  	X	 	
				
	 4.3.5
	  	Incoming Material Release	  		 	X
	
	 4.4 Building, Facilities, Utilities and Equipment

				
	 4.4.1
	  	General	  		 	X
				
	 4.4.2
	  	Equipment, Calibration and Preventative Maintenance	  		 	X
				
	 4.4.3
	  	Environmental Monitoring Program	  		 	X
	
	 4.5 Product Controls

				
	 4.5.1
	  	Master Batch Record	  	(X)	 	X
				
	 4.5.2
	  	Reprocessing and Rework	  	(X)	 	X
				
	 4.5.3
	  	Personnel Training	  		 	X
	
	 4.6 Packaging, Labeling and Printed Materials

				
	 4.6.1
	  	Master Batch Packaging Records	  	(X)	 	X
				
	 4.6.2
	  	Printed Material and Artwork	  	X	 	
				
	 4.6.3
	  	Test Methods and Method Validation	  	X	 	(X)
	
	 4.7 Exception Reports (Deviations / Investigations)

				
	 4.7.1
	  	Manufacturing Instruction Deviations	  		 	X
				
	 4.7.2
	  	Packaging Instructions Deviations	  		 	X
				
	 4.7.3
	  	Notification of Deviations	  		 	X

  

					
	 Quality Agreement
 QG01-05-T001-01
	  	

	  	Page 4 of 20

 

 
  

							
	
	 4.8 Release of Product

				
	 4.8.1
	  	Test Methods and Specifications	  	X	 	
				
		  	Provide executed batch records at least for all bulk batches to Client	  		 	X
				
		  	Provide detailed deviation reports to Client	  		 	X
				
	 4.8.2
	  	Batch Release for Shipment	  		 	X
				
	 4.8.3
	  	Certificate of Compliance	  		 	X
				
	 4.8.4
	  	Product Release	  	X	 	
	
	 4.9 Validation

				
	 4.9.1
	  	Master Validation Plan	  	(X)	 	X
				
	 4.9.2
	  	Cleaning Validation Program	  	(X)	 	X
				
	 4.9.3
	  	Analytical Method and Procedure Validation	  	(X)	 	X
	
	 4.10 Change Control

				
	 4.10.1
	  	General	  	X	 	X
	
	 4.11 Documentation

				
	 4.11.1
	  	Record Retention	  		 	X
				
	 4.11.2
	  	Batch Document Requisition	  		 	X
	
	 4.12 Laboratory Controls

				
	 4.12.1
	  	Specifications and Test Methods	  	X	 	X
				
	 4.12.2
	  	Out of Specifications (OOS) / Out of Trend (OOT)	  		 	X
	
	 4.13 Stability

				
	 4.13.1
	  	Sample Storage	  		 	X
				
	 4.13.2
	  	Stability Studies and Protocol	  	X	 	X
				
	 4.13.3
	  	Stability Failures	  		 	X
				
	 4.13.4
	  	Continue Stability on Termination of MSA	  		 	X
	
	 4.14 Annual Product Review

				
	 4.14.1
	  	General	  	X	 	X
	
	 4.15 Storage and Distribution

				
	 4.15.1
	  	General	  		 	X
				
	 4.15.2
	  	Product Storage and Shipment Changes	  	(X)	 	X
				
	 4.15.3
	  	Product Quarantine	  		 	X
	
	 4.16 Product Complaints

				
	 4.16.1
	  	Complaint Investigation	  	X	 	(X)
	
	 4.17 Product Recall

				
	 4.17.1
	  	Product Recall Notification	  	X	 	
				
	 4.17.2
	  	Government Agency Notification	  	X	 	
	
	 4.18 Reference and Retention Samples

				
	 4.18.1
	  	Excipient and Active Ingredient Reference Sample	  		 	X
				
	 4.18.2
	  	Finished Product Retention Sample	  		 	X

  

					
	 Quality Agreement
 QG01-05-T001-01
	  	

	  	Page 5 of 20

 

 
  

 SECTION 3: GENERAL 

 

	3.1	Any communications about the subject matter of this Agreement will be directed, in the first instance, to the person(s) identified in Appendix B. 

 

	3.2	Capitalized terms not otherwise defined herein will have the meaning specified in the MSA. 

  

	3.3	If any provision of this Agreement should be or found invalid, or unenforceable by law, the rest of the Agreement will remain valid and binding and the parties will negotiate a valid provision which meets as close as
possible the objective of the invalid provision. 

  

	3.4	If this Agreement requires modification so that the party affected cannot be reasonably expected to continue to perform under this Agreement, then the parties will negotiate and revise the Agreement accordingly.

  

	3.5	Any amendment of this Agreement will be made in writing and signed by both parties. 

  

	3.6	This Agreement will start on the Effective Date that is set forth on the cover page of this Agreement and will remain valid until all Quality obligations under all applicable MSA’s have been fulfilled.

  

	3.7	If there is any conflict between the terms of this Agreement and the MSA, the MSA will control except for any specific quality issue. 

 

	3.8	The “Background” provisions of Section 1 are incorporated into this Agreement. 

  

					
	 Quality Agreement
 QG01-05-T001-01
	  	

	  	Page 6 of 20

 

 
  

 SECTION 4: DESCRIPTION OF RESPONSIBILITIES 

 

	4.1	QUALITY MANAGEMENT 

  

	4.1.1	GMP, Health and Safety Compliance 

 Patheon will conduct operations in compliance with
applicable environmental, occupational health and safety laws, and cGMP regulations. 
  

	4.1.2	Client Audit Rights 

 Patheon will permit audits by the Client, on reasonable prior
written notice, of all relevant premises, procedures, and documentation that relate to Client’s Product. Client audits are limited to one audit per calendar year unless for cause. 

 

	4.1.3	Subcontracting 

 Patheon will not subcontract tasks to a third party without
Client’s consent. Patheon may subcontract raw material testing to other Patheon facilities and to other qualified third party laboratories. If Patheon employs a third party to perform any or part of the manufacturing, packaging, labeling,
inspection, testing, release and/or handling of Client Product, Patheon shall assure that the third party has been fully qualified via the Patheon’s third party qualification process prior to performing such activity(ies). A quality agreement
shall exist between Patheon and any third party contractor performing any or part of the manufacturing, packaging, labeling, testing, handling, and/or release of Client Product. 

 

	4.1.4	Self-Inspection 

 Patheon will perform self-inspections of its premises,
facilities, and processes used to manufacture, package, test, and store the Client’s starting, intermediate, and/or finished products in accordance with Patheon’s written standard operating procedures (“SOPs”) to ensure
compliance with cGMP and this Agreement. 
  

	4.2	REGULATORY REQUIREMENTS 

  

	4.2.1	Permits 

 The Client will be solely responsible for obtaining or maintaining, on a
timely basis, any permits or other regulatory approvals for the Products or the Specifications, including, without limitation, all marketing and post-marketing approvals. 

Patheon will obtain and maintain the appropriate manufacturing license(s) to allow for the Manufacturing Services. 

  

					
	 Quality Agreement
 QG01-05-T001-01
	  	

	  	Page 7 of 20

 

 
  

	4.2.2	Regulatory Filing / Registration Change Control 

 The Client will determine
whether changes to the Product or related to the Product will impact a regulatory filing and will apply for and receive approval for any required manufacturing amendment, change or addition to their Product marketing authorization. Upon request,
Patheon will assist in the preparation and review of pertinent sections of new or supplemental regulatory applications before filing. The Client will give Patheon copies of sections of product registration/regulatory submissions that are relevant to
the manufacture of the Product. The Client is responsible for all communications with Regulatory Authorities as well as for the approval, maintenance, and updating of marketing approval in a timely manner. 

 

	4.2.3	Regulatory Compliance 

 Patheon will ensure that Product(s) are manufactured and
tested in strict compliance with current US Federal regulatory and statutory requirements relating to Good Manufacturing Practices (GMP) (US 21 CFR parts 210 and 211 for the manufacture of finished medicinal product) as applicable, regulatory
approvals and local laws and regulations applicable at the site(s) of manufacture and/or testing. 
 Patheon warrants that is not debarred
under the U.S. Generic Drug Enforcement Act of 1992 and does not employ or use the services of any individual who is debarred or who has engaged in activities that could lead to being debarred. 

Patheon further warrants that they shall not use in any capacity the services of any person or company debarred or convicted of a crime for
which a person could be debarred. 
  

	4.2.4	Government Agency Inspections, Communication and Requisitions 

 Patheon will
permit all relevant inspections by regulatory authorities of premises, procedures, and documentation. 
 Patheon will notify the Client
within three Business Days of receipt of any notice of inspection from a regulatory authority and within one Business Day of any regulatory authority request for Product samples, batch documentation, or other information related to the Product. 

Patheon will notify the Client within one Business Day of receipt of any Form 483’s warning letter or the like from any regulatory agency
that relates to the Product; or if the supply of Product will be affected, or if the facilities used to produce, test or package the Product will be affected. 

The responses from Patheon related to the Product will be reviewed and approved by the Client before submission to the regulatory agency. But

  

					
	 Quality Agreement
 QG01-05-T001-01
	  	

	  	Page 8 of 20

 

 
  

 
Patheon reserves the right to respond to the regulatory agency without approval, if, in the reasonable opinion of Patheon’s Legal counsel, it is required to do so. 

 

	4.3	MATERIAL CONTROL 

  

	4.3.1	Test Methods and Specifications 

 The Client will give Patheon a copy of the
Specifications and test methods used if the Client issues raw material Specifications. 
  

	4.3.2	Material Destruction 

 Patheon has the right to either return to the Client or dispose of
any outdated or rejected material. If the material is disposed of, disposal will be consistent with the nature of the material and sent to a permitted waste disposal facility. Before disposal: 

 

	 	(i)	Patheon will send notice to the Client of Patheon’s intent to dispose of the material. If no direction is received from the Client, Patheon will dispose of the material no sooner than 90 days after the date of the
notice. 

  

	 	(ii)	The materials will be disposed and destroyed in compliance with local environmental regulations and performed in a secure and legal manner that prevents unauthorized use or diversion. 

Patheon will maintain destruction records in accordance with Patheon SOPs. 

 

	4.3.3	Vendor Audit Responsibility 

  

	4.3.3.1	Excipient and API Vendors: 

  

	 	(i)	If the Client stipulates an excipient or API vendor, the Client will audit and approve the vendor and ensure cGMP compliance in accordance with Section 4.3.4 of this Agreement. The Client stipulated vendor(s) will
be included on the Client’s approved vendor list (Appendix D). 

  

	 	(ii)	If Patheon stipulates the excipient vendor, Patheon will audit and approve the vendor and ensure cGMP compliance in accordance with Patheon’s SOPs. The Patheon stipulated vendor(s) will be included on
Patheon’s approved vendor list (Appendix C). 

  

	4.3.3.2	Packaging Component Vendors: 

  

	 	(i)	 If the Client stipulates a packaging component vendor, the Client will audit and approve the manufacturer and ensure cGMP compliance. The

  

					
	 Quality Agreement
 QG01-05-T001-01
	  	

	  	Page 9 of 20

 

 
  

	 	
Client stipulated vendor(s) will be included on the approved vendor list (Appendix D). 

  

	 	(ii)	If Patheon stipulates the packaging component vendor, Patheon will audit and approve the vendor and ensure cGMP compliance in accordance with Patheon’s SOP. The Patheon stipulated vendor(s) will be included on the
approved supplier list (Appendix C). 

  

	4.3.4	Client Furnished Materials 

 The Client is responsible for vendor qualification of Client
furnished materials and for providing a certificate of compliance confirming the following: 
  

	 	(i)	That the materials are compliant with the provisions outlined in the “Note for Guidance on minimizing the risk of transmitting spongiform encephalopathy agents via human and veterinary medicinal products”
(EMEA/410/01, Rev.2 or update); and 

  

	 	(ii)	A residual solvent certificate confirming that there is no potential for specific toxic solvents listed in the EP / USP / ICH residual solvents Class I, Class II or Class III to be present and the material, if tested,
will comply with established EP / USP / ICH requirements. If any of the solvents listed in the EP / USP / ICH residual solvents Class I, Class II or Class III are used in the manufacture or are generated in the manufacturing process, solvents of
concern will be indicated. 

  

	4.3.5	In-Coming Material Release 

 Before its use in the manufacture of any Product, all
material(s) will be inspected, tested, and released by Patheon against the Specification approved by the Client. 
 Patheon to certify that
raw materials and components under their control are compliant with the provisions outlined in the “Note for Guidance on minimizing the risk of transmitting spongiform encephalopathy agents via human and veterinary medicinal products”
(EMEA/410/01, Rev.2 or update). 
  

	4.4	BUILDING, FACILITIES, UTILITIES , AND EQUIPMENT 

  

	4.4.1	General 

 All buildings and facilities used in the manufacturing, packaging, testing and
storage of any materials and/or Product will be of suitable size, construction and location to facilitate cleaning, and will be maintained in a good state of repair. Maintenance and cleaning records will be kept in accordance with Patheon’s
SOPs. 

  

					
	 Quality Agreement
 QG01-05-T001-01
	  	

	  	Page 10 of 20

 

 
  

	4.4.2	Equipment, Calibration and Preventative Maintenance 

 All equipment used in the
manufacturing, packaging, testing, and storage of any materials and/or Product will be suitable for its intended use and appropriately located to allow for cleaning and maintenance. Calibration and maintenance records will be kept according to
Patheon SOPs for all critical equipment. Patheon will calibrate instrumentation and qualify computer systems used in the manufacture and testing of the Product in accordance with Patheon’s SOPs. 

 

	4.4.3	Environmental Monitoring Program 

 Patheon will perform and maintain an environmental
monitoring program. The collected data will be reviewed and interpreted by the responsible person within Patheon’s quality unit. Any out of limit results will be managed appropriately in accordance with Patheon SOPs. 

 

	4.5	PRODUCTION CONTROLS 

  

	4.5.1	Master Batch Record 

 The Client will give Patheon the Specifications and Patheon will
manufacture Product in accordance with the Specifications. 
 Patheon is responsible for preparing the master batch records for the Product.
The Client is responsible to review and approve the master batch records before the manufacture of the Product. 
 Patheon will not make
changes to master batch records except through the established Patheon change control system, and all master document revisions will be approved by the Client’s quality unit. Any changes made to issued batch records (before master revisions)
must be reviewed and approved by the Client’s quality unit before implementation unless otherwise agreed to in writing. 
  

	4.5.2	Reprocessing and Rework 

 Patheon will not reprocess or rework the Product without the
prior written consent from the Client. 
 Reprocessing is defined as the introduction of material back into the process and repeating a step,
(e.g. redrying, remilling) using the same equipment and techniques of the established manufacturing process. 
 Rework is defined as the
introduction of material to one or more processing steps that are different from the established manufacturing process. 

  

					
	 Quality Agreement
 QG01-05-T001-01
	  	

	  	Page 11 of 20

 

 
  

	4.5.3	Personnel Training 

 Patheon will give appropriate training to its employees. Each person
engaged in the manufacture, packaging, testing, storage, and shipping of the Product will have the education, training, and experience necessary, consistent with current GMP and safety training requirements. 

 

	4.6	PACKAGING, LABELING AND PRINTED MATERIALS 

  

	4.6.1	Master Batch Packaging Records 

 The Client will give Patheon the Specifications for all
packaging components. Patheon will create, control, issue, and execute in accordance with the master batch packaging record and the Specifications. The Client is responsible to review and approve the master batch records before the packaging of the
Product. 
 Patheon will not make changes to master batch packaging records except through the established Patheon change control system, and
all master document revisions will be approved by the Client’s quality unit. Any changes made to issued batch records (before Master revisions) must be reviewed and approved by the Client’s quality unit before implementation unless
otherwise agreed to in writing. 
  

  

					
	 Quality Agreement
 QG01-05-T001-01
	  	

	  	Page 12 of 20

 

 
  

	4.6.2	Printed Material and Artwork 

 The Client will give Patheon the Specifications for
artwork and labelling text (blister, carton, leaflet, label etc.). The labelling proofs must be reviewed and approved by the Client. 
  

	4.6.3	Test Methods and Method Validation 

 The Client will give Patheon the test methods and
method validation for packaging components. Where applicable, Patheon will provide test methods and validation for packaging components purchased from vendors on the Patheon approved vendor list only (Appendix C). 

 

	4.7	EXCEPTION REPORTS (DEVIATIONS / INVESTIGATIONS) 

  

	4.7.1	Manufacturing Instruction Deviations 

 Patheon will document, investigate, and resolve
deviations from approved manufacturing instructions or Specifications in accordance with Patheon’s SOPs. Patheon will report and obtain approval from the Client’s responsible person for deviation report (“DR”) type deviations
where there is a potential to affect Product quality. This Client approval will not be unreasonably withheld. Patheon will give the Client copies of all DR’s as part of the executed batch record. Any additional studies that may be needed as
part of the investigation are to be reviewed and approved by Client prior to the initiation of the study. 
  

	4.7.2	Packaging Instructions Deviations 

 Patheon will document, investigate, and resolve any
deviation from approved packaging instructions or Specifications according to Patheon SOPs. Patheon will report and obtain approval from the Client’s responsible person for DR type deviations where there is a potential to affect Product
quality. This Client approval will not be unreasonably withheld. Patheon will give the Client copies of all DR’s as part of the executed batch packaging record. 
  

	4.7.3	Notification of Deviations 

 Patheon will notify the Client within one Business Day if
any significant deviation occurs during manufacture or packaging of the Product, where the deviation has the potential to affect the quality, efficacy or availability of the Product. 

 

	4.8	RELEASE OF PRODUCT 

  

	4.8.1	Test Methods and Specifications  

  

					
	 Quality Agreement
 QG01-05-T001-01
	  	

	  	Page 13 of 20

 

 
  

 The Client will give Patheon the finished Product Specifications and will develop and give
Patheon supply validated analytical test methods for the finished Product. 
  

	4.8.2	Batch Release for Shipment 

 Batch review and release for shipment to the Client will be
the responsibility of Patheon’s Quality Assurance department who will act in accordance with Patheon’s SOPs. 
  

	4.8.3	Certificate of Compliance 

 For each batch released by Patheon for shipment to the
Client, Patheon will deliver to the Client a certificate of compliance that will include a statement that the batch has been manufactured in accordance with cGMPs and the Specifications. 

 

	4.8.4	Product Release 

 The Client will have sole responsibility for release of the Product to
the market. When Patheon qualified person (“QP”) services are employed, Patheon QP may release the Product for distribution on behalf of the Client. 
  

	4.9	VALIDATION 

  

	4.9.1	Master Validation Plan 

 Patheon will establish applicable master validation plans and
maintain a validation program for the Product. The Client will review and approve the master validation plan, performance qualification and process validation protocols and reports for the Product. 

 

	4.9.2	Cleaning Validation Program 

 The Client will give Patheon the toxicological information
to be used in the development of a cleaning program. Patheon will maintain an appropriate cleaning and cleaning validation program. 
  

	4.9.3	Analytical Method and Procedure Validation 

 The Client must ensure that its analytical
methods and manufacturing procedures (including packaging procedures) are validated. If the methods and procedures are not validated by the Client, then Patheon may assist in validation development at Client’s cost. 

 

	4.10	CHANGE CONTROL 

  

	4.10.1	General 

 Patheon will notify and obtain approval from the Client before implementing any
proposed changes to the process, materials, testing, equipment or 

  

					
	 Quality Agreement
 QG01-05-T001-01
	  	

	  	Page 14 of 20

 

 
  

 
premises, where the changes may directly affect the Product. This Client approval will not to be unreasonably withheld. 

The Client will be responsible for determining whether or not to initiate registration variation procedures and for maintaining adequate
control over the quality commitments of the marketing authorization made to the regulatory authorities by the Client for the Products. 

Following validation of a process change, Patheon will deliver a copy of the related validation report to the Client and the associated
stability data, if applicable, as it becomes available. 
  

	4.11	DOCUMENTATION 

  

	4.11.1	Record Retention 

 Patheon will maintain all batch records for a minimum of one year past
Product expiry date and supply all these records to the Client upon request. 
 Patheon will maintain records and evidence on the testing of
raw materials and packaging/labeling materials for five years after the materials were last used in the manufacture or packaging/labeling of the Product. 

At the end of the above noted retention period, the Client will be contacted concerning the future storage or destruction of the documents.

  

	4.11.2	Batch Document Requisition 

 At the request of the Client, Patheon will give the Client a
copy of any of the executed batch documents relating to Products within five Business Days of the request. 
  

	4.12	LABORATORY CONTROLS 

  

	4.12.1	Specifications and Test Methods 

 Patheon will test and approve starting material,
intermediate, and the finished Product in accordance with the approved Specifications, analytical methods, and Patheon’s SOPs. 

Patheon will provide copies of the internal versions of the analytical test methods to Client. 

The Client will give Patheon the Active Material Specifications including a certificate of analysis 

 

  

					
	 Quality Agreement
 QG01-05-T001-01
	  	

	  	Page 15 of 20

 

 
  

 The Client will give Patheon the test methods for Active Material and excipient’s (if
non-compendial). The Client is responsible for validating non-compendial testing methods. If these methods are not validated by the Client, then Patheon may assist in validation development at Client’s cost. 

 

	4.12.2	Out of Specifications (OOS) / Out of Trend (OOT) 

 Patheon will notify Client’s
quality unit of confirmed out-of-Specification (“OOS”) or out-of-trend (“OOT”) results within one Business Day. Patheon will generate a DR type deviation as per Patheon SOPs and obtain approval of the DR from the
Client’s responsible person within their quality unit. This Client approval will not be unreasonably withheld. Any additional studies that may be needed as part of the investigation are to be reviewed and approved by Client prior to the
initiation of the study. 
  

	4.13	STABILITY 

  

	4.13.1	Sample Storage 

 Patheon will store stability samples as required. 

 

	4.13.2	Stability Studies and Protocol 

 The Client will develop and validate stability
indicating assay(s) before process validation. If required, Patheon may assist at Client’s cost. 
 If applicable, Patheon will conduct
stability studies in accordance with the agreed and validated stability testing analytical methods at the agreed upon testing points in accordance with the approved stability protocol. 

Patheon will perform the stability testing described in a stability protocol agreed to by both Patheon and the Client. Patheon will give the
Client the stability data on an ongoing basis as agreed to by both parties. 
  

	4.13.3	Stability Failures 

 Patheon will notify the Client of any stability failure for Product
supplied to the Client. If a result indicates that a Product has failed to remain within stability Specifications, Patheon will notify the Client within one Business Day. 

Any trend in stability results indicating a potential OOS at a future stability test point should be communicated to the other party in written
form within 1 (one) month of identifying such trend. 
  

	4.13.4	Termination of MSA  

  

					
	 Quality Agreement
 QG01-05-T001-01
	  	

	  	Page 16 of 20

 

 
  

 If the MSA is terminated, Patheon will continue to give the Client the stability data
supporting the acceptability of the Product until all Product distributed by the Client has reached the end of its shelf-life. 
  

	4.14	ANNUAL PRODUCT REVIEW 

  

	4.14.1	General 

 The Client will complete the annual product review in accordance with
regulatory requirements of the Product marketed authorization. Patheon to prepare annual product review for third party commercial products and will give the Client copies of all information and correspondence necessary to support the annual product
reviews. 
  

	4.15	STORAGE AND DISTRIBUTION 

  

	4.15.1	General 

 Patheon will ship Product in accordance with the agreed qualified
transportation requirements provided by the Client to Patheon. 
  

	4.15.2	Product Storage and Shipment Changes 

 Patheon will communicate any proposed changes in
storage or shipping to the Client for review and approval. The Client approval will not be unreasonably withheld. 
  

	4.15.3	Product Quarantine 

 Patheon will have a system in place for assuring that unreleased Product is
not shipped unless authorized by the Client’s quality unit. 
  

	4.16	PRODUCT COMPLAINTS 

  

	4.16.1	Complaint Investigation 

 The Client will investigate and resolve all medical and
non-medical Product complaints. Patheon will investigate all Patheon manufacturing and packaging-type Product complaints related to the Manufacturing Services. The Client, using reasonable efforts, will retrieve complaint sample(s) and forward them
to Patheon in a timely manner to aid a complete and comprehensive investigation. Patheon will respond to Client in writing within 20 business days, with exception of critical complaints in which Patheon will respond within 15 days. If a longer
investigation is required Patheon will provide an investigation plan to Client. In this case both parties have to mutually agree upon the timeline. 

  

					
	 Quality Agreement
 QG01-05-T001-01
	  	

	  	Page 17 of 20

 

 
  

 If Patheon receives a complaint from a Client customer directly, Patheon must forward that
complaint to Client within 2 (two) business days of receipt. 
  

	4.17	PRODUCT RECALL 

  

	4.17.1	Product Recall Notification 

 The Client will notify Patheon about a Product recall or
other regulatory type product notification (e.g. field alert) as soon as possible, but, in any event, before informing the appropriate regulatory authorities. The Client will be responsible for all related recall activities. 

 

	4.17.2	Government Agency Notification 

 The Client will perform the Product recall and will
inform the appropriate regulatory authorities. Where legislated, Patheon reserves the right to notify regulatory authorities of Product quality issues. Patheon will inform the Client before notifying the regulatory authorities. 

 

	4.18	REFERENCE AND RETENTION SAMPLES 

  

	4.18.1	Excipient and Active Ingredient Reference Sample 

 Patheon will keep a reference sample
of each material received by Patheon and used to manufacture the Product. The reference sample will consist of at least two times the necessary quantity for all Quality Control tests required to determine whether the materials meet required
Specifications. 
 The reference samples will be stored by Patheon under controlled conditions in accordance with GMP storage requirements
for one year beyond the expiration date of the last batch of the product containing the materials. The reference samples will be made available by Patheon to the Client, if requested 

 

	4.18.2	Finished Product Retention Sample 

 Retention samples of finished Product will be
retained by Patheon for one year past Product expiry or for a longer period as required by law. Where applicable, the legal sample(s) of finished Product must be retained by the Client. 

* * * 

  

					
	 Quality Agreement
 QG01-05-T001-01
	  	

	  	Page 18 of 20

 

 
  

 IN WITNESS WHEREOF, the parties have caused their duly authorized officer to execute and deliver this Quality
Agreement as of the Effective Date identified on the first page: 
  

									
	Horizon Pharma Inc.	 		 	
					
	By:	 	/s/ Cara Weyker	 		 		 	Date: 10 Dec. 2013
		 	 Cara Weyker
  

Vice President, CMC Regulatory and Quality Systems
	 		 		 	

  

									
		 		 	
					
	By:	 	/s/ Jeff Sherman	 		 		 	Date: 10 Dec. 2013
		 	 Jeff Sherman, MD, FACP

Chief Medical Officer & Executive Vice President, Development, Manufacturing, and Regulatory Affairs
	 		 		 	

  

									
	 PATHEON PHARMACEUTICALS INC.
	 		 	
					
	By:	 	/s/ David J. Leuck	 		 		 	Date: 09 Dec. 2013
		 	 David J. Leuck

Associate Director Quality Compliance
	 		 		 	
		 		 		 		 	

			
		
	 APROVED BY LEGAL
  

FPM / 12-09-13

Initials     Date
	  	

  

					
	 Quality Agreement
 QG01-05-T001-01
	  	

	  	Page 19 of 20

 

 
  

 SECTION 5: APPENDICES 

 

	 	•	 	Appendix A: Product(s) 

  

	 	•	 	Appendix B: Quality Contacts 

  

	 	•	 	Appendix C: Patheon Approved Supplier List 

  

	 	•	 	Appendix D: Client Approved Supplier List 

  

	 	•	 	Appendix E: Patheon Approved Contract Laboratories List 

  

					
	 Quality Agreement
 QG01-05-T001-01
	  	

	  	Page 20 of 20

 

 
  

 APPENDIX A: PRODUCT(S) 

 

					
	 Products (s)
	  	 Package
	  	 Dosage (Strength)

	Vimovo	  	60 Count Bottles	  	500mg
		  	60 Count Bottles	  	375mg
		  	6 Count Bottles	  	500mg

  

					
	 Quality Agreement
 QG01-05-T001-01
	  	

	  	

 

 
  

 APPENDIX B: QUALITY CONTACTS 

 

					
	 	  	 Patheon
	  	 Horizon

	Responsibility	  	Quality Assurance	  	Quality Assurance
	Name	  	Garry Hedgepeth	  	Cara Weyker
	Title	  	Quality Assurance Manager-GMP Services	  	Vice President, CMC Regulatory and Quality Systems
	Phone	  	513-948-	  	224-383-3063
	Fax	  	513-948-7393	  	224-383-3001
	E-mail	  	Patty.Mclean@Patheon.com	  	cweyker@horizonpharma.com
	Address	  	 2110 E. Galbraith Rd

Cincinnati, OH 45237-1625
	  	 520 Lake Cook Rd., Suite 520

Deerfield, IL 60015

			
	Responsibility	  	Regulatory Affairs	  	Manufacturing Operations
	Name	  	Greg Hammer	  	Hans-Peter Zobel
	Title	  	QA Regulatory Leader	  	SVP, Global Manufacturing Operations
	Phone	  	513-948-3135	  	0041 (0)61 715 20 63
	Fax	  	513-948-7393	  	0041 (0)61 715 20 49
	E-mail	  	Gregory.Hammer@Patheon.com	  	hzobel@horizonpharma.com
	Address	  	 2110 E. Galbraith Rd

Cincinnati, OH 45237-1625
	  	 Kägenstrasse 17

CH-4153 Reinach

Switzerland

			
	Responsibility	  	Product Complaints	  	Manufacturing Operations
	Name	  	Tina Cranmer	  	Bill Iskos
		  	QA Complaints	  	VP, Manufacturing Operations
		  	513-948-7042	  	224-383-3040
		  	513-948-7393	  	224-383-3001
		  	cropatheoncomplaints@patheon.com	  	biskos@horizonpharma.com
	Address	  	 2110 E. Galbraith Rd

Cincinnati, OH 45237-1625
	  	 520 Lake Cook Rd., Suite 520

Deerfield, IL 60015

			
	Responsibility	  	Product Release	  	Product Release
	Name	  	Charles Venable	  	Ignacio Lopez
	Title	  	Quality Assurance Manager-Master Documents	  	Director Quality
	Phone	  	513-948-7783	  	224-383-3049

  

					
	 Quality Agreement
 QG01-05-T001-01
	  	

	  	

 

 
  

					
	Fax	  	513-948-7393	  	224-383-3001
	E-mail	  	Charles.Venable@Patheon.com	  	ilopez@horizonpharma.com
	Address	  	 2110 E. Galbraith Rd

Cincinnati, OH 45237-1625
	  	 520 Lake Cook Rd., Suite 520

Deerfield, IL 60015

			
	Responsibility	  	Account Manager	  	
	Name	  	
	Title	  	
	Phone	  	
	Fax	  	
	E-mail	  	
	Address	  	 2110 E. Galbraith Rd

Cincinnati, OH 45237-1625
	  	

  

					
	 Quality Agreement
 QG01-05-T001-01
	  	

	  	

 

 
  

 APPENDIX C: PATHEON APPROVED VENDOR LIST 

 

					
	 Part Number
	  	 Description
	  	 Vendor

	50004558	  	CROSCARMELLOSE SODIUM	  	FMC Biopolymer
	50018602	  	MAGNESIUM STEARATE 5712	  	Mallinckrodt
	70013874	  	SILICON DIOXIDE COLLOIDAL NF/EP/JP	  	Cabot Corp.
	70014144	  	POVIDONE
K90 NF/EP	  	ISP
	50004341	  	CARNAUBA WAX	  	Strohmeyer & Arpe
	50004447	  	ISOPROPYL ALCOHOL	  	Dow Chemical
	70012868	  	PLASACRYL	  	Emerson Resources
	70012869	  	OPADRY II WHITE 40F18389	  	Colorcon
	70012870	  	OPADRY CLEAR 00F19246	  	Colorcon
	70013591	  	OPACODE WB BLACK NS-78-17821	  	Colorcon
	70014142	  	EUDRAGIT L 30 D-55
NF/EP	  	Evonik Rohm GmbH
	70014143	  	POLYSORBATE 80 NF/EP	  	Croda Inc.
	70014146	  	TRIETHYL CITRATE NF/EP	  	Vertellus Specialties Inc.
	70016831	  	OPADRY YELLOW 05F92577	  	Colorcon
		  	Bottle—110cc	  	Rexam
		  	HDPE bottles—45cc	  	Amcor -
		  	PP Caps	  	Berry Plastics
		  	Liners	  	Selig FS1-7
		  		  	Unipac SafeGuard 100
		  	Silica Desiccants	  	Multisorb

  

					
	 Quality Agreement
 QG01-05-T001-01
	  	

	  	

 

 
  

 APPENDIX D: CLIENT APPROVED VENDOR LIST 

 

					
	 Part Number
	  	 Description
	  	 Vendor

	70014942	  	Esomeprazole	  	Minakem
	70015517	  	Naproxen	  	Divis

  

					
	 Quality Agreement
 QG01-05-T001-01
	  	

	  	

 

 
  

 APPENDIX E: PATHEON APPROVED CONTRACT LABORATORIES LIST 

Accugenix 
 223 Lake Dr. 

Newark Delaware 19702 

302-292-8888 
 Lancaster Labs 

2425 New Holland Pike 
 Lancaster
PA 17605 
 717-656-2300 

  

					
	 Quality Agreement
 QG01-05-T001-01
	  	

	  	

 Master Manufacturing Services Agreement 

 

 EXHIBIT C 

QUARTERLY ACTIVE MATERIALS INVENTORY REPORT 
  

			
	TO:	  	HORIZON PHARMA INC
		
	FROM:	  	PATHEON PHARMACEUTICALS INC. [or applicable Patheon entity]
		
	RE:	  	Active Materials quarterly inventory report under Section 2.2(a) of the Master Manufacturing Services Agreement dated October 31, 2013 (the “Agreement”)

 [...***...] 

  
  

***Confidential Treatment Requested 

- 2 - 

 Master Manufacturing Services Agreement 

 

 EXHIBIT D 

REPORT OF ANNUAL ACTIVE MATERIALS INVENTORY RECONCILIATION 

AND CALCULATION OF ACTUAL ANNUAL YIELD 
  

			
	TO:	  	HORIZON PHARMA INC.
		
	FROM:	  	PATHEON PHARMACEUTICALS INC. [or applicable Patheon entity]
		
	RE:	  	Active Materials annual inventory reconciliation report and calculation of Actual Annual Yield under Section 2.2(a) of the Master Manufacturing Services Agreement dated October 31, 2013 (the “Agreement”)

 [....***...] 

  
  

***Confidential Treatment Requested 

- 2 - 

 Master Manufacturing Services Agreement 

 

 [...***...] 

Based on the foregoing reimbursement calculation Patheon will reimburse Client the amount of
$            . 
 Capitalized terms used in this report have the meanings given to the terms in
the Agreement. 
 DATE:
                                        

  

			
	PATHEON PHARMACEUTICALS INC.
	[or applicable Patheon entity]
		
	Per:	 	 
	Name:	 	
	Title:	 	

  
  

***Confidential Treatment Requested 

- 2 - 

 Master Manufacturing Services Agreement 

 

 EXHIBIT E 

EXAMPLE OF PRICE ADJUSTMENT DUE TO CURRENCY FLUCTUATION 

Section 4.2(d) 
  

 

  
 - 2 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00231-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00231-of-00352.parquet"}]]